advancedmedical_10-12ga3.htm

10-12G/A 1 advancedmedical_10-12ga3.htm ADVANCED MEDICAL ISOTOPE CORP. FORM 10-12G/A 3RD AMENDMENT advancedmedical_10-12ga3.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10/A

(Amendment No. 3 )

GENERAL FORM FOR REGISTRATION OF SECURITIES

PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 0-53497

ADVANCED MEDICAL ISOTOPE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	80-0138937
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification Number)

8131 W. Grandridge Blvd. Suite 101, Kennewick WA	99336
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number: (509)736-4000

Copies to:

James C. Katzaroff

Advanced Medical Isotope Corporation

8131 W. Grandridge Blvd. Suite 101

Kennewick WA, 99336

(509)736-4000

Andrea Cataneo, Esq.

Peter DiChiara, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, NY 10006

(212) 930-9700

Securities to be registered under Section 12(b) of the Act: Not Applicable

Securities to be registered under Section 12(g) of the Exchange Act:

Title of each class		Name of Exchange on which to be so registered each class is to be registered
Common Stock, $.001 par value		N/A

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	o			Accelerated filer	o
Non-accelerated filer	o	(Do not check if a smaller reporting company)		Smaller reporting company	x

TABLE OF CONTENTS

ITEM 1.	DESCRIPTION OF BUSINESS.	4

ITEM 1A.	RISK FACTORS.	9

ITEM 2.	FINANCIAL INFORMATION.	16

ITEM 3.	DESCRIPTION OF PROPERTY.	22

ITEM 4.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.	22

ITEM 5.	DIRECTORS AND EXECUTIVE OFFICERS.	23

ITEM 6.	EXECUTIVE COMPENSATION.	24

ITEM 7.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.	31

ITEM 8.	LEGAL PROCEEDINGS.	31

ITEM 9.	MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.	31

ITEM 10.	RECENT SALES OF UNREGISTERED SECURITIES.	32

ITEM 11.	DESCRIPTION OF REGISTRANT’S SECURITIES TO BE REGISTERED.	33

ITEM 12.	INDEMNIFICATION OF DIRECTORS AND OFFICERS.	34

ITEM 13.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.	35

ITEM 14.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.	35

ITEM 15.	FINANCIAL STATEMENTS AND EXHIBITS.	36

	INDEX TO EXHIBITS	37

	SIGNATURES	38

As used in this Form 10, unless the context otherwise requires the terms “we,” “us,” “our,” and the “Company” refer to Advanced Medical Isotope Corporation, a Delaware corporation, and its subsidiaries.

FORWARD-LOOKING STATEMENTS

Except for statements of historical fact, certain information described in this document contains “forward-looking statements” that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would” or similar words. The statements that contain these or similar words should be read carefully because these statements discuss our future expectations, contain projections of our future results of operations or of our financial position, or state other “forward-looking” information. Advanced Medical Isotope Corporation believes that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able accurately to predict or control. Further, we urge you to be cautious of the forward-looking statements which are contained in this Form 10 because they involve risks, uncertainties and other factors affecting our operations, market growth, service, products and licenses. The factors listed below in the section captioned “Risk Factors” within Item 1A, “Description of Business,” as well as other cautionary language in this Form 10, describe such risks, uncertainties and events that may cause our actual results and achievements, whether expressed or implied, to differ materially from the expectations we describe in our forward-looking statements. The occurrence of any of the events described as risk factors could have a material adverse effect on our business, results of operations and financial position.

WHERE YOU CAN FIND MORE INFORMATION ABOUT US

When our Registration Statement on Form 10 becomes effective, we will file reports, proxy statements, information statements and other information with the Securities and Exchange Commission. You may read and copy this information, for a copying fee, at the SEC’s public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for more information on its public reference rooms. Our Securities and Exchange Commission filings are also available to the public from commercial document retrieval services, and at the web site maintained by the Securities and Exchange Commission at http://www.sec.gov.

Our internet address is www.isotopeworld.com. We will make available through a link to the SEC’s web site, electronic copies of the materials we file with the SEC (including our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K, the Section 16 reports filed by our executive officers, directors and 10% shareholders and amendments to those reports). To receive paper copies of our SEC materials, please contact us by mail addressed to James C. Katzaroff, Chief Executive Officer, Advanced Medical Isotope Corporation, 8131 W. Grandridge Blvd. Suite 101, Kennewick WA, 99336.

ITEM 1. DESCRIPTION OF BUSINESS.

Organizational History

Advanced Medical Isotope Corporation (the “Company”) was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“SMSC”) for the purpose of acquiring or investing in businesses which were developing and marketing active sports products, equipment, and apparel. In April 2000, Earth Sports Products, Inc (“ESP”), a corporation registered in Washington, merged with SMSC. In April 2000, HHH Entertainment, Inc (“HHH”), a Nevada corporation, merged with SMSC. As of the date of merger, HHH was the only stockholder of SMSC.

The Company has had limited activity since inception and was considered dormant from the period May 1, 2000 through December 31, 2005. On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation. The Company began planned principal operations in August 2007, but has not generated significant revenue. The Company plans to wholesale medical isotopes as well as to develop, produce and market medical isotopes.

On September 27, 2006, the Company acquired the assets of Neu-Hope Technologies, Inc (“NHTI”), a Florida corporation and a subsidiary of UTEK Corporation (“UTEK”), a Delaware Corporation, and $310,000 from UTEK for 100,000 shares of Series A Preferred Stock. 95,000 shares of Series Preferred Stock were issued to UTEK and 5,000 shares were issued to Aware Capital Corporation. At any time after September 27, 2007, UTEK’s 100,000 Series A Preferred Stock shares can be converted to our Common Stock in the amount of $3,350,000. The number of Common Stock shares shall be calculated based on the previous 10-day average closing price on the day of conversion. As of the end of trading on December 31, 2008, the 10-day average closing price was $0.422. In December 2007, 5,000 shares of the Company’s Series A preferred stock were converted to 299,642 shares of common stock at $.559 per share by Aware Capital Corporation. UTEK can then receive 7,541,469 shares of our Common Stock for its 95,000 shares of Series A Preferred Stock.

The Company conducted the acquisition in order to obtain cash and NHTI’s technology. UTEK provides its clients with externally developed technologies from universities, university incubators, federal labs, medical centers, and corporate research laboratories worldwide. To effectuate a technology transfer, such as our purchase of NHTI, UTEK creates a newly formed company to acquire a new technology from a university, medical center, corporation or federal research laboratory and then sell this newly formed company to a client, such as Advanced Medical Isotope Corporation for securities or cash.

The assets acquired by the Company were recorded at the value which the preferred stock can be converted into common stock, $3,350,000, as follows:

	As of September 27, 2006
Cash	$	310,000
License fee		3,040,000
Net assets acquired	$	3,350,000

The Company did not have any relationship with UTEK before the acquisition of Neu Hope Technologies. UTEK is a public corporation. It is our understanding that Dr. Clifford M. Gross, PhD, Chairman and Chief Executive Officer, Ms. Carole R. Wright, Chief Financial Officer and Mr. Douglas Schaedler, Chief Operating Officer, make the investment decisions on behalf of UTEK.

UTEK also entered into a technology transfer agreement with Manakoa Services Corporation. Manakoa Services Corporation has recently changed its name to TeslaVision Corporation. Mr. Katzaroff is an officer and a director of TeslaVision Corporation. TeslaVision Corporation is not a shell company but is not current in its reporting. Other than Mr. Katzaroff’s service as an officer of both corporations, there is no relationship between TeslaVision Corporation and Advanced Medical Isotope Corporation. UTEK Corporation is a publicly-held corporation that, pursuant to its public filings, completed 45 technology transfers during their fiscal years ended December 31, 2007 and 2006.

On June 13, 2007, the Company acquired the assets of the life sciences business segment of Isonics Corporation (Isonics), a California corporation. Isonics is a non-related business of the Company and neither company owns stock in the other. The Company acquired the assets in exchange for $850,000 cash payment for the purpose of combining the assets into our business of marketing medical isotopes. The assets acquired consist of intellectual property, agreements with third party companies for purchase and marketing of isotopes, customer lists, and equipment located in Buffalo, New York. Intellectual property, agreements with third parties and customer lists are stated at the Companies estimation of fair market value at the time of acquisition. None of the acquired assets hold any ongoing liabilities or contractual obligations that would result in additional cash transactions required by the Company.

Based on our financial history since inception, our auditor has expressed substantial doubt as to our ability to continue as a going concern. We are a development stage company that has a limited amount of revenue which has accumulated deficits since inception. If we cannot obtain sufficient funding, we may have to delay the implementation of our business strategy.

General Description

We are engaged in the production and distribution of medical isotopes and medical isotope technologies that are changing the practice of medicine and ushering in a new era of improved patient care. Isotopes are a form of chemical element with the same atomic number as another element but with a different atomic mass. Medical isotopes are used in molecular imaging, therapy, and nuclear medicine to diagnose, manage and treat diseases.

ITEM 1. DESCRIPTION OF BUSINESS. - continued

Currently, more than 15 million nuclear medicine procedures are performed each year in the U.S. Approximately one-third of all patients admitted to U.S. hospitals undergo at least one medical procedure that employs the use of medical isotopes.

We employ innovative production methods to offer a wide range of reliable, domestically produced medical isotopes as well as in vivo delivery systems to aid medical practitioners and medical researchers in the timely diagnosis and effective treatment of diseases such as cancer, heart disease, neurological disorders, and many other medical conditions.

Our objective is to empower physicians, medical researchers, and ultimately, patients, by providing them with essential medical isotopes that, until now, have not been practical or economical to produce, in an effort to detect, manage, and cure human disease, and improve the lives of patients.

Products

We currently offer the following products

Stable Isotopes:

We currently offer worldwide distribution of O-18 enriched water and a wide range of other stable isotopes. Our product line includes stable isotopes of the following elements: Antimony, Barium, Cadmium, Calcium, Cerium, Chromium, Copper, Dysprosium, Erbium, Europium, Gadolinium, Gallium, Germanium, Hafnium, Indium, Iron, Krypton, Lanthanum, Lead, Lutetium, Magnesium, Mercury, Molybdenum, Neodymium, Nickel, Osmium, Palladium, Platinum, Potassium, Rhenium, Rubidium, Ruthenium, Samarium, Selenium, Silicon, Silver, Strontium, Sulphur, Tellurium, Thallium, Tin, Titanium, Tungsten, Vanadium, Xenon, Ytterbium, Zinc, and Zirconium.

Many of our products are used in connection with Positron Emission Tomography (“PET”). In cancer, changes in biochemistry occur before tumor mass forms. As a result, PET can often identify the presence of disease earlier than a test which looks for a tumor mass. Isotopes identified by PET include radiopharmaceutical Fluorodeoxyglucose (“FDG”), a sugar compound that is labeled with radioactive fluoride.

Radio Pharmaceuticals:

F-18 FDG: We currently offer regional distribution of F-18 FDG from our Kennewick, WA production facility. Other regional production facilities are planned throughout the U.S. and abroad, including Los Angeles, Oahu, Idaho and Montana.

Indium-111: We plan to offer Indium Chloride and Indium Oxine during the first six months of 2009.

Radio Chemicals:

F-18: We currently offer regional distribution of F-18 from our Kennewick, WA production facility. Other regional production facilities are planned throughout the U.S. and abroad. This is the primary PET imaging isotope. It is used for medical and diagnostic purposes, such as cancer detection, heart imaging, and brain imaging.

Iodine-124: This is a radiotracer primarily used in PET imaging and to create images of human thyroid. Other treatment uses include apoptosis, cancer biotherapy, glioma, heart disease, mediastinal micrometastases, and thyroid cancer.

Indium-111: We currently offer In-111 Chloride bulk solution for U.S. distribution. This radio chemical is used for infection imaging, cancer treatments, and tracer studies.

Strontium-82: Used as a myocardial imaging agent, early detection of coronary artery disease, PET imaging, blood flow tracers

Germanium-68: It is used for study of thrombosis and atherosclerosis, PET imaging, detection of pancreatic cancer, and attenuation correction.

Actinium-225: Used for advanced research in therapy of leukemia and other cancers. It holds great promise for treating HIV/AIDS.

ITEM 1. DESCRIPTION OF BUSINESS. - continued

Products - continued

Generators:

Strontium-82/Rubidium-82 generators: Used as a myocardial imaging agent, early detection of coronary artery disease, PET imaging, blood flow tracers

Germanium-68/Gallium-68 generators: It is used for study of thrombosis and atherosclerosis, PET imaging, detection of pancreatic cancer, and attenuation correction.

Actinium-225/Bismuth-213 generators: Actinium-225 is the parent of Bismuth-213, an isotope which has been used in animal trials to kill human HIV virus. Bismuth-213 has been used in human clinical trials for the treatment of Acute Myelogenous Leukemia (AML).

Within the next three years, we intend to offer the following isotopes:

Carbon-11: Used in cancer diagnosis/staging. Radiotracer in PET scans to study normal/abnormal brain functions related to various drug addictions and is also used to evaluate disease such as Alzheimer’s, epilepsy, Parkinson’s and heart disease.

Cobalt-57: Used for gamma camera calibration. Also used as radiotracer in research and a source for X-ray fluorescence spectroscopy.

Copper-64: PET scanning, planar imaging, SPECT imaging, dosimetry studies, cerebral and myocardial blood flow. This isotope is used in stem cell research, and cancer treatments.

Iodine-123: Used in brain, thyroid, kidney, and myocardial imaging, cerebral blood flow (ideal for imaging) and neurological disease (Alzheimer's).

Molybdenum-99 / Technitium 99: It is the favored choice among medical professionals because its chemical properties allow it to be bonded to many different chemical materials, thus allowing use for a wide variety of diagnoses.

Thallium-201: Used in clinical cardiology, heart imaging, myocardial perfusion studies and cellular dosimetry.

Manufacturing

The cornerstone equipment selected for our production center is a proton linear accelerator. Our proton linear accelerator is designed to replace large and demanding cyclotron systems for the production of positron emitting isotopes. Large amounts of fluorine-18, carbon-11, nitrogen-13, and oxygen-15 can be produced for synthesis into compounds used in oncology, cardiology, neurology, and molecular imaging. The radio-labeled glucose analog, FDG, can be synthesized and distributed for use in Positron Emission Tomography.

Based on our experience in the industry, it is our belief that no other accelerator in North America has sufficient flexibility to produce the full spectrum of PET imaging radioisotopes, as well as other high-demand isotopes, both short and long lived, for diagnostic and therapeutic applications.

We are also engaged in a number of collaborative efforts with U.S. national laboratories and universities, along with several international teaming partners. These collaborative effort projects include complementary isotope manufacturing technologies as well as isotope devices. We have entered into agreements to produce isotopes at Idaho State University, the University of Missouri at Columbia, the State University of New York at Buffalo, and the University of Utah. These regional university centers will allow us to become a local supplier for the short-lived isotopes like Fluorine 18 as well as being a domestic supplier of several other isotopes in demand by the medical community.

In November 2007, we entered into an agreement with the Idaho Accelerator Center (IAC), located on the campus of Idaho State University in Pocatello, ID, to create a regional medical isotope production center. The IAC will investigate the production of a variety of isotopes at IAC facilities and we will proceed with conceptual planning for production facility development. We intend to use the IAC to develop and manufacture medical isotopes.

ITEM 1. DESCRIPTION OF BUSINESS. - continued

Manufacturing - continued

In May 2008, we entered into a research agreement with the University of Utah related to the use of brachytherapy seeds for cancer treatments. Pursuant to the research agreement, we will pay total project costs that will not exceed $45,150. We hope to work with the University of Utah to develop and manufacture cancer treatments using brachytherapy seeds.

In June 2008, we entered into a research agreement with the University of Missouri related to the production of radio isotopes. Pursuant to the research agreement, we will pay total project costs that will not exceed $75,000. We also entered into an option agreement in June 2008 with the University of Missouri. The option agreement gives us a one-year option to enter into a licensing agreement to utilize certain intellectual property held by the University of Missouri for the production of medical, research, and industrial radioisotopes. If the University of Missouri’s intellectual property functions as early analysis have indicated, this production facility could be a manufacturing source of critical health care radio isotopes.

License Agreement

On September 27, 2006, we acquired the assets of NHTI from UTEK. Included in the acquired assets was a Non-Exclusive License Agreement with the Regents of the University of California (“University”) for a neutron generator in exchange for preferred stock valued at $3,040,000 on September 27, 2006, discounted using a 4.25% incremental borrowing rate, and a $2,897,625 present value. This license agreement is stated at cost, less accumulated amortization computed based on a useful life of three years. The license agreement is being amortized using a useful life of three years.

NHTI paid a non-refundable fee in the amount of $25,000 in connection with the license agreement. The license fee is non-refundable unless our commercialization plan is deemed unacceptable by the University. If the plan is deemed unacceptable, the license agreement will terminate. To date, no commercialization plan has been deemed acceptable or unacceptable. In consideration for the license, we agreed to pay royalties equal to the greater of three percent of the selling price of each licensed product we sell or the maintenance fee according to the following schedule:

2008	$	10,000
2009	$	15,000
2010	$	15,000
2011	$	45,000
2012 and each year thereafter	$	60,000
	$	145,000

The License Agreement may be cancelled by giving 90 days written notice to the University.

Raw Materials

Some of the materials used in the products we manufacture are currently available only from a limited number of suppliers; many of which are from international suppliers. We obtain many of our stable isotopes from suppliers in Russia. The Company plans to expand the availability of its supplies and products utilizing manufacturing capability at reactors located at the U.S. Department of Energy's National Laboratories (“National Laboratories”) as well as production capabilities at various universities and foreign countries other than Russia. This strategy will reduce the risk associated with concentrating isotope production at a single reactor facility. We obtain supplies, hardware, handling equipment and packaging from several different U.S. suppliers.

Customers

Our customers include a broad range of hospitals, universities, research centers and national laboratories, in addition to academic and government institutions. These customers are located in essentially all major U.S. and international markets. Sales for the years ended December 31, 2007 consisted of imported stable isotopes. Sales to our customers whose sales were greater than 10% of our total sales for the year ended December 31, 2007 totaled 24.9%, 17.5%, and 15.5% of total revenues in 2007. We are not, however, dependent on one or a few major customers as, given our current net losses, the termination of any agreements with current customers would not materially increase our net losses.

In July 2008, we began production of F-18 in our production facilities in Kennewick, Washington. Sales of F-18 for the quarter ended March 31, 2009 totaled approximately 87% of total revenue. Sales of F-18 for the year ended December 31, 2008 totaled approximately 29% of total revenue. Sales to our customers whose sales were greater than 10% of our total sales for the year ended December 31, 2008 totaled 17.8%, 14.2%, and 11.7% of total revenues in 2008.

The company is also working with United Pharmacy Partners Inc (UPPI). UPPI has a network of approximately 120 nuclear pharmacies within the United States. We have entered into an affiliation agreement with UPPI to provide to the UPPI network preferred prices and special terms and conditions for certain products that we anticipate to manufacture or re-sell during 2009 and 2010.

ITEM 1. DESCRIPTION OF BUSINESS. - continued

Competitors

The suppliers of radioisotopes for diagnosis, treatment, and research for a wide variety of diseases, in particular cancer, vary in size and product offerings. Competition is limited because there are many complications and regulatory hurdles, including licensing, government approvals and capital outlays associated with starting an isotope company. Many current competitors are international companies.

Further, competition is limited as some competitors are closing their facilities or limiting their production. In November 2007, Canadian supplier MDS Nordion was forced to shut down its radioisotope production facility. At one time, the U.S. government was supposed to be the source of medical isotopes, but over the course of the last two decades, it has either closed or failed to adequately fund its production facilities.

About 90% of all the non PET radioisotopes used in the United States are imported from two companies. Approximately half of these were imported directly from the now-defunct MDS Nordion plant and the other half supplied by Covidien (formerly Mallinkrodt). The remaining 10% that are produced in the United States are manufactured in a fragmented, piecemeal manner with companies producing a single isotope instead of a wide variety.

Employees

As of March 31, 2009, we had six full time employees. At any given time, we utilize eight to ten contract employees to assist with the company operations. We do not have a collective bargaining agreement with any of our employees and we believe our relations with our employees are good.

Research and Development / Intellectual Property

We spent approximately $90,150 and $1,250 during the years ended December 31, 2008 and December 31, 2007, respectively, on research and development. This cost was incurred to a University for tests involved in the making of isotopes.

Additionally the Company has made through acquisitions the following investments in patent licenses and intellectual property during 2007:

$75,000 for a patent license fee, good for the life of the patent, for the production of Actinium 225;

	·	$3,040,000 of preferred stock issuance for a patent license, good for the life of the patent, of a Neutron Generator; and

	·	$658,750 for the purchase of a company in order to acquire the rights of intellectual property related to the process for the production of isotopes, customer lists, contracts and agreements with third party companies, and certain equipment. The amortization of these items is computed using the straight-line method over the following estimated useful lives:

Intellectual property	3 years
Contracts and agreements	3 years
Customer lists	2 years

In January 2007 AMIC received a license for United States Patent 6,680,993. The patent concerns methods and processes directed to the preparation of Actinium-225 and daughters having high radiochemical and radionuclidic purity. These isotopes may be used for the preparation of therapeutic radiopharmaceuticals such as those containing monoclonal antibodies, proteins, peptides, antisense, statin, natural products and hormones. Additionally, the alpha-emitting radionuclide Actinium-225 and its daughters may be used for both therapeutic and diagnostic purposes.

ITEM 1. DESCRIPTION OF BUSINESS. - continued

Government Regulation

Significant areas of regulation and intervention include the following:

Environmental and Health Compliance. We are committed to conducting our activities so that there is no or only minimal damage to the environment; there is no assurance, however, that its activities will not at times result in liability under environmental and health regulations.

We spent approximately $950,000 on our facility to meet environmental regulation, including the cost of confinement of the facility, exhaust and air balance systems and waste storage facilities. As we expand our manufacturing capability, we will be subject to extensive government regulation and intervention both in the United States and in all foreign jurisdictions in which we conduct business.

The current ongoing continuing costs of compliance are immaterial. Future costs and expenses resulting from such liability may, however, materially negatively impact our operations and financial condition. Overall, environmental and health laws and regulations will continue to affect our businesses worldwide.

Import/Export Regulation. We are subject to significant regulatory oversight of our import and export operations due to the nature of our product offerings. Penalties for non-compliance can be significant and violation can result in adverse publicity for the Company.

Financial Accounting Standards. Our financial results can be impacted by new or modified financial accounting standards.

Other Regulations. Our operations are subject to U.S. Nuclear Regulatory Commission, Food and Drug Administration, Department of Transportation, and Department of Homeland Security regulations. The extent these regulations are or become burdensome, our business development could be adversely affected.

ITEM 1A. RISK FACTORS.

RISKS ASSOCIATED WITH OUR BUSINESS

Our business plan is at an early stage of development and has a limited operating history.

We have a limited operating history upon which you can base an evaluation of our business and prospects. As a start-up company in the early stage of development, there are substantial risks, uncertainties, expenses and difficulties to which our business is subject. To address these risks and uncertainties, we must do the following:

	·	Successfully execute our business strategy;

	·	Respond to competitive developments; and

	·	Attract, integrate, retain and motivate qualified personnel.

There can be no assurance that at this time we will operate profitably or that it will have adequate working capital to meet our obligations as they become due. We cannot be certain that our business strategy will be successful or that we will successfully address the risks that face our business. In the event that we do not successfully address these risks, its business, prospects, financial condition, and results of operations could be materially and adversely affected.

ITEM 1A. RISK FACTORS. - continued

RISKS ASSOCIATED WITH OUR BUSINESS - continued

We have increasing cash requirements.

We have generated material operating losses since inception. We have incurred a net loss of $11,761,268 from January 1, 2006 (inception) through March 31, 2009 , including a net loss of $1,360,499 for the quarter ended March 31, 2009 and $6,158,755 for the year ended December 31, 2008. We expect to continue to experience net operating losses. Historically, we have relied upon outside investor funds to maintain our operations and develop our business. We anticipate raising additional capital within the next 12 months from investors for working capital as well as business expansion and we can provide no assurance that additional investor funds will be available on terms acceptable to us. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. If we are unable to generate profits and unable to obtain additional financing to meet our working capital requirements, we may have to curtail our business.

We will need to increase the size of our organization and may experience difficulties in managing growth.

We are a small organization with a minimal number of employees. We expect to experience a period of significant expansion in headcount, facilities, infrastructure and overhead and anticipate that further expansion will be required to address potential growth and market opportunities. Future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate managers. Our future financial performance and its ability to compete effectively will depend, in part, on the ability to manage any future growth effectively.

We are dependent on key personnel and consultants and the loss of these key personnel And consultants could have a material adverse effect on our business, results of operations or financial condition.

Our success is heavily dependent on the continued active participation of our current executive officers listed under “Management.” We do not have key-man insurance on any of our officers or consultants. We are highly dependent upon certain consultants and collaborating scientists. Loss of the services of one or more of our officers or consultants could have a material adverse effect upon our business, results of operations or financial condition. Certain key employees have no employment contracts.

If we are unable to hire qualified personnel our business and financial condition may suffer.

Our success and achievement of our growth plans depend on our ability to recruit, hire, train and retain other highly qualified technical and managerial personnel. Competition for qualified employees among pharmaceutical and biotechnology companies is intense, and the loss of any of such persons, or an inability to attract, retain and motivate any additional highly skilled employees required for the expansion of our activities, could have a materially adverse effect on us. Our inability to attract and retain the necessary technical and managerial personnel and consultants and scientific and/or regulatory consultants and advisors could have a material adverse effect on our business, results of operations or financial condition.

We may rely on third parties to represent us locally in international markets and our revenue may depend on their efforts.

Our future success may depend, in part, on our ability to enter into and maintain collaborative relationships with one or more third parties, the collaborator’s strategic interest in the products under development and such collaborator’s ability to successfully market and sell any such products. We intend to pursue collaborative arrangements regarding the sales and marketing of our products, however, we may not be able to establish or maintain such collaborative arrangements, or if we are able to do so, they may not have effective sales forces. To the extent that we decide not to, or are unable to, enter into collaborative arrangements with respect to the sales and marketing of our proposed products, significant capital expenditures, management resources and time will be required to establish and develop an in-house marketing and sales force with technical expertise. To the extent that we depend on third parties for marketing and distribution, any revenues received by us will depend upon the efforts of such third parties, which may not be successful.

ITEM 1A. RISK FACTORS. - continued

RISKS ASSOCIATED WITH OUR BUSINESS - continued

Our revenues depend upon suitable markets.

Our revenues depend upon the successful production, marketing, and sales of the various isotopes we currently market and expect to market in the future. The rate and level of market acceptance of these products may vary depending on the perception by physicians and other members of the healthcare community of its safety and efficacy as compared to that of competing products, if any; the clinical outcomes of any patients treated; the effectiveness of our sales and marketing efforts in the United States, Europe, and Russia; any unfavorable publicity concerning our products or similar products; price of our products relative to other products or competing treatments; any decrease in current reimbursement rates from the Centers for Medicare and Medicaid Services or third-party payers; regulatory developments related to the manufacture or continued use of our products; availability of sufficient supplies to either purchase or manufacture our products; ability to produce sufficient quantities of our products; and the ability of physicians to properly utilize our products and avoid excessive levels of radiation to patients. Any material adverse developments with respect to the commercialization of the products we currently market or expect to market may cause us to continue to incur losses rather than profits in the future.

Our future growth is largely dependent upon our ability to develop new technologies that achieve market acceptance with acceptable margins.

Our businesses operate in global markets that are characterized by rapidly changing technologies and evolving industry standards. Accordingly, our future growth rate depends upon a number of factors, including our ability to (i) identify emerging technological trends in our target end-markets, (ii) develop and maintain competitive products, (iii) enhance our products by adding innovative features that differentiate our products from those of our competitors, and (iv) develop, manufacture and bring products to market quickly and cost-effectively.

Our ability to develop new products based on technological innovation can affect our competitive position and requires the investment of significant resources. These development efforts divert resources from other potential investments in our businesses, and they may not lead to the development of new technologies or products on a timely basis or that meet the needs of our customers as fully as competitive offerings. In addition, the markets for our products may not develop or grow as we currently anticipate. The failure of our technologies or products to gain market acceptance due to more attractive offerings by our competitors could significantly reduce our revenues and adversely affect our competitive standing and prospects.

Because we have a history of losses, our future profitability is uncertain and we have not been a reporting company for a substantial period of time, our common stock is a speculative investment.

We are engaged in the production and distribution of medical isotopes and medical isotope technologies. Medical isotopes are used in molecular imaging, therapy, and nuclear medicine to diagnose, manage and treat diseases. We employ innovative production methods to offer a wide range of reliable, domestically produced medical isotopes. Companies that are implementing innovative technologies are speculative investments.

Our Chief Executive Officer, Mr. James C. Katzaroff, is an investor in companies that are developing emerging technologies. Mr. Katzaroff is an officer and a director of TeslaVision Corporation. TeslaVision Corporation is not a shell company but is not current in its reporting and has not been profitable. Other than Mr. Katzaroff’s service as an officer of both corporations, there is no relationship between TeslaVision Corporation and Advanced Medical Isotope Corporation. TeslaVision Corporation has recently changed its name from Manakoa Services Corporation.

UTEK, a company which we entered into a technology transfer agreement, is also a speculative investor. UTEK Corporation is a publicly-held corporation that, pursuant to its public filings, completed 45 technology transfers, including one with Manakoa Services Corporation, during their fiscal years ended December 31, 2007 and 2006.

Since an investment in our common stock is a speculative investment, you should not invest in our company unless you are in a position to lose the entire amount of such investment.

General economic conditions in markets in which we do business can impact the demand for our goods and services. Decreased demand for our products and services could have a negative impact on our financial performance and cash flow.

Demand for our products and services, in part, depends on the general economic conditions affecting the countries and industries in which we do business. A downturn in economic conditions in a country or industry that we serve may negatively impact demand for our products and services, in turn negatively impacting our operations and financial results. Further, changes in demand for our products and services can magnify the impact of economic cycles on our businesses. Unanticipated contract terminations by current customers can negatively impact operations, financial results and cash flow.

Volatility in raw material and energy costs, interruption in ordinary sources of supply and an inability to recover unanticipated increases in energy and raw material costs from customers could result in lost sales or significantly increase the cost of doing business.

Market and economic conditions affecting the costs of raw materials, utilities, energy costs, and infrastructure required to provide for the delivery of those goods and services, are beyond our control and any disruption or halt in supplies, or rapid escalations in costs could affect our ability to manufacture products or to competitively price our products in the marketplace. To date to ultimate impact of these energy costs increases have been mitigated through price increases or offset through improved process efficiencies, however, continuing escalation of energy costs could have a negative impact upon business performance.

ITEM 1A. RISK FACTORS. - continued

RISKS ASSOCIATED WITH OUR BUSINESS - continued

We are subject to uncertainties regarding reimbursement for use of our products.

Hospitals and freestanding clinics may be less likely to purchase our products if they cannot be assured of receiving favorable reimbursement for treatments using our products from third-party payers, such as Medicare and private health insurance plans. Third-party payers are increasingly challenging the pricing of certain medical services or devices, and we cannot be sure that they will reimburse our customers at levels sufficient for us to maintain favorable sales and price levels for our products. There is no uniform policy on reimbursement among third-party payers, and we can provide no assurance that our products will continue to qualify for reimbursement from all third-party payers or that reimbursement rates will not be reduced. A reduction in or elimination of third-party reimbursement for treatments using our products would likely have a material adverse effect on our revenues.

Our earnings, cash flow and financial position are exposed to financial market risks worldwide, including interest rate and currency exchange rate fluctuations and exchange rate controls. Fluctuations in domestic and world markets could adversely affect interest rates and impact our ability to obtain credit or attract investors. In order to reduce this risk the Company is structuring future agreements in such a manner that they provide for early termination provisions by the Company and continued development of the Company core business segments to such an extent that additional investment would not be required to sustain the Company as a going concern.

Our patented technologies may infringe on other patents, which may expose us to costly litigation.

It is possible that our patented technologies may infringe on patents or other rights owned by others. We may have to alter our products or processes, pay licensing fees, defend an infringement action or challenge the validity of the patents in court, or cease activities altogether because of patent rights of third parties, thereby causing additional unexpected costs and delays to us. Patent litigation is costly and time consuming, and we may not have sufficient resources to pursue such litigation. If we do not obtain a license under such patents, are found liable for infringement or are not able to have such patents declared invalid, we may be liable for significant money damages, may encounter significant delays in bringing products to market or may be precluded from participating in the manufacture, use or sale of products or methods of treatment requiring such licenses.

Protecting our intellectual property is critical to our innovation efforts.

We own or have a license to use several U.S. and foreign patents and patent applications, trademarks and copyrights. Our intellectual property rights may be challenged, invalidated or infringed upon by third parties or we may be unable to maintain, renew or enter into new licenses of third party proprietary intellectual property on commercially reasonable terms. In some non-U.S. countries, laws affecting intellectual property are uncertain in their application, which can affect the scope or enforceability of our patents and other intellectual property rights. Any of these events or factors could diminish or cause us to lose the competitive advantages associated with our intellectual property, subject us to judgments, penalties and significant litigation costs, and/or temporarily or permanently disrupt our sales and marketing of the affected products or services.

We may not be able to protect our trade secrets and other unpatented proprietary technology which could give our competitors an advantage over us.

We rely upon trade secrets and other unpatented proprietary technology. We may not be able to adequately protect our rights with regard to such unpatented proprietary technology or competitors may independently develop substantially equivalent technology. We seek to protect trade secrets and proprietary knowledge, in part through confidentiality agreements with our employees, consultants, advisors and collaborators. Nevertheless, these agreements may not effectively prevent disclosure of our confidential information and may not provide us with an adequate remedy in the event of unauthorized disclosure of such information and as a result our competitors could gain a competitive advantage. Operational hazards could result in the spread of contamination within our facility and require additional funding to correct.

ITEM 1A. RISK FACTORS. - continued

RISKS ASSOCIATED WITH OUR BUSINESS - continued

We may incur material losses and costs as a result of product liability claims that may be brought against us.

We face an inherent business risk of exposure to product liability claims in the event that products supplied by us fail to perform as expected or such failure results, or is alleged to result, in bodily injury, and possible adverse publicity, which could damage our reputation by raising questions about our products' safety and efficacy, and could interfere with our efforts to market our products.

We are subject to the risk that certain third parties may mishandle our product.

We rely on third parties, such as Federal Express, to deliver our products, and on other third parties to package our products in certain specialized packaging forms requested by customers. We are subject to the risk that these third parties may mishandle our product, which could result in adverse effects, particularly given the radioactive nature of some of our products. A successful product liability claim against us in excess of our available insurance coverage or established reserves may have a material adverse effect on our business. Although we currently maintain liability insurance in amounts we believe are commercially reasonable, any product liability we incur may exceed our insurance coverage.

We are subject to extensive government regulation in jurisdictions around the globe in which we do business. Regulations address, among other things, environmental compliance, import/export restrictions, healthcare services, taxes and financial reporting, and can significantly increase the cost of doing business, which in turn can negatively impact our operations, financial results and cash flow.

As we expand our manufacturing capability, we will be subject to extensive government regulation and intervention both in the United States and in all foreign jurisdictions in which we conduct business. Compliance with applicable laws and regulations will result in higher capital expenditures and operating costs and changes to current regulations with which we comply can necessitate further capital expenditures and increases in operating costs to enable continued compliance. Additionally, from time to time, we may be involved in proceedings under certain of these laws and regulations. Foreign operations are subject to political instabilities, restrictions on funds transfers, import/export restrictions and currency fluctuation.

Our operations expose us to the risk of material environmental liabilities.

We are subject to potentially material liabilities related to the remediation of environmental hazards and to personal injuries or property damages that may be caused by hazardous substance releases and exposures. We are subject to various federal, state, local and foreign government requirements regulating the discharge of materials into the environment or otherwise relating to the protection of the environment. These laws and regulations can impose substantial fines and criminal sanctions for violations, and require installation of costly equipment or operational changes to limit emissions and/or decrease the likelihood of accidental hazardous substance releases. We expect to incur capital and operating costs to comply with these laws and regulations. In addition, changes in laws, regulations and enforcement of policies, the discovery of previously unknown contamination or new technology or information related to individual sites, or the imposition of new clean-up requirements or remedial techniques could require us to incur costs in the future that would have a negative effect on our financial condition or results of operations.

Future production increases will depend on our ability to acquire larger quantities of O-18.

We currently obtain O-18 through international sources. The amount of O-18 that can be produced from a given reactor source is limited by the power level and volume available within the reactor for irradiating targets. There is no assurance that the Company will have a continuing sufficient supply of O-18 and if sufficient supplies are attained, we will need to increase our manufacturing staff.

ITEM 1A. RISK FACTORS. - continued

RISKS ASSOCIATED WITH OUR BUSINESS - continued

We Rely Heavily On A Limited Number Of Suppliers.

Some of the products we market and some of the materials used in the products we manufacture are currently available only from a limited number of suppliers; many of which are from international suppliers. The Company plans to expand the availability of its supplies and products utilizing manufacturing capability at reactors located at National Laboratories as well as production capabilities at various universities and foreign countries other than Russia. This strategy will reduce the risk associated with concentrating isotope production at a single reactor facility. Failure to obtain deliveries from these sources could have a material adverse effect on our production and there may be a delay before we could locate alternative suppliers. We may not be able to locate alternative suppliers capable of producing the level of output of at the quality standards we require. Additional factors that could cause interruptions or delays in our source of materials include limitations on the availability of raw materials or manufacturing performance experienced by our suppliers and a breakdown in our commercial relations with one or more suppliers. Some of these factors may be completely out of our and our suppliers’ control. We do not have formal written agreements with any key supplier. Any interruption or delay in the supply of materials required to produce our products could harm our business if we were unable to obtain an alternative supplier or substitute equivalent materials in a cost-effective and timely manner.

RISKS RELATED TO OUR COMMON STOCK

There is a limited public market for our common stock. Failure to develop or maintain a trading market could negatively affect the value of our shares and make it difficult or impossible for shareholders to sell their shares

To date there is a limited trading market in our common stock on the Pink Sheets. Failure to develop or maintain an active trading market could negatively affect the value of our shares and make it difficult for our shareholders to sell their shares or recover any part of their investment in us. The market price of our common stock may be highly volatile. In addition to the uncertainties relating to our future operating performance and the profitability of our operations, factors such as variations in our interim financial results, or various, as yet unpredictable factors, many of which are beyond our control, may have a negative effect on the market price of our common stock.

Our stock price is likely to be volatile.

There is generally significant volatility in the market prices and limited liquidity of securities of early stage companies, and particularly of early stage medical product companies. Contributing to this volatility are various events that can affect our stock price in a positive or negative manner. These events include, but are not limited to: governmental approvals, refusals to approve, regulations or actions; market acceptance and sales growth of our products; litigation involving the Company or our industry; developments or disputes concerning our patents or other proprietary rights; changes in the structure of healthcare payment systems; departure of key personnel; future sales of our securities; fluctuations in our financial results or those of companies that are perceived to be similar to us; investors’ general perception of us; and general economic, industry and market conditions. If any of these events occur, it could cause our stock price to fall.

Future sales by shareholders, or the perception that such sales may occur, may depress the price of our common stock.

The sale or availability for sale of substantial amounts of our shares in the public market, including shares issuable upon conversion of outstanding preferred stock or exercise of warrants and options, or the perception that such sales could occur, could adversely affect the market price of our common stock and also could impair our ability to raise capital through future offerings of our shares. As of March 31, 2009 and December 31, 2008, we had 49,691,124 and 36,778,611 outstanding shares of common stock , respectively .

In March 2009 one of the members of the Board of Directors converted 95,000 shares of the Company’s Series A Preferred Stock into 10,857,142 shares of the Company’s common stock. The board member acquired the Company’s Series A Preferred Stock from UTEK in February 2009. The Series A Preferred Stock conversion was based on the Company’s common stock’s average closing price for the ten trading days before the date of conversion. The following additional shares were reserved as of December 31, 2008 for issuance: 3,533,321 shares upon exercise of outstanding options and 2,075,700 shares upon exercise of outstanding warrants. Any decline in the price of our common stock may encourage short sales, which could place further downward pressure on the price of our common stock and may impair our ability to raise additional capital through the sale of equity securities.

ITEM 1A. RISK FACTORS. - continued

RISKS RELATED TO OUR COMMON STOCK - continued

Our controlling shareholders may exercise significant control over us.

As of March 31, 2009, our directors, executive officers and principal shareholders beneficially owned approximately 57.7% of the outstanding shares of our common stock. Our shareholders do not have cumulative voting rights with respect to the election of directors. If our principal shareholders vote together, they could effectively elect all of our directors.

The issuance of shares upon exercise of derivative securities may cause immediate and substantial dilution to our existing shareholders.

The issuance of shares upon the exercise of warrants and options may result in substantial dilution to the interests of other shareholders since these selling shareholders may ultimately convert or exercise and sell all or a portion of the full amount issuable upon exercise. If all derivative securities were converted or exercised into shares of common stock, there would be an approximate additional 6,000,000 shares of common stock outstanding as a result. The issuance of these shares will have the effect of further diluting the proportionate equity interest and voting power of holders of our common stock.

We do not expect to pay any dividends for the foreseeable future.

We do not anticipate paying any dividends to our shareholders for the foreseeable future. The terms of certain of our outstanding indebtedness substantially restrict the ability of us to pay dividends. Accordingly, shareholders must be prepared to rely on sales of their common stock after price appreciation to earn an investment return, which may never occur. Any determination to pay dividends in the future will be made at the discretion of our Board of Directors and will depend on our results of operations, financial conditions, contractual restrictions, restrictions imposed by applicable law and other factors our Board deems relevant.

Our common stock is subject to the “Penny Stock” rules of the SEC and the trading market in our securities is limited, which makes transactions in our common stock cumbersome and may reduce the value of an investment in our stock.

The Securities and Exchange Commission has adopted Rule 3a51-1 which establishes the definition of a "penny stock," for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, Rule 15g-9 requires that a broker or dealer approve a person's account for transactions in penny stocks; and the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

In order to approve a person's account for transactions in penny stocks, the broker or dealer must obtain financial information and investment experience objectives of the person; and make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form:

	·	sets forth the basis on which the broker or dealer made the suitability determination; and

	·	that the broker or dealer received a signed, written agreement from the investor prior to the transaction.

Generally, brokers may be less willing to execute transactions in securities subject to the "penny stock" rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our stock.

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

ITEM 2. FINANCIAL INFORMATION.

Management’s Discussion and Analysis of Financial Condition and Results of Operation

Results of Operations – March 31, 2009 Compared to March 31, 2008

The following table sets forth information from our statements of operations for the three months ended March 31, 2009 and 2008.

	Three Months Ended March 31, 2009			Three Months Ended March 31, 2008
Revenues	$	60,975			$	32,335
Cost of goods sold		21,836				17,537
Gross profit		39,139				14,798
Operating expenses		610,824				1,466,738
Operating loss		(571,685	)			(1,451,940	)
Non-operating expenses		(606,944	)			-
Interest expense		(181,870	)			(16,076	)
Net income (loss)	$	(1,360,499	)		$	(1,468,016	)

Details related to Revenues and Cost of Goods Sold for the three months ended March 31, 2009 and 2008.

	Three Months Ended March 31, 2009		Three Months Ended March 31, 2008
Revenues
Stable Isotopes	$	7,875		$	32,335
F-18		53,100			-
Total Revenue	$	60,975		$	32,335

Cost of Goods Sold
Stable Isotopes	$	6,500		$	17,537
F-18		15,336			-
Total Cost of Goods Sold	$	21,836		$	17,537

Revenue

Revenue was $60,975 for the three months ended March 31, 2009 and $32,335 for the three months ended March 31, 2008. During 2007 we began our stable isotope marketing program which was acquired through the purchase of the Life Science division of Isonics, Inc. During the three months ended March 31, 2008, we continued the stable isotope marketing program generating all of the $32,335 revenues for that period compared to $7,875 of the three months ended March 31, 2009 revenues attributable to stable isotopes. In July 2008 we established our linear accelerator production center and began the production and marketing of F-18 in August 2008, accounting for $53,100 of the total three months ended March 31, 2009 revenues.

Cost of Goods Sold

Cost of Goods Sold for the three months ended March 31, 2009 was $21,836. Cost of goods sold for the three months ended March 31, 2008 was $17,537. The cost of goods sold of $17,537 for the three months ended March 31, 2008, 54.2% of revenues, was our cost of the stable isotopes included in revenues. The $21,836 cost of goods sold for the three months ended March 31, 2009 consists of $6,500, 82.5% of associated revenues for stable isotopes and $15,336, 28.9% of associated revenues, was our costs for the F-18 production (consisting mostly of supplies). The reason for the increase in the cost of goods sold percentage from the three months ended March 31, 2008 (54.2%) to the three months ended March 31, 2009 (82.5%) for stable isotopes was due to a reduction in sales price for stable isotopes we were able to obtain. We have worked with our supplier in an attempt to reduce our costs for stable isotopes in an effort to keep the cost of goods sold in line with available pricing for the product.

ITEM 2. FINANCIAL INFORMATION. - continued

Results of Operations - continued

Operating Expenses

Operating expenses for the three months ended March 31, 2009 and 2008 was $610,824 and $1,466,738 respectively. The decrease in operating expenses from 2008 to 2009 can be attributed largely to amortization of licenses and intangible assets ($6,250 for the three months ended March 31, 2009 versus $310,740 for the three months ended March 31, 2008), professional fees ($169,687 for the three months ended March 31, 2009 versus $252,433 for the three months ended March 31, 2008), stock options granted ($87,236 for the three months ended March 31, 2009 versus $638,628 for the three months ended March 31, 2008) and payroll expense ($100,129 for the three months ended March 31, 2009 versus $140,924 for the three months ended March 31, 2008) and an increase in depreciation ($134,418 for the three months ended March 31, 2009 versus $9,562 for the three months ended March 31, 2008).

	Three Months Ended March 31, 2009		Three Months Ended March 31, 2008
Depreciation and amortization expense	$	140,668	$	320,302

Professional fees		169,687		252,433
Stock options granted		87,236		638,628
Payroll expenses		100,129		140,924
General and administrative expenses		112,939		106,753
Sales and marketing expense		165		7,698
	$	610,824	$	1,466,738

Non-Operating Expense

Non operating expense for the three months ended March 31, 2009 and 2008 was $788,814 and $16,076, respectively. The increase in non-operating loss is due to an increase in interest expense ($181,870 for the three months ended March 31, 2009 versus $16,076 for the three months ended March 31, 2008), and loss on settlement of debt ($606,944 for the three months ended March 31, 2009 versus $0 for the three months ended March 31, 2008).

Net Loss

Our net loss for the three months ended March 31, 2009 and 2008 was $1,360,499, and $1,468,016, respectively.

Results of Operations - December 31, 2008 Compared to December 31, 2007

The following table sets forth information from our statements of operations for the years ended December 31, 2008 and 2007.

	Year Ended December 31, 2008			Year Ended December 31, 2007
Revenues	$	268,242		$	130,055
Cost of goods sold		155,457			55,841
Gross profit		112,785			74,214
Operating expenses		6,052,087			2,664,621
Operating loss		(5,939,302	)		(2,590,407	)
Non-operating expenses		-			(40,000	)
Interest expense		(219,453	)		(238,984	)
Net income (loss)	$	(6,158,755	)	$	(2,869,391	)

Revenue

Revenue was $268,242 for the twelve months ended December 31, 2008. During 2007, beginning in August, we began our stable isotope marketing program which was complemented by the purchase of the Life Science division of Isonics, Inc. During 2008, we continued the stable isotope marketing program generating $191,742 of total 2008 revenues. We also established our linear accelerator production center and began the production and marketing of F-18 in August 2008, accounting for $76,500 of the total 2008 revenues.

Cost of Goods Sold

Cost of Goods Sold for the twelve months ended December 31, 2008 was $155,457. Cost of goods sold for our fiscal year ended December 31, 2007 was $55,841. The cost of goods sold of $55,841 for 2007, 42.9% of revenues, was our cost of the stable isotopes included in revenues. The $155,457 cost of goods sold for 2008 consists of $116,402, 60.7% of revenues, for stable isotopes and $39,055, 51.1% of revenues, was our costs for the F-18 production (consisting mostly of supplies). The reason for the increase in the cost of goods sold percentage from 2007 (42.9%) to 2008 (60.7%) for stable isotopes was due to a reduction in sales price for stable isotopes we were able to obtain. We have worked with our supplier in an attempt to reduce our costs for stable isotopes in an effort to keep the cost of goods sold in line with available pricing for the product.

Operating Expenses

Operating expenses for the twelve months ended December 31, 2008 and 2007 was $6,052,087 and $2,664,621, respectively. The increase in operating expenses from 2007 to 2008 can be attributed largely to depreciation and amortization of licenses, fixed assets and intangible assets ($1,531,214 for the year ended December 31, 2007 versus $1,135,841 for the year ended December 31, 2007), write off of the net unamortized balance of impaired assets ($903,535 for the year ended December 31, 2008 versus $0.00 for the year ended December 31, 2007), professional fees ($1,281,557 for the year ended December 31, 2008 versus $607,379 for the year ended December 31, 2007), stock options granted ($1,211,392 for the year ended December 31, 2008 versus $592,447 for the year ended December 31, 2007) and additional payroll expense ($574,228 for the year ended December 31, 2008 versus $197,557 for the year ended December 31, 2007).

ITEM 2. FINANCIAL INFORMATION. - continued

Results of Operations - continued

	Year Ended December 31, 2008		Year Ended December 31, 2007
Depreciation and amortization expense	$	1,531,214	$	1,135,841
Impairment expense		903,535		-
Professional fees		1,281,557		607,379
Stock options granted		1,211,392		592,447
Payroll expenses		574,228		197,557
General and administrative expenses		510,813		129,012
Sales and marketing expense		39,348		2,385
	$	6,052,087	$	2,664,621

Net Loss

Our net loss for the year ended December 31, 2008 and 2007 was $6,158,755 and $2,869,391, respectively, as a result of the above-mentioned factors.

Liquidity and Capital Resources

Quarter Ended March 31, 2009

At March 31, 2009, we had negative working capital of $2,969,687, as compared to $6,278,593 at December 31, 2008. During the three months ended March 31, 2009 we had positive cash flow of 134,539 compared with an increase of $340,358 for the three months ended March 31, 2008. During the three months ended March 31, 2009 we used $168,680 of cash in operations compared with a use of $371,622 in the first three months of 2008, due primarily to a higher net loss in 2008. We expended $598 for investing activities in the first quarter of 2009 as compared to $1,203,427 used in 2008, primarily to purchase fixed assets. In 2008, we used $829,800 to purchase an accelerator. In the first three months of 2009, we had proceeds from financing activities equal to $303,817 compared to proceeds of $1,860,899 from financing activities in the comparable period in 2008. Proceeds in the first quarter of 2008 included a $1,197,611 increase in proceeds from capital leases and a $420,280 increase in proceeds from the cash sales of our common shares. As of March 31, 2009, we had $0 commitments for capital expenditures.

Year Ended December 31, 2008

At December 31, 2008, we had negative working capital of $4,491,859, as compared to $3,373,417 at December 31, 2007, and $3,244,190 at December 31, 2006. During the twelve months ended December 31, 2008 we experienced negative cash flow from operations of $1,543,998, and we expended $1,710,590 for investing activities while adding $3,286,711 from financing activities. As of December 31, 2008, we had $150,000 commitments for capital expenditures.

Net cash used for operating activities in 2008 was 1,543,998 compared to 312,978 in 2007. The $1,231,020 increase in cash used was a result of a net loss that was $3,298,364 higher in 2009 partially offset by higher non-cash expenses included in the 2008 net loss, primarily $1,211,392 for common stock issued for services in 2008, an increase of $1,093,072 compared against $118,320 in 2007 and $903,535 for the impairment of intangible assets in 2008. In 2008, our management concluded the patent license for the Neutron Generator was no longer of value to the Company and wrote off the net unamortized portion balance of $643,917 early. Further, in 2008, our management concluded the intangible assets acquired from Isonics were no longer of value and wrote off the total net unamortized portion balance of $259,618 early. The issues affecting the value and related writeoff of our intangible assets did not affect any of our fixed assets.

Net cash used in investing activities in 2008 increased $154,483 to $1,710,590 from $1,556,107 in 2007 as a result of an additional $788,639 used to purchase equipment in 2008, partially offset by cash used to buy intangible assets in 2007. In 2008, we used $829,800 to purchase an accelerator.

Net cash provided by financing activities in 2008 increased $1,377,474 to $3,286,711 from $1,909,237 in 2007. The increase was primarily a result of a $1,051,128 increase in proceeds from capital leases and a $477,281 increase in proceeds from the cash sales of our common shares, partially offset by an increase of $249,501 in principal payments on our capital leases.

We have generated material operating losses since inception. We have incurred a net loss of $11,761,268 from January 1, 2006 (inception) through March 31, 2009 , including a net loss of $1,360,499 for the three months ended March 31, 2009 . We expect to continue to experience net operating losses. Historically, we have relied upon outside investor funds to maintain our operations and develop our business. We anticipate raising additional capital within the next twelve months from investors for working capital as well as business expansion and we can provide no assurance that additional investor funds will be available on terms acceptable to us. If we are unable to obtain additional financing to meet our working capital requirements, we may have to curtail our business.

Based on the current cash run rate, approximately $1,000,000 will be needed to fund operations for an additional year. As disclosed in the risk factors, we are presently taking steps to raise additional funds to continue operations for the next 12 months and beyond. We will need to raise an additional $10,000,000 in the next year to develop three isotope manufacturing centers and complete our aggressive growth plans. We may, however, choose to modify our growth and operating plans to the extent of available funding, if any.

The recent economic events, including the substantial decline in global capital markets, as well as the lack of liquidity in the capital markets, could impact our ability to obtain financing and our ability to execute our business plan. Although market conditions have deteriorated, we believe healthcare institutions will continue to purchase the medical solutions that we distribute. As a development stage company with modest sales from our inception, we are unable to determine the effect of the recent economic crises on our sales.

ITEM 2. FINANCIAL INFORMATION. - continued

Contractual Obligations (payments due by period)

Contractual Obligation	Total Payments Due		Less than 1 Year		1-3 Years		3-5 Years		More than 5 Years
Capital Lease Obligation	$	2,138,852	$	352,118	$	1,213,149	$	573,585	$	-
Production center lease		185,497		46,872		138,625		-		-
Corporate office lease		86,041		60,736		25,305		-		-
License agreement with Regents of the University of California		335,000		25,000		70,000		180,000		60,000
Total	$	2,745,390	$	484,726	$	1,447,079	$	753,585	$	60,000

The capital lease obligations represent two lease agreements for $1,875,000 and $631,000, secured by equipment and personal guarantee of two of the major shareholders we obtained during September 2007. The purpose of the lease agreements is to acquire a Pulsar 10.5 PET Isotope Production System for a contracted amount of $1,875,000 plus ancillary equipment and facility for $631,000.

For the year ended December 31, 2007, we had a long term liability of $581,630 compared to a long term liability of $0 for the year ended December 31, 2006. The long term liability is related to two capital lease obligations we obtained in September 2007 that are secured by equipment and the personal guarantee of the two major shareholders. The lease allowed the company to acquire a Pulsar 7 PET Isotope Production System and ancillary equipment.

We began renting office and warehouse space effective August 1, 2007, located in Kennewick, Washington from a non-affiliated shareholder. The lease agreement calls for monthly rental payments starting at $3,500, increasing every August 1st until they become $4,762 as of August 1, 2011. During the year ended December 31, 2008 the Company incurred rent expenses for this facility totaling $43,400. In addition, the lease agreement calls for the issuance of $187,500 in common stock valued at $.40 per share for a total of 416,667 shares. The company recognized the issuance of all 416,667 shares in 2007 and will amortize the $187,500 value of that stock over the sixty month term of the lease. For the twelve months ended December 31, 2008 and the twelve months ended December 31, 2007 the Company amortized $37,500 and $15,625, respectively, of this stock issuance and recognized it as rent expense.

Future minimum rental payments required under the Company’s current rental agreement in excess of one year as of December 31, 2008, are as follows:

Twelve months ended December 31, 2009	$	46,872
Twelve months ended December 31, 2010		50,622
Twelve months ended December 31, 2011		54,671
Twelve months ended December 31, 2012		33,332
Total	$	185,497

Additionally, in June 2008, the Company entered into a twelve month lease for its corporate offices with three four month options to renew, but in no event will the lease extend beyond May 31, 2010. The lease agreement calls for monthly rental payments of $5,061 per month. During the twelve months ended December 31, 2008 the Company incurred rent expenses for this facility totaling $31,708. Future minimum rental payments required under the Company’s current rental agreement in excess of one year as of December 31, 2008, are as follows:

Twelve months ended December 31, 2009	$	60,736
Twelve months ended December 31, 2010		25,305
Twelve months ended December 31, 2011		-
Twelve months ended December 31, 2012		-
Total	$	86,041

ITEM 2. FINANCIAL INFORMATION. - continued

Off-Balance Sheet Arrangements

The Company does not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, results of operations, liquidity or capital expenditures.

Recent Accounting Pronouncements

In February 2006, the FASB issued SFAS No. 155 "Accounting for Certain Hybrid Financial Instruments-an amendment of FASB Statements No. 133 and 140" ("FAS 155"). FAS 155 addresses the following: a) permits fair value re-measurement for any hybrid financial instrument that contains an embedded derivative that otherwise would require bifurcation; b) clarifies which interest-only strips and principal-only strips are not subject to the requirements of Statement 133; c) establishes a requirement to evaluate interests in securitized financial assets to identify interests that are freestanding derivatives or that are hybrid financial instruments that contain an embedded derivative requiring bifurcation; d) clarifies that concentrations of credit risk in the form of subordination are not embedded derivatives; and e) amends Statement 140 to eliminate the prohibition on a qualifying special-purpose entity from holding a derivative financial instrument that pertains to a beneficial interest other than another derivative financial instrument. SFAS 155 is effective for all financial instruments acquired or issued after the beginning of an entity's first fiscal year that begins after September 15, 2006. Adoption of this standard did not have a material impact on the Company’s financial statements.

In March 2006, the FASB issued SFAS 156 - "Accounting for Servicing of Financial Assets - an amendment of FASB Statement No. 140" ("SFAS 156"). SFAS 156 is effective for the first fiscal year beginning after September 15, 2006. SFAS 156 changes the way entities account for servicing assets and obligations associated with financial assets acquired or disposed of. Adoption of this standard did not have a material impact on the Company’s financial statements.

In July 2006, the Financial Accounting Standards Board issued Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - an Interpretation of FASB Statement No. 109" (the "Interpretation"). The Interpretation establishes for all entities a minimum threshold for financial statement recognition of the benefit of tax positions, and requires certain expanded disclosures. The Interpretation is effective for fiscal years beginning after December 31, 2006, and is to be applied to all open tax years as of the date of effectiveness. Adoption of this standard did not have a material impact on the Company’s financial statements.

In September 2006, the FASB issued Statement of Financial Accounting Standard No. 157, "Fair Value Measurements" (“SFAS 157”). This statement defines fair value, establishes a fair value hierarchy to be used in generally accepted accounting principles and expands disclosures about fair value measurements. Although this statement does not require any new fair value measurements, the application could change current practice. The statement is effective for fiscal years beginning after November 15, 2007. Adoption of this standard did not have a material impact on the Company’s financial statements.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Liabilities" ("SFAS No. 159"). SFAS No. 159 provides companies with an option to report selected financial assets and liabilities at fair value, and establishes presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. The new guidance is effective for fiscal years beginning after November 15, 2007. Adoption of this standard did not have a material impact on the Company’s financial statements.

In September 2006, the staff of the Securities and Exchange Commission issued SAB No. 108 which provides interpretive guidance on how the effects of the carryover or reversal of prior year misstatements should be considered in quantifying a current year misstatement. SAB 108 becomes effective in fiscal 2007. Adoption of this standard did not have a material impact on the Company’s financial statements.

In December 2006, the FASB approved FASB Staff Position (FSP) No. EITF 00-19-2, "Accounting for Registration Payment Arrangements" ("FSP EITF 00-19-2"), which specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement, whether issued as a separate agreement or included as a provision of a financial instrument or other agreement, should be separately recognized and measured in accordance with SFAS No. 5, "Accounting for Contingencies". FSP EITF 00-19-2 also requires additional disclosure regarding the nature of any registration payment arrangements, alternative settlement methods, the maximum potential amount of consideration and the current carrying amount of the liability, if any. The guidance in FSP EITF 00-19-2 amends FASB Statements No. 133, "Accounting for Derivative Instruments and Hedging Activities", and No. 150, "Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity", and FASB Interpretation No. 45, "Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others", to include scope exceptions for registration payment arrangements.

ITEM 2. FINANCIAL INFORMATION. - continued

Recent Accounting Pronouncements - continued

FSP EITF 00-19-2 is effective immediately for registration payment arrangements and the financial instruments subject to those arrangements that are entered into or modified subsequent to the issuance date of this FSP, or for financial statements issued for fiscal years beginning after December 15, 2006, and interim periods within those fiscal years, for registration payment arrangements entered into prior to the issuance date of this FSP. Adoption of this standard did not have a material impact on the Company’s financial statements.

Quantitative and Qualitative Disclosures about Market Risk

We have not entered into any derivative contracts.

Principal Accounting Policies

Use of estimates

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fixed Assets

Fixed assets are carried at the lower of cost or net realizable value. Production equipment with a cost of $2,500 or greater and other fixed assets with a cost of $1,500 or greater are capitalized. Major betterments that extend the useful lives of assets are also capitalized. Normal maintenance and repairs are charged to expense as incurred. When assets are sold or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is recognized in operations.

Depreciation is computed using the straight-line method over the following estimated useful lives. Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset.

Management of the Company periodically reviews the net carrying value of all of its equipment on an asset by asset basis. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down. Although management has made its best estimate of the factors that affect the carrying value based on current conditions, it is reasonably possible that changes could occur which could adversely affect management’s estimate of net cash flows expected to be generated from its assets, and necessitate asset impairment write-downs.

License Fees

License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets. The Company periodically reviews the carrying values of patents in accordance with SFAS No. 144 and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value.

Intangible Assets

Intangible assets resulted from the purchase, for cash, from Isonics Corporation, the rights to intellectual property related to the production of isotopes, customer lists, contracts and agreements with third party companies, and certain equipment. The Company allocated the purchase price to each of the assets based upon the Companies believe of the long term value of each of those assets and comparison to replacement cost, where that information was available. Intangible assets are stated at cost, less accumulated amortization. Amortization of intangible assets is computed using the straight-line method over the estimated economic useful life of the assets. The Company periodically reviews the carrying values of intangible assets in accordance with SFAS No. 144 and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value.

ITEM 2. FINANCIAL INFORMATION. - continued

Revenue Recognition

The Company applies the provision of SEC Staff Accounting Board (“SAB”) No. 104, Revenue Recognition. SAB No. 104, which supersedes SAB No. 101, Revenue Recognition in Financial Statements, provides guidance on the recognition, presentation and disclosure of revenue in financial statements. SAB No. 104 outlines the basic criteria that must be met to recognize revenue and provides guidance for the disclosure of revenue recognition policies. The Company recognized revenue related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or determinable, and (iv) collectability is reasonably assured.

The Company recognizes revenue once an order has been received and shipped to the customer. Prepayments, if any, received from customers prior to the time products are shipped are recorded as deferred revenue. In these cases, when the related products are shipped, the amount recorded as deferred revenue is recognized as revenue. The Company does not accrue for sales returns and other allowances as it has not experienced any returns or other allowances.

Research and Development Costs

Research and developments costs, including salaries, research materials, administrative expenses and contractor fees, are charged to operations as incurred. The cost of equipment used in research and development activities which has alternative uses is capitalized as part of fixed assets and not treated as an expense in the period acquired. Depreciation of capitalized equipment used to perform research and development is classified as research and development expense in the year computed.

Fair value of financial instruments

The carrying amounts of cash, receivables and accrued liabilities approximate fair value due to the short-term maturity of the instruments.

Stock-based compensation

Effective January 1, 2006, the Company adopted SFAS No. 123 (Revised 2004), Share-Based Payment, which requires that compensation related to all stock-based awards, including stock options, be recognized in the financial statements based on their estimated grant-date fair value. The Company has estimated expected forfeitures, as required by SFAS No. 123R, and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.

ITEM 3. DESCRIPTION OF PROPERTY.

On July 17, 2007, the Company entered into a lease at 6211 West Okanogan Avenue, Kennewick Washington, 99336 (“the premises”) to be used as the company’s production center. The term of the lease was five years and it commenced on August 1, 2007. Monthly rent for the first year of tenancy was $3,500. Under the terms of the lease, the monthly rent would increase 8 percent each year so that monthly rent for the year beginning August 1, 2008 was $3,780, monthly rent for the year beginning August 1, 2009 will be $4,092. The landlord of this space is a shareholder of the company, though one that holds less than 5 percent of the total outstanding shares.

ITEM 4. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

A. Security ownership of certain beneficial owners.

The following table sets forth, as of March 31 2009, the number of shares of Common Stock owned of record and beneficially by executive officers, directors and persons who hold 5% or more of the outstanding Common Stock of the Company. As of March 31, 2009, there were 49,666,124 shares outstanding.

Name and Address	Amount and Nature of Beneficial Ownership (1)		Percentage of Class
James C. Katzaroff, CEO and Chairman		7,419,002		14.8
L. Bruce Jolliff, CFO		550,000		1.1
Carlton Cadwell, Director		18,420,145		37.0

All Officers and Directors as a group (5 individuals)		29,414,147		52.1


* less than 1 percent

(1)

In determining beneficial ownership of our common stock as of a given date, the number of shares shown includes shares of common stock which may be acquired on exercise of warrants or options or conversion of convertible securities within 60 days of that date. In determining the percent of common stock owned by a person or entity on March 31, 2009, (a) the numerator is the number of shares of the class beneficially owned by such person or entity, including shares which may be acquired within 60 days on exercise of warrants or options and conversion of convertible securities, and (b) the denominator is the sum of (i) the total shares of common stock outstanding on March 31, 2009, and (ii) the total number of shares that the beneficial owner may acquire upon conversion of the preferred and on exercise of the warrants and options. Unless otherwise stated, each beneficial owner has sole power to vote and dispose of its shares. Beneficial ownership of shares includes 350,000 options currently exercisable by James C. Katzaroff and 550,000 options currently exercisable by L. Bruce Jolliff and 100,000 options currently exercisable by Carlton Cadwell.

ITEM 5. DIRECTORS AND EXECUTIVE OFFICERS.

Our officers and directors and additional information concerning them are as follows:

NAME	AGE	POSITION
James C. Katzaroff	51	CEO and Chairman
L. Bruce Jolliff	58	Chief Financial Officer
Carlton Cadwell	64	Director

James C. Katzaroff, Chief Executive Officer and Chairman

James C. Katzaroff is the founder of Advanced Medical Isotope Corporation. Initially a financial consultant with Wall Street firms Bateman Eichler, Smith Barney and EF Hutton, Mr. Katzaroff has been responsible for senior-level corporate strategy, fostering investment banking relationships, and served as a senior financial advisor for numerous start-ups and development-stage companies. From 1998 to 2001, Mr. Katzaroff held senior positions including Chief Financial Officer, Senior Vice President of Finance, Senior Vice President, and Corporate Secretary of Telemac Corporation, an international communications company active in the wireless telephony market. In 2001 he became Chairman and CEO of Apogee Biometrics, and in 2004 became President of Manakoa Services Corporation, currently serving as its interim CEO. He holds a Bachelor’s Degree in Business Economics from the University of California, Santa Barbara, and has completed advanced management courses at the University of Washington.

Leonard Bruce Jolliff, Chief Financial Officer

Mr. Jolliff joined Advanced Medical Corporation as chief financial officer in 2006. For nine years prior to joining the Company, Mr. Jolliff was a sole practitioner in the role of CFO for Hire and as a Forensic Accountant, working with companies ranging from Fortune 500 to small family operations. Mr. Jolliff is a CPA and a member of the Washington Society of CPAs. He is also a CFE and a member of the Association of Certified Fraud Examiners. Mr. Jolliff has held CFO and Controller positions in an array of industries and has worked as a CPA in public practice.

Carl Cadwell, Director

Dr. Cadwell joined Advanced Medical Corporation as a director in 2006. Dr. Cadwell brings over 30 years of experience in business management, strategic planning, and implementation. He co-founded Cadwell Laboratories, Inc. in 1979 and has served as its President since its inception. Cadwell Laboratories, Inc. is a major provider of neurodiagnostic medical devices and is the parent company of QuickMed, Inc., an electronic medical records company. After receiving his bachelor’s degree from the University of Oregon in 1966 and a doctoral degree from the University of Washington in 1970, he began his career serving in the United States Army as a dentist for 3 years. From 1973 to 1980, Dr. Cadwell practiced dentistry in private practice and started several businesses.

Dr. Michael Korenko, Director

For the past three years Dr. Korenko has performed as the Business Development Manager for the Curtiss-Wright Electro-Mechanical Corporation. His responsibilities have been for the business development, technology transfer, joint ventures, teaming agreements and acquisitions in the Western United States and Canada. Previously Dr. Korenko, for five years, was the Chief Operating Officer for Curtiss-Wright Electro-Mechanical Corporation. His responsibilities were for internal operations of a $190 million engineering/manufacturing business in the utility and defense business sectors. Dr. Korenko was the Westinghouse Vice President in charge of the 300 and 400 areas, including the Fast Flux Testing Facility (FFTF) and all the engineering, safety analysis, and projects for the Hanford site. He was also the Executive Vice President of Closure for Safe Sites of Colorado at Rocky Flats. Dr. Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defense, reporting to Secretary Cap Weinberger. Mike Korenko currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year. Most relevant to AMIC, Dr. Korenko is the co-inventor with AMIC Chief Science Officer Dr. Robert Schenter, of a patent-pending process converting nuclear waste into medical isotopes.

William E. Root resigned, effective May 12, 2009, as one of our directors citing constraints upon his availability to continue to serve as a director. On May 12, 2009, the Board of Directors of the Company appointed Dr. Michael Korenko to its Board of Directors to the Board to fill the vacancy created by the resignation of Mr. Root. Dr. Korenko will serve a term expiring at the next annual meeting or until his successor is elected and qualified. Upon Dr. Korenko’s acceptance of the appointment, the Company granted Dr. Korenko a three-year option to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.26 per share.

ITEM 5. DIRECTORS AND EXECUTIVE OFFICERS. - continued

B. Significant Employees.

Fu-Min Su, Chief Radiochemist

Fu Min Su, Ph.D., was appointed AMIC's Chief Radio-Chemist and Radiation Safety Officer in 2007. With over 20 years experience in medical isotope R&D and manufacture, Dr. Su is also knowledgeable in the area of coordinating and conducting clinical trials. He has worked as a senior scientist for a several bio-technology firms, including NeoRx Corporation from 1987 through 1998, Nycomed-Amersham Imaging in 1999, Bristol-Myers Squibb from 2000 to 2006, and Cellectar, LLC in 2007, during which time he developed various radiopharmaceuticals, isotope production methods and generator systems. Dr. Su has authored a number of scientific papers, and has written numerous abstracts for the Journal of Nuclear Medicine. He also holds several patents relating to radionuclide production and preparation. Dr. Su received his Ph.D. from the University of Washington.

C. Family Relationships. None.

D. Involvement in Certain Legal Proceedings.

There have been no events under any bankruptcy act, no criminal proceedings and no judgments, injunctions, orders or decrees material to the evaluation of the ability and integrity of any director, executive officer, promoter or control person of Registrant during the past five years.

E. Committees

The Board of Directors acts as the Audit Committee and the Board has no separate committees. The Company has no qualified financial expert sitting on the Board at this time because it has not been able to hire a qualified candidate. Further, the Company believes that it has inadequate financial resources at this time to hire such an expert. The Company intends to continue to search for a qualified individual for hire.

ITEM 6. EXECUTIVE COMPENSATION.

Equity Compensation, Pension or Retirement Plans

No retirement, pension, profit sharing, stock option or insurance programs or other similar programs have been adopted by the Company for the benefit of its employees.

ITEM 6. EXECUTIVE COMPENSATION. - continued

Executive Compensation

The following table sets forth information concerning the total compensation that we have paid or that has accrued on behalf of our chief executive officer and other executive officers with annual compensation exceeding $100,000 during the years ended December 31, 2006, December 31, 2007 and December 31, 2008.

Summary Compensation Table

Name & Position	Year	Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensation ($)		Changes in Pension Value and Nonqualified Deferred Compensation Earnings ($)		All Other Compensation ($)		Total ($)
James C. Katzaroff,	2006	$	36,053	$	0	$	0	$	0	$	0	$	0	$	0	$	36,053
CEO and Chairman	2007	$	112,034	$	0	$	0	$	67,215	$	0	$	0	$	0	$	179,249
	2008	$	192,109	$	0	$	0	$	50,819	$	0	$	0	$	0	$	242,928
William J. Stokes,	2006	$	0	$	0	$	105,000	$	0	$	0	$	0	$	0	$	105,000
President (1)	2007	$	0	$	30,000	$	70,000	$	0	$	0	$	0	$	0	$	100,000
	2008	$	40,000	$	8,500	$	0	$	0	$	0	$	0	$	0	$	48,500
L. Bruce Jolliff,	2006	$	0	$	0	$	0	$	0	$	0	$	0	$	0		-
CFO (2)	2007	$	101,124	$	0	$		$	1,046,837	$	0	$	0	$	0	$	1,147,961
	2008	$	139,267	$	25,000	$	0	$	25,409	$	0	$	0	$	0	$	189,676
Fu-Min Su,	2006	$	0	$	0	$	0	$	0	$	0	$	0	$	0	$	0
Chief Radiochemist	2007	$	0	$	0	$	0	$	0	$	0	$	0	$	0	$	0
	2008	$	74,615	$	5,000	$	76,750	$	25,409	$	0	$	0	$	0	$	181,774

(1)

Mr. Stokes did not receive the compensation required by his employment agreement. The Board of Directors issued stock awards to Mr. Stokes in place of his salary. William J. Stokes resigned, effective May 21, 2009, as our President citing constraints upon his availability to continue to serve as an officer. Pursuant to his employment agreement, we are not liable for any severance payments to Mr. Stokes.

(2)

Mr. Jolliff received an additional $1,124 and $39,267 to compensate him for additional duties he performed that were not contemplated in his employment contract.

Narrative to Summary Compensation Table

We have employment agreements with L. Bruce Jolliff and Fu-Min Su that determine the compensation paid to each of them. Our Chief Executive Officer, James C. Katzaroff, does not have a written employment agreement and therefore no structured amount or schedule of pay so no accruals are made for his compensation. In 2007 and 2008, he received $112,034 and $192,109, respectively, in salary. During this period of limited liquidity for the Company the CEO has taken limited compensation. Through June 11, 2009, he has received only $37,500 in salary.

We paid bonuses to certain employees based on their performance, our need to retain such employees and funds available. All bonus payments were approved by our board of directors.

L. Bruce Jolliff

In August 2007, Mr. Jolliff signed an employment agreement with the Company and will receive a salary of $100,000 per year. He will also receive 1,500,000 options (500,000 options per year beginning in August 2008) to purchase the Company’s common stock at $0.50. The Company may terminate the agreement without cause at any time upon 30 days' written notice. Upon termination, the Company will pay Mr. Jolliff a severance allowance of two month's salary.

Dr. Fu Min-Su

In January 2008, the Company entered into a five-year employment agreement with Dr. Fu Min-Su pursuant to which the Company agreed to pay Dr. Fu Min-Su an annual salary equal to $90,000.

In the event the employment is terminated by the Company without cause, by Dr. Fu Min-Su for good reason or a change in control, the Company will have to provide Dr. Fu Min-Su with one month of his base salary and any portion of an annual bonus allocated by the Board of Directors, disability and other welfare plan benefits for a period of one year from the date of termination and pro-rated vesting of all outstanding options, stock grants, shares of restricted stock and any other equity incentive compensation; provided, that the stock options shall be exercisable only until the earlier to occur of (A) two years from the date of the termination, or (B) the date the option would have otherwise expired if Dr. Fu Min-Su had not terminated employment.

During the term of the employment agreement, including any extension thereof, and for a period of one year thereafter, Dr. Fu Min-Su shall not, provide services that he provides for the Company for a business in the production, import for resale, and distribution of radioisotopes for use in the medical industries.

ITEM 6. EXECUTIVE COMPENSATION. - continued

Options Granted to Named Executive Officers

During January 2007, the Company granted James C. Katzaroff an option to purchase an aggregate of 250,000 shares of the Company’s common stock at an exercise price of $.29 per share. The options are fully vested and expire January 23, 2010. The quoted market price of the common stock at the time of issuance of the options was $.27 per share.

During May 2007, the Company granted L. Bruce Jolliff an option to purchase an aggregate of 1,500,000 shares of the Company’s common stock at an exercise price of $.50 per share. The options vest at 500,000 shares May 2008, 500,000 shares May 2009, and 500,000 shares May 2010 and expire May 2012. The quoted market price of the common stock at the time of issuance of the options was $.70 per share.

During November 2008, the Company granted James C. Katzaroff an option to purchase 100,000 shares and L. Bruce Jolliff and option to purchase 50,000 shares of the Company’s common stock. All options issued in November 2008 have an exercise price of $.55 per share and are fully vested and expire on November 26, 2011. The quoted market price of the common stock at the time of issuance of the options was $.51 per share.

Outstanding Equity Awards

The following table sets forth all outstanding equity awards held by our Named Executive Officers as of the end of last fiscal year.

			Option Awards										Stock Awards
Name	Grant Date		Number of Securities Underlying Unexercised Options (#) Exercisable		Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)		Number of Securities Underlying Unexercised Options (#) Unexercisable		Option Exercise Price ($)		Option Expiration Date		Number of Shares or Units of Stock That Have Not Vested (#)		Market Value of Shares or Units of Stock That Have Not Vested ($)		Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)		Equity Incentive Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)
James C. Katzaroff		1-23-07		250,000		-		-	$	0.29		1-23-2010		-		-		-		-
		11-26-08		100,000		-		-	$	0.55		11-26-2011		-		-		-		-
L. Bruce Jolliff		5-16-07		500,000		-		1,000,000	$	0.50		5-16-2012		-		-		-		-
		11-26-08		50,000		-		-	$	0.55		11-26-2011		-		-		-		-
Fu-Min Su		11-26-08		50,000		-		-	$	0.55		11-26-2011		-		-		-		-

Equity Compensation, Pension or Retirement Plans

No retirement, pension, profit sharing, stock option or insurance programs or other similar programs have been adopted by the Company for the benefit of its employees.

Audit Committee

Presently, our Board of Directors is performing the duties that would normally be performed by an audit committee. We intend to form a separate audit committee, and plan to seek potential independent directors. In connection with our search, we plan to appoint an individual qualified as an audit committee financial expert.

OPTIONS/SARS GRANT

During January 2007, the Company granted its three board members, Carlton Cadwell, James C. Katzaroff and William E. Root, options to purchase an aggregate of 250,000 shares each of the Company’s common stock at an exercise price of $.29 per share. The options are fully vested and expire January 23, 2010. The quoted market price of the common stock at the time of issuance of the options was $.27 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $72,500 for each of the board members, for an aggregate of $217,500, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2007. The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		4.79	%
Dividend yield		0.00	%
Volatility factor		329.1	%
Weighted average expected life	3 years

ITEM 6. EXECUTIVE COMPENSATION. - continued

OPTIONS/SARS GRANT - continued

During April 2007, the Company granted a non-employee consultant options to purchase an aggregate of 100,000 shares of the Company’s common stock at an exercise price of $.50 per share. The options are fully vested and expire April 2010. The quoted market price of the common stock at the time of issuance of the options was $.85 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $50,000, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2007. The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		4.60	%
Dividend yield		0.00	%
Volatility factor		329.1	%
Weighted average expected life	3 years

During May 2007, the Company granted its Chief Financial Officer, L. Bruce Jolliff, options to purchase an aggregate of 1,500,000 shares of the Company’s common stock at an exercise price of $.50 per share. The options vest at 500,000 shares May 2008, 500,000 shares May 2009, and 500,000 shares May 2010 and expire May 2012. The quoted market price of the common stock at the time of issuance of the options was $.70 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $750,000, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2007 on a pro-rata bases of the months worked compared to the total of the vesting schedule. The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		4.67	%
Dividend yield		0.00	%
Volatility factor		257.3	%
Weighted average expected life	5 years

During April 2007, the Company appointed a local County Commissioner, past County Board of Supervisors, and past County Treasurer as the Chairman of its Government Affairs Advisory Board. In exchange for his local interaction with local government on our behalf we granted him options to purchase an aggregate of 100,000 shares of the Company’s common stock at an exercise price of $.50 per share. The options are fully vested and expire April 2010. The quoted market price of the common stock at the time of issuance of the options was $.85 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $50,000, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2007. The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		4.60	%
Dividend yield		0.00	%
Volatility factor		329.1	%
Weighted average expected life	3 years

ITEM 6. EXECUTIVE COMPENSATION. - continued

OPTIONS/SARS GRANT - continued

During December 2007, the Company granted the non-employee consultant acting as the Project Manager on the Company’s construction project, in accordance with the terms of his contract, options to purchase 122,400 shares of the Company’s common stock, at an exercise price of $.17 per share. The options are fully vested and expire December 31, 2012. The quoted market price of the common stock at the time of issuance of the options was $.72 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $87,975 and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2007. The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		3.49	%
Dividend yield		0.00	%
Volatility factor		257.3	%
Weighted average expected life	5 years

During February 2008, the Company granted a non-employee consultant, in exchange for banking and financing leads and opportunities, options to purchase 714,286 shares of the Company’s common stock, at an exercise price of $1.05 per share. The options are fully vested and expire February 12, 2009. The quoted market price of the common stock at the time of issuance of the options was $.65 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $461,827 and was recorded as stock-based compensation in the accompanying financial statements for the nine months ended September 30, 2008. The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		2.05	%
Dividend yield		0.00	%
Volatility factor		312.5	%
Weighted average expected life	1 year

During March 2008, the Company granted the non-employee consultant acting as the Project Manager on the Company’s construction project, in accordance with the terms of his contract, options to purchase 106,800 shares of the Company’s common stock, at an exercise price of $.17 per share. The options are fully vested and expire March 31, 2013. The quoted market price of the common stock at the time of issuance of the options was $.84 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $89,565 and was recorded as stock-based compensation in the accompanying financial statements for the nine months ended September 30, 2008. The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		2.48	%
Dividend yield		0.00	%
Volatility factor		257.3	%
Weighted average expected life	5 years

During June 2008, the Company granted the consultant acting as the non-employee Project Manager on the Company’s construction project, in accordance with the terms of his contract, options to purchase 39,600 shares of the Company’s common stock, at an exercise price of $.17 per share. The options are fully vested and expire June 30, 2013. The quoted market price of the common stock at the time of issuance of the options was $.69 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $27,276 and was recorded as stock-based compensation in the accompanying financial statements for the nine months ended September 30, 2008. The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		3.49	%
Dividend yield		0.00	%
Volatility factor		257.5	%
Weighted average expected life	5 years

ITEM 6. EXECUTIVE COMPENSATION. - continued

OPTIONS/SARS GRANT - continued

During July 2008, the Company granted a non-employee consultant, along with his appointment as the Chair of the Company’s Scientific Advisory Board, options to purchase 100,000 shares of the Company’s common stock, at an exercise price of $.50 per share. The options are fully vested and expire January 29, 2011. The quoted market price of the common stock at the time of issuance of the options was $.40 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $39,850 and was recorded as stock-based compensation in the accompanying financial statements for the nine months ended September 30, 2008. The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		2.87	%
Dividend yield		0.00	%
Volatility factor		337.6	%
Weighted average expected life	3 years

During November 2008, the Company granted stock options to the following:

Two board members, James C. Katzaroff and Carlton Cadwell, options to purchase an aggregate of 100,000 shares each and one board member, William E. Root, options to purchase an aggregate of 25,000 shares of the Company’s common stock. The fair value of the options totaled $50,819, $50,819, and $12,705, for an aggregate of $114,343, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

five non-executive employees options to purchase the following shares: 50,000, 25,000, 10,000, 10,000, and 5,000, for an aggregate of 100,000 shares of the Company’s common stock and our Chief Financial Officer, L. Bruce Jolliff, options to purchase 50,000 shares of the Company’s common stock. The fair value of the options totaled $25,409, $25,409, $12,705, $5,082, $5,082, and $2,541, for an aggregate of $76,228, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

non-employee consultant, in exchange for financial and marketing expertise options to purchase an aggregate of 25,000 shares of the Company’s common stock The fair value of the options totaled $12,705 and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

non-employee consultant, in exchange for his strategic business advice as an expert in our industry, options to purchase an aggregate of 75,000 shares of the Company’s common stock The fair value of the options totaled $38,114 and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

non-employee consultant, in exchange for marketing efforts, options to purchase an aggregate of 5,000 shares of the Company’s common stock The fair value of the options totaled $2,541 and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

All options issued in November 2008 have an exercise price of $.55 per share and are fully vested and expire on November 26, 2011. The quoted market price of the common stock at the time of issuance of the options was $.51 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		1.51	%
Dividend yield		0.00	%
Volatility factor		337.22	%
Weighted average expected life	3 years

ITEM 6. EXECUTIVE COMPENSATION. - continued

DIRECTOR COMPENSATION

Non-management directors received the following compensation:

Name		Fees earned or paid in cash ($)		Stock awards ($)		Option awards ($)		All other compensation ($)		Total ($)
	2006		-		-	$	17,500		-	$	17,500
Carlton Cadwell	2007		-			$	67,215		-	$	67,215
	2008		-			$	50,819		-	$	50,819
	2006		-			$	17,500		-	$	17,500
William E. Root	2007		-			$	67,215		-	$	67,215
	2008		-		-	$	12,705		-	$	12,705

William E. Root resigned, effective May 12, 2009, as one of our directors citing constraints upon his availability to continue to serve as a director.

During September 2006, the Company granted three board members options to purchase an aggregate of 250,000 shares each of the Company’s common stock and granted the Chief Executive Officer options to purchase 1,000,000 shares of the Company’s common stock, all at an exercise price of $.07 per share. The options are fully vested and expire September 1, 2009. The quoted market price of the common stock at the time of issuance of the options was $.07 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $17,500 for each of the board members and $70,000 for the CEO, for an aggregate of $122,500, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2006. All these were exercised in 2007.

During January 2007, the Company granted three board members options to purchase an aggregate of 250,000 shares each of the Company’s common stock at an exercise price of $.29 per share. The options are fully vested and expire January 23, 2010. The quoted market price of the common stock at the time of issuance of the options was $.27 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $67,215 for each of the board members, for an aggregate of $201,645, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2007.

During November 2008, the Company granted two board members options to purchase an aggregate of 100,000 shares each and one board member options to purchase an aggregate of $25,000 shares of the Company’s common stock at an exercise price of $.55 per share. The options are fully vested and expire November 26, 2011. The quoted market price of the common stock at the time of issuance of the options was $.51 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $50,819 for each of the two board members receiving 100,000 shares and $12,705 for the one board member receiving $25,000 shares for an aggregate of $114,343, and was recorded as stock-based compensation.

POTENTIAL CONFLICTS OF INTEREST

James C. Katzaroff, Chief Executive Officer and Chairman of the Board owns a substantial interest in Mirari Corporation (“Mirari”). The Company has had business dealing with Mirari. See Item 7 “CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS” below.

COMMITTEES OF THE BOARD OF DIRECTORS

We intend to appoint such persons to the Board of Directors and committees of the Board of Directors as are expected to be required to meet the corporate governance requirements imposed by a national securities exchange, although we are not required to comply with such requirements until we elect to seek listing on a securities exchange. We do not currently have any independent directors.

ITEM 7. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

James C. Katzaroff took part in founding and organizing the business of the Company and is a promoter of the Company as defined by Rule 405 of the Securities Act of 1933. James C. Katzaroff will not receive any compensation in connection with this registration statement. During the past five years, James C. Katzaroff received the salary, bonus and options disclosed in the Summary Compensation Table.

Indebtedness from related parties

In February and March of 2009, we received $22,800 from James C. Katzaroff for funds needed to meet operating expenses. The Company repaid $4,700 leaving a balance of $18,100 at March 31, 2009. There is no interest being charged on these loans.

We had a $200,000 revolving line of credit with Washington Trust Bank that was to expire in September 2009. We had $199,908 in borrowings under the line of credit as of October 28, 2008 at which time the line of credit was paid off and replaced with a loan from James C. Katzaroff and Carlton Cadwell. The loan calls for $4,066 monthly payments, including 8% interest, beginning November 30, 2008, with a balloon payment for the balance at October 31, 2009. There is no security held as collateral for this loan. As of December 31, 2008, all payments were current on this shareholder loan.

James C. Katzaroff, Chief Executive Officer and Chairman of the Board owns a substantial interest in Mirari. In 2006, the company purchased a note receivable of $28,500, from a non-related individual, due from Mirari, a Washington corporation, and an affiliate under common control. This amount was written off as an investment loss in 2006. Additionally, during the year 2006, we advanced funds on behalf of Mirari for rent and administrative costs in the amount of $33,000. This amount was written off as bad debt in 2006. It is management’s intention to acquire all the assets, which consists of certain intellectual property related to nuclear facilities, and common stock of Mirari during the year 2009. There have not been, however, any negotiations between us and Mirari.

In November 2006 the Company received $30,000 from an employee, who is not an officer, in the form of a loan and in April 2007 received another $50,000 from the same employee. The loan did not bear interest and was due on demand. In June 2007 the Company extinguished the $80,000 debt through the issuance of 160,000 shares of the Company’s common stock. The fair market value at the time was $.75, resulting in a $40,000 loss from extinguishment of debt. The employee, who was not an affiliate of any officer or principal shareholder of the Advanced Medical Isotope Corporation made the loan to help us with our liquidity.

Rent and other administrative expenses

The Company began renting office space located in Kennewick, Washington from Apogee Biometrics, Inc. (“ABI”), an affiliate under common control, in January 2006. Commencing January 1, 2006, the parties verbally agreed that the Company would make monthly rent payments of $3,500 on a month-to-month basis. In addition, the Company paid 36% of certain administrative expenses utilized by both parties. During the years ended December 31, 2007 and 2006 the Company incurred rent and administrative expenses to ABI totaling $15,147 and $59,500 respectively. The Company made payments to ABI totaling $15,147 and $59,500 during the years ended December 31, 2007 and 2006 respectively. The Company terminated the rental agreement with ABI.

ITEM 8. LEGAL PROCEEDINGS.

Presently, there are not any material pending legal proceedings to which the Registrant is a party or as to which any of its property is subject, and the Registrant does not know nor is it aware of any legal proceedings threatened or contemplated against it.

ITEM 9. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS.

(a) Market Information.

Our common stock has traded over-the-counter on the OTC Pink Sheets under the symbol “ADMD.PK” since May 2006. The following table sets forth the quarterly high and low bid information for our common stock for the period January 1, 2006 through December 31, 2008:

	High Bid		Low Bid
Fiscal Year Ended December 31, 2006

First Fiscal Quarter	$	.01	$	.0001
Second Fiscal Quarter		.35		.0030
Third Fiscal Quarter		.26		.0500
Fourth Fiscal Quarter		.24		.1100

Fiscal Year Ended December 31, 2007

First Fiscal Quarter	$	1.04	$	0.10
Second Fiscal Quarter		0.98		0.64
Third Fiscal Quarter		0.87		0.39
Fourth Fiscal Quarter		0.50		0.40

Fiscal Year Ended December 31, 2008

First Fiscal Quarter	$	0.84	$	0.56
Second Fiscal Quarter		0.89		0.44
Third Fiscal Quarter		0.78		0.35
Fourth Fiscal Quarter		0.72		0.26

ITEM 9. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS. - continued

Holders

As of March 31, 2009 there were 49,666,124 shares of common stock outstanding and approximately 135 stockholders of record.

Transfer Agent and Registrar

Our transfer agent is American Registrar & Transfer Co., 342 East 900 South, Salt Lake City, UT 84111; telephone (801) 363-9065.

Dividend Policy

We have not paid any cash dividends on our common stock to date and do not anticipate we will pay dividends in the foreseeable future. The payment of dividends in the future will be contingent upon revenues and earnings, if any, capital requirements, and our general financial condition. The payment of any dividends will be within the discretion of the then Board of Directors. It is the present intention of the Board of Directors to retain all earnings, if any, for use in the business operations. Accordingly, the Board does not anticipate declaring any dividends in the foreseeable future.

Warrants, Options and Convertible Debt

There are no outstanding options or warrants that would entitle any person to purchase our preferred stock. Currently, there are outstanding options and warrants to purchase shares of our common stock. We currently do not have any compensation plan under which equity securities are authorized for issuance.

ITEM 10. RECENT SALES OF UNREGISTERED SECURITIES.

Set forth below is information regarding the issuance and sales of our securities without registration for the past three (3) years from the date of this Registration Statement. No such sales involved the use of an underwriter, no advertising or public solicitation were involved, and no commissions were paid in connection with the sale of any securities.

Preferred Stock

On September 26, 2006, we issued 95,000 shares of Series A preferred stock to UTEK Corporation in connection with our acquisition of Neu-Hope Technologies, Inc.

On September 26, 2006, we issued 5,000 shares of Series A preferred stock to Aware Capital Corporation in connection with our acquisition of Neu-Hope Technologies, Inc.

Common Stock

The below shares of common stock were sold or issued primarily pursuant to an exemption from registration under Section 4(2) of the Securities Act. These shares of common stock are restricted securities and may not be resold for a period of up to one year from the date of the acquisition. Once we have been subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act for a period of 90 days and if we have filed all of our required reports under such act at the time of sale, the applicable holding period will be shortened to six months, assuming that other requirements of Rule 144 of the Securities Act are met, or unless sold or transferred in transactions that are exempt under applicable federal and state securities laws or pursuant to registration thereunder.

Names/Identities of Persons to whom Securities Issued	Issue Date	Amount of Shares Issued		Price of Shares		Aggregate Value of Securities Issued ($)		Purpose of Issuance
Consultant	May 2006		600,000	$	0.20	$	120,000	Consulting services
William J. Stokes	August 2006		1,500,000	$	0.18	$	270,000	Compensation for Officer
Consultant	September 2006		250,000	$	0.18	$	45,000	Consulting services
Consultant	September 2006		300,000	$	0.18	$	54,000	Legal services
Consultant	September 2006		500,000	$	0.18	$	90,000	Compensation as Chief Scientific Officer

ITEM 10. RECENT SALES OF UNREGISTERED SECURITIES. - continued

Common Stock - continued

Names/Identities of Persons to whom Securities Issued	Issue Date	Amount of Shares Issued		Price of Shares		Aggregate Value of Securities Issued ($)		Purpose of Issuance
Consultant	February 2007		250,000	$	0.30	$	75,000	Patent license
Consultant	March 2007		250,000	$	0.87	$	217,500	Business consulting services
Investors	April 2007		112,277	$	0.71	$	79,717	Private Offering
Consultant	May 2007		250,000	$	0.07	$	120,000	Exercise of Options
Consultant	June 2007		160,000	$	0.75	$	120,000	Settlement of Debt
Carl Cadwell	June 2007		2,215,000	$	0.40	$	850,000	Private Offering
Landlord	August 2007		416,667	$	0.45	$	187,500	Prepaid rent
Consultant	September 2007		100,000	$	0.82	$	82,000	Business consulting services
Consultants	November 2007		117,000	$	0.74	$	86,580	Legal services
Consultant	November 2007		15,000	$	0.75	$	11,250	Consulting services
Consultant	December 2007		25,000	$	0.75	$	18,750	Consulting services
Consultant	December 2007		7,000	$	0.82	$	5,740	Bonus
William J. Stokes	December 2007		1,000,000	$	0.07	$	70,000	Exercise of Options (Company paid exercise price)
Preferred Stockholder	December 2007		299,642	$	0.56	$	167,495	Stock Conversion
Investors	January 2008		137,500	$	0.40	$	55,000	Private Offering
Consultant	January 2008		250,000	$	0.29	$	72,500	Exercise of Warrants
Investors	February 2008		950,000	$	0.40	$	380,000	Private Offering
Investors	February 2008		825,893	$	0.22	$	185,688	Private Offering (received in 2007)
Consultant	March 2008		299,642	$	0.78	$	233,720	Business consulting services
Investors	March 2008		550,700	$	0.40	$	220,280	Private Offering
Investors	April 2008		92,856	$	0.18	$	185,688	Private Offering (received in 2007)
Consultants	April 2008		310,000	$	0.75	$	232,500	Business consulting services
Consultant	July 2008		3,818	$	0.63	$	2,405	Business consulting services
Investors	July 2008		250,000	$	0.40	$	100,000	Private Offering
Investors	August 2008		150,000	$	0.40	$	60,000	Private Offering
Consultants	September 2008		100,000	$	0.55	$	54,688	Loan Fee
Consultant	October 2008		87,900	$	0.53	$	46,857	Business consulting services
Consultant	October 2008		35,000	$	0.58	$	20,300	Business consulting services
Consultants	September 2008		20,000	$	0.43	$	8,746	Loan Fee
Consultant	November 2008		129,765	$	0.17	$	72,500	Exercise of Options
Consultant	November 2008		35,000	$	0.35	$	15,750	Business consulting services
Consultant	November 2008		375,000	$	0.51	$	191,250	Business consulting services
Investors	November 2008		333,333	$	0.30	$	100,000	Private Offering
Consultant	December 2008		27,253	$	0.33	$	9,099	Business consulting services
Consultants	December 2008		150,000	$	0.31	$	46,053	Loan Fee
Consultant	January 2009		190,000	$	0.27	$	51,300	Accounts payable for services
Consultant	February 2009		80,000	$	0.42	$	33,600	Business consulting services
Consultant	March 2009		25,000	$	0.35	$	33,600	Business consulting services
Consultant	March 2009		150,000	$	0.35	$	52,500	Accounts payable for services
Consultant	March 2009		33,333	$	0.35	$	11,666	Business consulting services
Consultants	March 2009		40,000	$	0.28	$	11,032	Loan Fee
Investor	March 2009		37,037	$	0.27	$	10,000	Private offering
Investor	March 2009		1,500,000	$	0.15	$	225,000	Private offering
Investor	April 2009		55,556	$	0.27	$	15,000	Private offering
Investor	April 2009		525,000	$	0.20	$	105,000	Private offering
Investor	April 2009		50,000	$	0.31	$	15,500	Rent for offices
Investor	April 2009		20,000	$	0.35	$	7,000	Issued to Convertible Noteholder

In March 2009 the Company received $100,000 in exchange for a convertible, 10%, one year, note. The note plus interest is convertible at the option of the note holder into common stock shares at $0.15 per share. In addition the Company issued the note holder 40,000 shares of its common stock as a loan origination fee.

In April 2009 the Company received $50,000 in exchange for a one year convertible note at ten percent interest. The note and the interest can be converted into stock at $.40 at election of note holder. The note holder also received 20,000 shares of common stock for entering into this transaction.

ITEM 11. DESCRIPTION OF REGISTRANT’S SECURITIES TO BE REGISTERED.

The Company is authorized by its Certificate of Incorporation to issue an aggregate of 100,000,000 shares of common stock, par value $0.001 per share (the "Common Stock") and 100,000 shares of Series A preferred stock, par value $0.001 per share (the “Preferred Stock”). The Series A preferred stock is not being registered.

ITEM 11. DESCRIPTION OF REGISTRANT’S SECURITIES TO BE REGISTERED. - continued

As of March 31, 2009, 49,666,124 shares of Common Stock were issued and outstanding. Additionally, as of March 31, 2009 there are 5,609,021 of options and warrants outstanding ranging in exercise price of $.17 to $1.05 and expiring as early as January 2009 out to as late as December 2013.

All outstanding shares of Common Stock are of the same class and have equal rights and attributes. The holders of Common Stock are entitled to one vote per share on all matters submitted to a vote of stockholders of the Company. All stockholders are entitled to share equally in dividends, if any, as may be declared from time to time by the Board of Directors out of funds legally available. In the event of liquidation, the holders of Common Stock are entitled to share ratably in all assets remaining after payment of all liabilities. The stockholders do not have cumulative or preemptive rights.

The description of certain matters relating to the securities of the Company is a summary and is qualified in its entirety by the provisions of the Company's Certificate of Incorporation and By-Laws, copies of which have been filed as exhibits to this Form 10.

ITEM 12. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses including attorneys' fees, judgments, fines and amounts paid in settlement in connection with various actions, suits or proceedings, whether civil, criminal, administrative or investigative other than an action by or in the right of the corporation, a derivative action, if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, if they had no reasonable cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses including attorneys' fees incurred in connection with the defense or settlement of such actions, and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The statute provides that it is not exclusive of other indemnification that may be granted by a corporation's certificate of incorporation, bylaws, agreement, a vote of stockholders or disinterested directors or otherwise.

The Company’s Certificate of Incorporation provides that it will indemnify and hold harmless, to the fullest extent permitted by Section 145 of the Delaware General Corporation Law, as amended from time to time, each person that such section grants us the power to indemnify.

The Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

•

any breach of the director's duty of loyalty to the corporation or its stockholders;

•

acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law;

•

payments of unlawful dividends or unlawful stock repurchases or redemptions; or

•

any transaction from which the director derived an improper personal benefit.

The Company’s Certificate of Incorporation provides that, to the fullest extent permitted by applicable law, none of our directors will be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director. Any repeal or modification of this provision will be prospective only and will not adversely affect any limitation, right or protection of a director of our company existing at the time of such repeal or modification.

ITEM 13. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

Our financial statements together with the related notes and the report of HJ & Associates, L.L.C. and Cordovan and Honeck LLP, independent registered public accounting firms, are set forth in Item 15 of this Form 10.

ITEM 14. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

On March 5, 2008, we dismissed Cordovan and Honeck LLP (“C&H LLP”) as our independent registered public accounting firm. On March 5, 2008, we engaged HJ & Associates as our new independent registered public accounting firm. Our board of directors has approved the dismissal of C&H LLP and the appointment of HJ & Associates as our new independent registered public accounting firm.

During the fiscal year ended December 31, 2006, and the subsequent interim periods through March 5, 2008, there were no disagreements between our company and C&H LLP on any matter listed under Item 304 Section (a)(1)(iv) of Regulation S-K, including accounting principles or practices, financial statement disclosure or auditing scope or procedure which, if not resolved to the satisfaction of C&H LLP would have caused C&H LLP to make reference to the matter in its reports on our financial statements. For the fiscal year ended December 31, 2006, the reports of C&H LLP on our financial statements for those fiscal years then ended did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principle, except that such report on our consolidated financial statements contained an explanatory paragraph with respect to uncertainty as to the Company's ability to continue as a going concern.

During the fiscal year ended December 31, 2006 and the subsequent periods through March 5, 2008, prior to engaging HJ & Associates, we did not consult HJ & Associates regarding either:

the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered our financial statements, and neither a written report was provided to our company nor oral advice was provided that HJ & Associates concluded was an important factor considered by our company in reaching a decision as to the accounting, auditing or financial reporting issue; or

any matter that was either subject of disagreement or event, as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instruction to Item 304 of Regulation S-K, or a reportable event, as that term is explained in Item 304(a)(1)(iv) of Regulation S-K.

During the fiscal year ended December 31, 2006 and the subsequent periods through March 5, 2008, prior to engaging HJ & Associates, HJ & Associates has not provided our company with either written or oral advice that was an important factor considered by our company in reaching a decision to change our company’s new principal independent accountant from C&H LLP to HJ & Associates.

We requested C&H LLP that they furnish us with a letter addressed to the SEC stating whether they agree with the statements made in this Form 10, and if not, stating the aspects with which they do not agree. A copy of the letter provided by C&H LLP, dated February 17, 2009, is attached as an exhibit.

ITEM 15. FINANCIAL STATEMENTS AND EXHIBITS.

Advanced Medical Isotope Corporation

(A Development Stage Company)

Index to Financial Statements

	Page

Report of Independent Registered Public Accounting Firm for 2008 and 2007	F-1

Financial Statements:

Balance Sheets as of December 31, 2008 and 2007	F-2

Statements of Operations for the years ended December 31, 2008 and 2007	F-3

Statements of Shareholders’ Equity (Deficit) for the years ended December 31, 2008 and 2007	F-4

Statements of Cash Flow for the years ended December 31, 2008 and 2007	F-7

Notes to Financial Statements for the years ended December 31, 2008 and 2007	F-8

Balance Sheets as of March 31, 2009 and December 31, 2008	F-32

Statements of Operations for the three months ended March 31, 2009	F-33

Statements of Shareholders' Equity (Deficit) for the period ended March 31, 2009	F-34

Statements of Cash Flows for the three months ended March 31, 2009 and the three months ended March 31, 2008	F-35

Notes to the Consolidated Financial Statements for the three months ended March 31, 2009 and the year ended December 31, 2008	F-37

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of

Advanced Medical Isotope Corporation

Kennewick, Washington

We have audited the consolidated balance sheets of Advanced Medical Isotope Corporation (A Development Stage Company) as of December 31, 2008 and 2007, and the related consolidated statements of operations, stockholders’ equity (deficit) and cash flows for the years then ended and from inception of the development stage on January 1, 2006 through December 31, 2008. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Advanced Medical Isotope Corporation as of December 31, 2008 and 2007 and the results of their operations and their cash flows for the years then ended and from inception of the development stage on January 1, 2006 through December 31, 2008 in conformity with U.S. generally accepted accounting principles.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses, used significant cash in support of its operating activities and, based upon current operating levels, requires additional capital or significant restructuring to sustain its operation for the foreseeable future. Management’s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

We were not engaged to examine management's assertion about the effectiveness of Advanced Medical Isotope Corporation’s internal control over financial reporting as of December 31, 2008 and 2007, and, accordingly, we do not express an opinion thereon.

/s/ HJ & Associates, LLC

HJ & Associates, LLC

Salt Lake City, Utah

March 30, 2009

F-1

Advanced Medical Isotope Corporation
(A Development Stage Company)
Balance Sheets

ASSETS
	December 31,			December 31,
	2008			2007

Current Assets:
Cash and cash equivalents	$	86,631		$	54,508
Accounts receivable		35,747			12,000
Prepaid expenses		3,000			-
Prepaid expenses paid with stock, current portion		140,579			239,250
Inventory		7,100			28,400

Total current assets		273,057			334,158

Fixed assets, net of accumulated depreciation		2,272,784			875,044

Other assets:
License fees, net of amortization		27,083			1,661,875
Intangible assets, net of amortization		-			511,701
Patents		24,594			-
Prepaid expenses paid with stock, long-term portion		96,875			161,563
Deposits		155,406			5,928

Total other assets		303,958			2,341,067

Total assets	$	2,849,799		$	3,550,269

LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)

Current liabilities:
Accounts payable	$	580,258		$	180,488
Accrued interest payable		188,956			171,628
Payroll liabilities payable		9,098			45,163
Preferred stock redeemable as common		3,182,405			3,182,405
Line of credit		-			40,908
Loan from shareholder		194,599			-
Convertible notes payable		257,481			-
Current portion of capital lease obligations		352,119			86,983
Total current liabilities		4,764,916			3,707,575

Long term liabilities:
Capital lease obligations, net of current portion		1,786,734			581,630
Total liabilities		6,551,650			4,289,205

Shareholders’ Equity (Deficit):
Preferred stock, $.001 par value; 100,000 authorized;
95,000 and 95,000 shares issued and outstanding, respectively		95			95
Common stock, $.001 par value; 100,000,000 shares authorized;
36,778,611 and 31,664,631 shares issued and outstanding,
respectively		36,779			31,655
Paid in capital		9,546,087			6,152,861
Common stock subscriptions		-			202,500
Accumulated deficit prior to the development stage		(2,884,043	)		(2,884,043	)
Deficit accumulated during the development stage		(10,400,769	)		(4,242,014	)

Total shareholders’ equity (deficit)		(3,701,851	)		(738,936	)

Total liabilities and shareholders’ equity (deficit)	$	2,849,799		$	3,550,269

The accompanying notes are an integral part of these financial statements.

F-2

Advanced Medical Isotope Corporation

(A Development Stage Company)

Statements of Operations

							From inception of
							development stage
	Years ended						on January 1, 2006
	December 31,						through December
	2008			2007			31, 2008

Revenues	$	268,242		$	130,055		$	398,297
Cost of goods sold		155,457			55,841			211,298
Gross profit		112,785			74,214			186,999


Operating expenses
Sales and marketing expenses		39,348			2,385			51,733
Start up costs		-			-			62,510
Amortization expense		1,531,214			1,135,841			2,989,013
Impairment expense		903,535			-			903,535
Professional fees		1,281,557			607,379			2,468,144
Stock options granted		1,211,392			592,447			1,943,839
Payroll expenses		574,228			197,557			771,785
General and administrative expenses		510,813			129,012			747,750
Total operating expenses		6,052,087			2,664,621			9,938,310

Operating loss		(5,939,302	)		(2,590,407	)		(9,751,311	)

Non-operating income (expense):
Interest expense		(219,453	)		(238,984	)		(551,958	)
Investment loss		-			-			(28,500	)
Loss on conversion of shareholder loan		-			(40,000	)		(69,000	)
Non-operating income
(expense), net		(219,453	)		(278,984	)		(649,458	)

Loss before Income Taxes		(6,158,755	)		(2,869,391	)		(10,400,769	)

Income Tax Provision		-			-			-

Net loss		(6,158,755	)	$	(2,869,391	)	$	(10,400,769	)

Loss per common share	$	(0.18	)	$	(0.10	)

Weighted average common shares
outstanding		34,745,710			28,744,391

The accompanying notes are an integral part of these financial statements.

F-3

Advanced Medical Isotope Corporation

(A Development Stage Company)

Statements of Changes in Shareholders’ Equity (Deficit)

																	Deficit
																	Accumulated
	Series A Preferred																during
	Stock				Common Stock				Paid in		Subscriptions			Accumulated			development
	Shares		Amount		Shares		Amount		Capital		Receivable			Deficit			Stage			Total
Balances at December 31,
2005, prior to inception of
development stage
company		-	$	-		23,237,045	$	23,237	$	2,830,806	$	30,000		$	(2,884,043	)	$	-		$	-
Common stock issued for:
Services as of May 15, 2006
($.20 per share)		-		-		600,000		600		119,400		-			-			-			120,000
Compensation as of August 15,
2006 ($.18 per share)		-		-		1,500,000		1,500		268,500		-			-			-			270,000
Services September 1, 2006
($.18 per share)		-		-		250,000		250		44,750		-			-			-			45,000
Debt settlement October 10,
2006 ($.18 per share)		-		-		300,000		300		53,700		-			-			-			54,000
Compensation as of
September 1, 2006
($.18 per share)		-		-		500,000		500		89,500		-			-			-			90,000
Issuance of common stock
options August and
September 2006 pursuant
to exercise of options		-		-		-		-		140,000		-			-			-			140,000
Issuance of shares
December 6, 2006 for cash
received in 1999		-		-		150,000		150		29,850		(30,000	)		-			-			-
Issuance of preferred shares
September 22, 2006 for
acquisition of license
fees		100,000		100		-		-		-		-			-			-			100
Net loss		-		-		-		-		-		-			-			(1,372,623	)		(1,372,623	)
Balances at December 31,
2006		100,000		100		26,537,045		26,537		3,576,506		-			(2,884,043	)		(1,372,623	)		(653,523	)

Common stock issued for:
Patent license as of
February 2007 ($.30
per share)		-		-		250,000		250		74,750		-			-			-		$	75,000
Services March 2007
($.87 per share)		-		-		250,000		250		217,250		-			-			-		$	217,500
Cash April 2007
($.71 per share)		-		-		112,277		112		79,605		-			-			-		$	79,717
Options exercised May
2007 ($.07 per share)		-		-		250,000		250		17,250		-			-			-		$	17,500
Debt April 2007 ($.75
per share		-		-		160,000		160		119,840		-			-			-		$	120,000
Cash June 2007 ($.40
per share)		-		-		2,125,000		2,125		847,875		-			-			-			850,000
Prepaid rent August 2007
($.45 per share)		-		-		416,667		417		187,083		-			-			-			187,500
Services September 2007
($.82 per share)		-		-		100,000		100		81,900		-			-			-			82,000

F-4

Statements of Changes in Shareholders’ Equity (Deficit) - continued

																		Deficit
																		Accumulated
	Series A Preferred																	during
	Stock						Common Stock				Paid in		Subscriptions		Accumulated			development
	Shares			Amount			Shares		Amount		Capital		Receivable		Deficit			Stage			Total

Services November 2007
($.74 per share)		-			-			117,000		117		86,463		-		-			-			86,580
Services November 2007
($.75 per share)		-			-			15,000		15		11,235		-		-			-			11,250
Services December 2007
($.75 per share)		-			-			25,000		25		18,725		-		-			-			18,750
Options exercised December
2007 ($.07 per share)		-			-			1,000,000		1,000		69,000		-		-			-			70,000
Services December 2007
($.82 per share)		-			-			7,000		7		5,733		-		-			-			5,740
Convert 5,000 convertible
preferred shares ($.559
per share)		(5,000	)		(5	)		299,642		300		167,200		-		-			-			167,495
Cash received July 2007 for
shares issued in 2008		-			-			-		-		-		10,000		-			-			10,000
Cash received August 2007
for shares issued in 2008		-			-			-		-		-		20,000		-			-			20,000
Cash received September
2007 for shares issued in
2008		-			-			-		-		-		17,500		-			-			17,500
Cash received November
2007 for shares issued in
2008		-			-			-		-		-		150,000		-			-			150,000
Cash received December
2007 for shares issued in
2008		-			-			-		-		-		5,000		-			-			5,000
Granting of common stock
options December 2007		-			-			-		-		592,446		-		-			-			592,446
Net loss		-			-			-		-		-		-		-			(2,869,391	)		(2,869,391	)
Balances at December 31,
2007		95,000			95			31,664,631		31,665		6,152,861		202,500		(2,884,043	)		(4,242,014	)		(738,936	)
Common stock issued for:
Cash January 2008 ($.40
per share)		-			-			137,500		137		54,863		-		-			-			55,000
Options exercised 2008
($.29 per share)		-			-			250,000		250		72,250		-		-			-			72,500
Cash February 2008
($.40 per share)		-			-			950,000		950		379,050		-		-			-			380,000
Services March 2008
($.78 per share)		-			-			299,642		299		233,421		-		-			-			233,720
Cash March 2008
($.40 per share)		-			-			550,700		551		219,729		-		-			-			220,280
Services April 2008
($.75 per share)		-			-			310,000		310		232,190		-		-			-			232,500
Services July 2008
($.63 per share)		-			-			3,818		4		2,401		-		-			-			2,405
Cash July 2008 ($.40
per share		-			-			250,000		250		99,750		-		-			-			100,000
Cash August 2008
($.40 per share)		-			-			150,000		150		59,850		-		-			-			60,000
Loan fee September 2008
($.55 per share)		-			-			100,000		100		54,588		-		-			-			54,688

F-5

Statements of Changes in Shareholders’ Equity (Deficit) - continued

																		Deficit
																		Accumulated
	Series A Preferred																	during
	Stock				Common Stock				Paid in			Subscriptions			Accumulated			development
	Shares		Amount		Shares		Amount		Capital			Receivable			Deficit			Stage			Total

Services October 2008
($.53 per share)		-		-		87,900		88		46,499			-			-			-			46,587
Services October 2008
($.58 per share)		-		-		35,000		35		20,265			-			-			-			20,300
Loan fee November 2008
($.43 per share)		-		-		20,000		20		8,726			-			-			-			8,746
Options exercised November
2008 ($.17 per share)		-		-		129,765		130		21,930			-			-			-			22,060
Services November 2008
($.45 per share)		-		-		35,000		35		15,715			-			-			-			15,750
Services November 2008
($.51 per share)		-		-		375,000		375		190,875			-			-			-			191,250
Cash November 2008
($.30 per share)		-		-		333,333		333		99,667			-			-			-			100,000
Services December 2008
($.33 per share)		-		-		27,573		28		9,072			-			-			-			9,099
Loan fee December 2008
($.31 per share)		-		-		150,000		150		45,903			-			-			-			46,053
Issuance of shares February,
2008 for cash received
in 2007		-		-		825,893		826		184,862			(185,688	)		-			-			-
Stock offering costs March,
2008		-		-		-		-		(233,720	)		-			-			-			(233,720	)
Issuance of shares April,
2008 for cash received
in 2007		-		-		92,856		93		16,719			(16,812	)		-			-			-
Granting of stock options
June 2008		-		-		-		-		753,140			-			-			-			753,140
Granting of stock options
September 2008		-		-		-		-		127,086			-			-			-			127,086
Granting of stock options
December 2008		-		-		-		-		331,166			-			-			-			331,166
Intrinsic value of convertible
debt issued October 2008		-		-		-		-		24,996			-			-			-			24,996
Intrinsic value of convertible
debt issued November 2008		-		-		-		-		322,234			-			-			-			322,234
Net Loss		-		-		-		-		-			-			-			(6,158,755	)		(6,158,755	)
Balances at December 31,
2008		95,000	$	95		36,778,611	$	36,778	$	9,546,088			-		$	(2,884,043	)	$	(10,400,769	)	$	(3,701,851)

The accompanying notes are an integral part of these financial statements.

F-6

Advanced Medical Isotope Corporation

(A Development Stage Company)

Statements of Cash Flow

							From inception of
							development stage on
	Year ended			Year ended			January 1, 2006 through
	December 31, 2008			December 31, 2007			December 31, 2008
CASH FLOW FROM OPERATING ACTIVITIES:

Net Loss	$	(6,158,755	)	$	(2,869,391	)	$	(10,400,769	)

Adjustments to reconcile net loss to net cash
used by operating activities:
Depreciation of fixed assets		288,256			22,313			310,569
Amortization of licenses and intangible assets		1,242,958			1,135,841			2,700,757
Amortization of prepaid expense paid with stock		208,609			247,688			533,797
Amortization of debt discount		39,198			-			39,198
Impairment of intangible assets		903,535			-			903,535
Common stock issued for services		1,211,392			118,320			1,743,712
Stock options issued for services		347,422			592,447			1,079,869
Stock issued for repairs and maintenance		7,875			-			7,875
Loss on conversion of shareholder loan		-			40,000			40,000
Changes in operating assets and liabilities:
Accounts receivable		(23,747	)		(12,000	)		(35,747	)
Inventory		21,300			(28,400	)		(7,100	)
Prepaid expenses		(3,000	)		-			(3,000	)
Deposits		(149,478	)		(5,930	)		(155,408	)
Accounts payable		326,530			180,489			507,019
Payroll liabilities		(36,065	)		45,163			9,098
Stock based consulting fees payable		212,644			-			212,644
Accrued interest		17,328			125,565			188,956
Accrued interest (rolled into notes payable)		-			94,917			142,375

Net cash used by operating activities		(1,543,998	)		(312,978	)		(2,182,620	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Cash acquired from investment		-			-			310,000
Cash used to acquire equipment		(1,685,996	)		(897,357	)		(2,583,353	)
Cash used to acquire patents		(24,594	)		-			(24,594	)
Cash used to acquire intangible assets		-			(658,750	)		(658,750	)

Net cash provided by investing activities		(1,710,590	)		(1,556,107	)		(2,956,697	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds received from bank line of credit		179,000			40,908			219,908
Payments on line of credit		(219,908	)		-			(219,908	)
Proceeds from Washington Trust debt		199,908			-			199,908
Payments on Washington Trust debt		(5,309	)		-			(5,309	)
Proceeds from convertible debt		675,000			-			675,000
Proceeds from officers related party debt		48,000			-			48,000
Payments on officer related party debt		(48,000	)		-			(48,000	)
Proceeds from capital lease		1,748,142			697,014			2,445,156
Principal payments on capital lease		(277,902	)		(28,401	)		(306,303	)
Proceeds received from shareholder loan		-			50,000			80,000
Proceeds from cash sales of common shares		915,280			894,716			1,809,996
Proceeds from exercise of options and warrants		72,500			52,500			125,000
Proceeds from subscription shares payable		-			202,500			202,500

Net cash provided by financing activities		3,286,711			1,909,237			5,225,948

Net increase in cash and cash equivalents		32,123			40,152			86,631

Cash and cash equivalents, beginning of period		54,508			14,356			-

CASH AND CASH EQUIVALENTS, END OF PERIOD	$	86,631		$	54,508		$	86,631

Supplemental disclosures of cash flow information:
Cash paid for interest	$	25,772		$	18,502		$	44,274
Cash paid for income taxes	$	-		$	-		$	-

The accompanying notes are an integral part of these financial statements.

F-7

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 1: NATURE OF ORGANIZATION

Nature of Organization

Advanced Medical Isotope Corporation (the “Company” or “AMIC”) was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“SMSC”) for the purpose of acquiring or investing in businesses which were developing and marketing active sports products, equipment, and apparel. The Company has had limited activity since inception and was considered dormant from the period May 1, 2000 through December 31, 2005. On September 6, 2006, the Company changed its name to Advanced Medical Isotope Corporation. AMIC has an authorized capital of 100,000,000 shares of Common Stock, $.001 par value per share and 100,000 of Series A Preferred Stock, $.001 par value per share. The Company is considered a development stage company in accordance with Statement of Financial Accounting Standard (“SFAS”) No. 7 for its operations beginning January 1, 2006. The company has had no significant revenues and planned principal operations have not yet commenced. The Company plans to wholesale medical isotopes as well as to develop, produce, and market medical isotopes.

Savage Mountain Sports Corporation mergers

In April 2000, Earth Sports Products, Inc (“ESP”), a corporation registered in Washington, merged with SMSC. ESP had an authorized capital of 100,000,000 shares of Common Stock, $.001 par value per share. As of the date of the merger, ESP had 3,377,206 shares of Common Stock issued and outstanding. As of the date of the merger, SMSC had 1,000 shares of Common Stock issued and outstanding, all of which were held by HHH Entertainment, Inc (“HHH”), a Nevada corporation.

In April 2000, HHH merged with SMSC. On the date of the merger, HHH had authorized capital stock of 100,000,000 shares of Common Stock, $.001 par value per share. As of the date of the merger, HHH had 23,237,045 shares of Common Stock issued and outstanding.

Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Historically, we have relied upon outside investor funds to maintain our operations and develop our business. We anticipate we will continue to require funding from investors for working capital as well as business expansion during this fiscal year and we can provide no assurance that additional investor funds will be available on terms acceptable to us. These factors, among others, may indicate that the Company will be unable to continue as a going concern for a reasonable time. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered by entrance into established markets and the competitive environment in which we operate.

We anticipate a requirement of $3 million in funds over the next twelve months to maintain current operation activities. In addition we anticipate a requirement of approximately $7 million in funds over the next twelve months due to the anticipation of adding additional staff in the future assuming we are successful in selling our medical isotopes and/or the start of development by us on future manufacturing sites or other projects. Currently we have approximately $86,631 cash on hand which means there will be an anticipated shortfall of nearly the full $10 million requirement in additional funds over the next twelve months. There are currently commitments to vendors for products and services purchased, plus, the employment agreements of the CFO and other employees of the company and our current lease commitments that will necessitate liquidation of the Company if we are unable to raise additional capital. The current level of cash is not enough to cover the fixed and variable obligations of the Company.

F-8

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 1: NATURE OF ORGANIZATION - continued

Assuming we are successful in our sales/development effort we believe that we will be able to raise additional funds through the sale of our stock to either current or new shareholders. There is no guarantee that we will be able to raise additional funds or to do so at an advantageous price.

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of estimates

Cash equivalents

For the purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents.

Accounts Receivable

Accounts receivables are stated at the amount that management of the Company expects to collect from outstanding balances. Management provides for probable uncollectible amounts through an allowance for doubtful accounts. Additions to the allowance for doubtful accounts are based on management’s judgment, considering historical write-off’s, collections and current credit conditions. Balances which remain outstanding after management has used reasonable collection efforts are written off through a charge to the allowance for doubtful accounts and a credit to the applicable accounts receivable. Payments received subsequent to the time that an account is written off are considered bad debt recoveries. As of December 31, 2008, the Company has experienced no bad debt write offs from operations.

F-9

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

Related Party Note Receivable

The Company, in 2006, advanced funds on behalf of Mirari (a Washington corporation, and an affiliate under common control) for rent and administrative costs in the amount of $33,000. This balance was written off as bad debt in 2006. It is management’s intention to acquire all the assets and common stock of Mirari during the year 2009.

Inventory

Inventory is reported at the lower of cost or market, determined using the first-in, first-out basis, or net realizable value. All inventories consist of Finished Goods. The company had no Raw Materials or Work in Process.

Fixed Assets

Depreciation is computed using the straight-line method over the following estimated useful lives:

Production equipment	3 to 7 years
Office equipment	2 to 5 years
Furniture and fixtures	2 to 5 years

Leasehold improvements and capital lease assets are amortized over the shorter of the life of the lease or the estimated life of the asset.

The Company has adopted the provisions of Statement of Accounting Standards (SFAS) No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. The provisions of SFAS No. 144 require that an impairment loss be recognized when the estimated future cash flows (undiscounted and without interest) expected to result from the use of an asset are less than the carrying amount of the asset. Measurement of an impairment loss is based on the estimated fair value of the asset if the asset is expected to be held and used.

Management of the Company reviews the net carrying value of all of its equipment on an asset by asset basis whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. These reviews consider the net realizable value of each asset, as measured in accordance with the preceding paragraph, to determine whether impairment in value has occurred, and the need for any asset impairment write-down.

The types of events and circumstances that management believes could indicate impairment are as follows:

A significant decrease in the market price of a live-lived asset.

A significant adverse change in the extent or manner in which a long-lived asset is being used or in its physical condition.

A significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, including an adverse action or assessment by a regulator.

An accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset.

A current period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset.

A current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

The fair value of assets is first determined by quoted market prices, if available. Otherwise, the estimate of fair value is based on the best information available in the circumstances, including prices for similar assets and the results of using other valuation techniques. If quoted market prices are not available a present value technique is often the best available valuation technique with which to estimate fair value. Two present value techniques, expected present value and traditional present value, are provided for in SFAS No. 144. It is believed that an expected present value technique is superior to a traditional present value technique, especially in situations in which the timing or amount of estimated future cash flows is certain.

The traditional approach is useful for many measurements, especially those in which comparable assets and liabilities can be observed in the marketplace. However the traditional approach does not provide the tools needed to address some complex measurement problems, including the measurement of nonfinancial assets and liabilities for which no market for the item or a comparable item exists. The traditional approach places most of the emphasis on selection of an interest rate. A proper search for “the rate commensurate with the risk” requires analysis of at least two items – one asset or liability that exists in the marketplace and has an observed interest rate and the asset or liability being measured. The appropriate rate of interest for the cash flows being measured must be inferred from the observable rate of interest in some other asset or liability and, to draw that inference, the characteristics of the cash flows must be similar to those of the asset being measured.

Although management has made its best estimate of the factors that affect the carrying value based on current conditions, it is reasonably possible that changes could occur which could adversely affect management’s estimate of net cash flows expected to be generated from its assets, and necessitate asset impairment write-downs.

F-10

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

Investments

The Company purchased from a nonrelated individual the interest in a related company, Mirari, for $28,500. This investment was written off in 2006. The Company intends to acquire all the assets and common stock of Mirari during the year 2009.

License Fees

License fees resulted from the acquisition of a patent license, for the production of Actinium 225, from a related individual for common stock valued, at the time of acquisition, at $75,000, and from the result of the acquisition of a patent license, for a Neutron Generator, from Neu-Hope Technologies for preferred stock valued, at the time of acquisition, at $3,040,000, discounted for 4.25% incremental borrowing rate to $2,897,625. License fees are stated at cost, less accumulated amortization. Amortization of license fees is computed using the straight-line method over the estimated economic useful life of the assets.

The Company periodically reviews the carrying values of patents in accordance with SFAS No. 144 and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. In accordance with this policy, management concluded the patent license for the Neutron Generator was no longer of value to the Company. This decision resulted in the Company writing off the net unamortized portion balance of $643,917 early. The issues affecting the value and related writeoff of our license fees did not affect any of our fixed assets.

Amortization is computed using the straight-line method over the estimated useful live of three years. Amortization of license fees was $990,875 and $988,792 for the years ended December 31, 2008 and 2007, respectively. Based on the license fees recorded at December 31, 2008, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for each year ending December 31 is expected to be as follows: $25,000 for 2009, and $2,083 for 2010.

Intangible Assets

The Company periodically reviews the net carrying values of intangible assets in accordance with SFAS No. 144 and any impairments are recognized when the expected future operating cash flows to be derived from such assets are less than their carrying value. In accordance with this policy, management concluded the intangible assets acquired from Isonics were no longer of value to the Company. This decision resulted in the Company writing off the total net unamortized portion balance of $259,618 early. The issues affecting the value and related writeoff of our intangible assets did not affect any of our fixed assets.

F-11

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

Amortization was computed using the straight-line method over the following estimated useful lives:

Intellectual property	3 years
Contracts and agreements	3 years
Customer lists	2 years

Amortization of intangible assets was $252,083 and $147,049 for the years ended December 31, 2008 and 2007, respectively. All intangible assets were fully written off as of December 31, 2008 and so no further amortization of intangible assets will be recognized from these assets in ensuing years.

Patents

Patent filing costs totaling $24,594 have been capitalized at December 31, 2008. The patents are pending and are being developed, as such, they are not being amortized. Management has determined that the economic life of the patents to be 10 years and amortization, over such 10-year period and on a straight-line basis, will begin once the patents have been issued. The Company evaluates the recoverability of intangible assets, including patents on a continual basis utilizing the guidance of SFAS 142, “Goodwill and Other Intangible Assets”. Several factors are used to evaluate intangibles, including, but not limited to, management’s plans for future operations, recent operating results and projected and expected undiscounted future cash flows.

Revenue Recognition

Revenue for the for the first half of fiscal year ended December 31, 2008 and all of the fiscal year ended December 31, 2007 was derived solely from the sales of Oxygen 18, which is used in the production of medical isotopes. In July 2008 the Company also began recognizing revenue from the production of Fluoride 18 produced with the Linear Accelerator. The Company recognizes revenue once an order has been received and shipped to the customer. Prepayments, if any, received from customers prior to the time products are shipped are recorded as deferred revenue. In these cases, when the related products are shipped, the amount recorded as deferred revenue is recognized as revenue. The Company does not accrue for sales returns and other allowances as it has not experienced any returns or other allowances.

Net loss per share

The Company accounts for its income (loss) per common share according to SFAS No. 128, Earnings Per Share. Under the provisions of SFAS No. 128, primary and fully diluted earnings per share are replaced with basic and diluted earnings per share. Basic earnings/loss per share is computed by dividing income (loss) available to common shareholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) for the period, and does not include the impact of any potentially dilutive common stock equivalents. The computation of diluted earnings per share is similar to basic earnings per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if potentially dilutive common shares had been issued.

Securities, all of which represent common stock equivalents, that could be dilutive in the future as of December 31, 2008 and 2007 are as follows:

	2008		2007

Convertible debt		1,269,541		-
Preferred stock		7,577,381		4,700,358
Common stock options		5,609,021		5,447,400

Total potential dilutive securities		14,455,943		10,147,758

F-12

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

Research and Development Costs

The Company incurred $90,150 and $1,250 research and development costs for the years ended December 31, 2008 and 2007 respectively.

Advertising and Marketing Costs

Advertising and marketing costs are expensed as incurred except for the cost of tradeshows which are deferred until the tradeshow occurs. There were no tradeshow expenses incurred and not expensed as of the years ended December 31, 2008 and 2007.

Shipping and Handling Costs

Shipping and handling costs are expensed as incurred and included in cost of product sales.

Legal Contingencies

In the ordinary course of business, the Company is involved in legal proceedings involving contractual and employment relationships, product liability claims, patent rights, and a variety of other matters. The Company records contingent liabilities resulting from asserted and unasserted claims against it, when it is probable that a liability has been incurred and the amount of the loss is reasonably estimable. The Company discloses contingent liabilities when there is a reasonable possibility that the ultimate loss will exceed the recorded liability. Estimated probable losses require analysis of multiple factors, in some cases including judgments about the potential actions of third-party claimants and courts. Therefore, actual losses in any future period are inherently uncertain. Currently, the Company does not believe any probable legal proceedings or claims will have a material impact on its financial position or results of operations. However, if actual or estimated probable future losses exceed the Company’s recorded liability for such claims, it would record additional charges as other expense during the period in which the actual loss or change in estimate occurred.

F-13

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

Income taxes

In June 2006, the FASB issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes, an Interpretation of FASB Statement No. 109, Accounting for Income Taxes (FIN 48), to create a single model to address accounting for uncertainty in tax positions. FIN 48 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. FIN 48 also provides guidance on de-recognition, measurement, classification, interest, and penalties, accounting in interim periods, disclosure and transition.

The Company or one of its subsidiaries files income tax returns in the U.S. federal jurisdiction, and Delaware. The Company did not have any tax expense for the years ended December 31, 2008 and 2007. The Company did not have any deferred tax liability or asset on its balance sheet on December 31, 2008 and 2007.

The Company adopted FIN 48 as of January 1, 2007, and the adoption did not have a material impact to the Company's consolidated financial statements and did not result in any unrecognized tax benefits. Interest costs and penalties related to income taxes, if any, will be classified as interest expense and general and administrative costs, respectively, in the

Company's consolidated financial statements. For the years ended December 31, 2008 and 2007, the Company did not recognize any interest or penalty expense related to income taxes. The Company believes that it is not reasonably possible for the amounts of unrecognized tax benefits to significantly increase or decrease within the next 12 months.

Fair value of financial instruments

The carrying amounts of cash, receivables and accrued liabilities approximate fair value due to the short-term maturity of the instruments.

Stock-based compensation

We account for equity instruments issued in exchange for the receipt of goods or services from non-employees in accordance with the consensus reached by the Emerging Issues Task Force, or EITF, in Issue No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services . Costs are measured at the fair market value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of the date on which there first exists a firm commitment for performance by the provider of goods or services or on the date performance is complete. The Company recognizes the fair value of the equity instruments issued that result in an asset or expense being recorded by the company, in the same period(s) and in the same manner, as if the Company has paid cash for the goods or services.

F-14

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 2: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - continued

Recent accounting pronouncements

In September 2006, the FASB issued Statement No. 157, “Fair Value Measurements” (“SFAS No. 157”). SFAS No. 157 addresses how companies should measure fair value when they are required to use a fair value measure for recognition or disclosure purposes under GAAP. SFAS No. 157 defines fair value, establishes a framework for measuring fair value and expands the required disclosures about fair value measurements. SFAS No. 157 is effective for fiscal years beginning after November 15, 2007, with earlier adoption permitted. Management believes adoption of SFAS No. 157 will not have a material impact on the Company’s financial statements.

In September 2006, the SEC issued Staff Accounting Bulletin No. 108, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements, or SAB No. 108. SAB No. 108 addresses how the effects of prior year uncorrected misstatements should be considered when quantifying misstatements in current year financial statements. SAB No. 108 requires companies to quantify misstatements using a balance sheet and income statement approach and to evaluate whether either approach results in quantifying an error that is material in light of relevant quantitative and qualitative factors. When the effect of initial adoption is material, companies will record the effect as a cumulative effect adjustment to beginning of year retained earnings and disclose the nature and amount of each individual error being corrected in the cumulative adjustment. The adoption of SAB No. 108 did not have a material impact on the Company’s financial statements.

In February 2007, the FASB issued Statement No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities” (“SFAS No. 159”), an amendment of FASB Statement No. 115. SFAS No. 159 addresses how companies should measure many financial instruments and certain other items at fair value. The objective is to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007, with earlier adoption permitted. Management is assessing the impact of the adoption of SFAS No. 159.

NOTE 3: FIXED ASSETS

Fixed assets consist of the following at December 31, 2008 and 2007:

	2008			2007
Production equipment	$	2,113,218		$	191,250
Building		446,772			-
Office equipment		20,128			-
Leasehold improvements		3,235			-
Construction in progress		-			706,107
		2,583,353			897,357
Less accumulated depreciation		(310,569	)		(22,313	)
	$	2,272,784		$	875,044

Construction in progress consists of progress payments made for equipment and facilities that was completed in May 2008. These payments were funded through the Capital Lease Obligations. All assets are pledged as collateral against the Capital Lease obligation.

Depreciation expense related to fixed assets is as follows:

	December 31, 2008		December 31, 2007
Production equipment	$	252,759	$	22,313
Building		54,707		-
Leasehold improvements		560		-
Office equipment		2,543		-
Construction in progress		-		-
	$	310,569	$	22,313

F-15

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 4: INTANGIBLE ASSETS

Intangible assets consist of the following at December 31, 2007 and 2006:

	2008			2007
Intellectual property	$	250,750		$	250,750
Contracts and agreements		213,000			213,000
Customer lists		195,000			195,000
		658,750			658,750
Less accumulated amortization		(658,750	)		(147,049	)
	$	-		$	511,701

NOTE 5: RELATED PARTY TRANSACTIONS

Indebtedness from related parties

In 2006, the company purchased a note receivable of $28,500, from a non-related individual, due from Mirari, Inc (“Mirari”), a Washington corporation, and an affiliate under common control. This amount was written off as an investment loss in 2006. Additionally, during the year 2006, AMIC advanced funds on behalf of Mirari for rent and administrative costs in the amount of $33,000. This amount was written off as bad debt in 2006. It is management’s intention to acquire all the assets and common stock of Mirari during the year 2009.

In November 2006 the Company received $30,000 from a shareholder and officer in the form of a loan and in April 2007 received another $50,000 from the same shareholder. In June 2007 the Company extinguished the $80,000 debt through the issuance of 160,000 shares of the Company’s common stock. The fair market value at the time was $.75, resulting in a $40,000 loss from extinguishment of debt.

Rent and other administrative expenses

The Company began renting office space located in Kennewick, Washington from Apogee Biometrics, Inc. (“ABI”), an affiliate under common control, in January 2006. Commencing January 1, 2006, the parties verbally agreed that the Company would make monthly rent payments of $3,500 on a month-to-month basis. In addition, the Company pays 36% of certain administrative expenses utilized by both parties. During the years ended December 31, 2008 and 2007 the Company incurred rent and administrative expenses to ABI totaling $0 and $15,147 respectively. The Company made payments to ABI totaling $0 and $15,147 during the years ended December 31, 2008 and 2007 respectively.

The Company terminated the rental agreement with ABI and began renting office and warehouse space, known as the Production Facility, effective August 1, 2007, located in Kennewick, Washington from a shareholder holding less that 5% of the total shares outstanding. The lease agreement calls for monthly rental payments starting at $3,500, increasing every August 1st until they become $4,762 as of August 1, 2011. During the years ended December 31, 2008 and 2007 the Company incurred rent expenses for this facility totaling $43,400 and $17,500, respectively. In addition, the lease agreement called for the issuance of $187,500 in common stock valued at $.40 per share for a total of 416,667 shares. The company recognized the issuance of all 416,667 shares in 2007 and will amortize the $187,500 value of that stock over the sixty month term of the lease. For the years ended December 31, 2008 and 2007 the Company amortized $37,500 and $15,625 of this stock issuance and recognized it as rent expense.

Additionally, in June 2008, the Company entered into a twelve month lease for its corporate offices with three four month options to renew, but in no event will the lease extend beyond May 31, 2010. The lease agreement calls for monthly rental payments of $5,061 per month. During the years ended December 31, 2008 and 2007 the Company incurred rent expenses for this facility totaling $31,708 and $0, respectively.

F-16

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 5: RELATED PARTY TRANSACTIONS - continued

Future minimum rental payments required under the Company’s current rental agreements in excess of one year as of December 31, 2008, are as follows:

	Production Facility		Corporate Offices		Total
Twelve months ended December 31, 2009	$	46,872	$	60,736	$	107,608
Twelve months ended December 31, 2010		50,622		25,305		75,927
Twelve months ended December 31, 2011		54,671		-		54,671
Twelve months ended December 31, 2012		33,332		-		33,332

Total	$	185,497	$	86,041	$	271,538

Rental expense for the years ending December 31, 2008 and 2007 consisted of the following:

		December 31,
		2008		2007
ABI		$	-	$	15,147
Office and warehouse lease effective August 1, 2007
	Monthly rental payments		43,400		17,500
	Rental expense in the form of stock issuance		37,500		15,625
Corporate office			31,708		-
Total Rental Expense		$	112,608	$	28,397

NOTE 6: ASSET ACQUISITION

On June 13, 2007, the Company acquired some of the assets of Isonics Corporation (Isonics); a California corporation. Isonics is a non-related business of the Company and neither company owns stock in the other. The Company acquired the assets in exchange for $850,000 cash payment for the purpose of establishing itself in a turnkey distribution business of medical isotopes. The assets acquired consist of intellectual property, agreements with third party companies for purchase and marketing of isotopes, customer lists, and equipment located in Buffalo, New York. None of the acquired assets hold any ongoing liabilities or contractual obligations that would result in additional cash transactions required by the Company.

Intellectual property, agreements with third parties and customer lists are stated at the Companies estimation of fair market value at the time of acquisition, less accumulated amortization. Amortization of these items is computed using the straight-line method over the estimated economic useful life of the assets ranging from 2-3 years.

F-17

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 6: ASSET ACQUISITION - continued

Amortization of these items was $252,083 and $147,049 for the years ended December 31, 2008 and 2007, respectively. All intangible assets were fully written off as of December 31, 2008 and so no further amortization of intangible assets will be recognized from these assets in ensuing years.

Depreciation of the equipment was $38,250 and $22,313 for the years ended December 31, 2008 and 2007, respectively. Based on the value of these items recorded at December 31, 2008, and assuming no subsequent impairment of the underlying assets, the annual amortization expense for each year ending December 31 is expected to be as follows: $38,250 for 2009, $38,250 for 2010, $38,250 for 2011, and $15,938 for 2012.

The assets acquired by the Company were recorded at the estimated fair market value as of the date of acquisition, or $850,000, as follows:

Intellectual property related to the production of Indium-111 as focused
on the chemical separation of Indium from a Cadmium-112 target	$	70,750
Consulting expense incurred by Isonics for training of Indium-111 production		150,000
License fees paid by Isonics for Indium-111 production		30,000
Customer list associated with the Indium-111 production		65,000
Total purchase price allocated to Indium-111 production				315,750

Contract with Kurchatov Institute dated July 14, 2004 for the purchase
Of Actinium-225		71,000
Contract with Institute for Physics and Power Engineering for the
Purchase of Actinium-225		71,000
Customer list associated with the purchases of Actinium-225		65,000
Total purchase price allocated to Actinium-225 purchases				207,000

Service Agreement with Global Scientific Technologies and Center of
Molecular Research in connection with the production, marketing,
and sale of Oxygen-18		71,000
Customer list associated with the sale of Oxygen-18		65,000
Total purchase price allocated to Oxygen-18 production
and marketing				136,000
Equipment located at Central Radiopharmaceutical Services, Buffalo, New York				191,250
			$	850,000

F-18

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 7: LICENSE FEE ACQUISITION

On September 27, 2006, the Company acquired the assets of Neu-Hope Technologies, Inc (“NHTI”), a Florida corporation from UTEK Corporation (“UTEK”), a Delaware corporation. UTEK is a shareholder of less than 5% of the Company’s issued and outstanding common stock. The Company acquired NHTI’s assets from UTEK in exchange for 100,000 shares of the Company’s Series A preferred stock. At any time after September 27, 2007, these Series A preferred stock shares can be converted to unrestricted common stock in the amount of $3,350,000. The number of shares shall be calculated based on the previous 10 day average closing price on the day of conversion. The Company conducted the acquisition in order to obtain NHTI’s cash, rights, and customer relationships. The assets acquired by the Company were recorded at the value which the preferred stock can be converted into common stock, $3,350,000, as follows:

	As of
	September 27, 2006
Cash	$	310,000
License fee		3,040,000
Net assets acquired	$	3,350,000

In December 2007, 5,000 shares of the Company’s Series A preferred stock were converted to 299,642 shares of common stock at $.559 per share

On August 30, 2006, NHTI entered into a Non-Exclusive License Agreement with the Regents of the University of California. NHTI paid a non-refundable License Issue Fee in the amount of $25,000. The license fee is non-refundable unless the Company’s commercialization plan is deemed unacceptable by the University. If the plan is deemed unacceptable, the license agreement will terminate and may be converted to a non-exclusive license. To date, no commercialization plan has been deemed acceptable or unacceptable.

In consideration for the license, the Company agreed to the following payments:

$25,000 License Issue Fee, described above;

$25,000 upon submission by University of California to U.S. Federal Drug Administration (or comparable agency) of either notification of or request for approval of (as applicable), a Licensed Product;

$100,000 upon satisfaction of necessary requirements (e.g., notification or receipt of approval, as applicable) by Federal Drug Administration (or comparable agency) for commercial sale of a Licensed Product;

Royalties equal to the greater of three percent of the Selling Price of each Licensed Product Licensee sells or the maintenance fee according to the following schedule:

2006	$	0
2007	$	0
2008	$	10,000	(not yet paid)
2009	$	15,000
2010	$	15,000
2011	$	45,000
2012 and each year thereafter	$	60,000

F-19

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 8: PREPAID EXPENSES PAID WITH STOCK

The Company has issued stock with companies for various service agreements extending beyond December 31, 2008; however all of which are expected to expire sometime within the next twelve months. Additionally, the Company issued stock for prepaid rent which will expire annually through July 2012 at the rate of $37,500 per year. Prepaid Expenses are expected to mature as follows:

2009	$	140,579
2010		37,500
2011		37,500
2012		21,875
	$	237,454

NOTE 9: BANK LINE OF CREDIT and SHAREHOLDER LOAN

The Company had a $200,000 revolving line of credit with Washington Trust Bank that was to expire in September 2009. The Company had $199,908 in borrowings under the line of credit as of October 28, 2008 at which time was paid off and replaced with a loan from two of the major shareholders. The loan calls for $4,066 monthly payments, including 8% interest, beginning November 30, 2008, with a balloon payment for the balance at October 31, 2009. There is no security held as collateral for this loan. As of December 31, 2008, all payments were current on this shareholder loan.

NOTE 10: CAPITAL LEASE OBLIGATIONS

During September 2007, the Company obtained two Master Lease Agreements for $1,875,000 and $631,000, with interest on both leases accruing at 8.6% annually, secured by equipment and personal guarantee of two of the major shareholders. These long-term agreements shall be deemed Capital Lease Obligations for purposes of financial statement reporting. The purpose of the lease is to acquire a Pulsar 10.5 PET Isotope Production System for a contracted amount of $1,875,000 plus ancillary equipment and facility for $933,888. Advances made by the Lessor for the benefit of the Company, less payments, total $2,138,853 as of December 31, 2008:

In accordance with paragraph 10 of SFAS 13, this capital lease and its resulting obligation is recorded at an amount equal to the present value at the beginning of the lease term of minimum lease payments during the lease term, excluding any portion of the payments representing taxes to be paid by the Company. This amount does not exceed the fair value of the leased property at the lease inception, so the recorded amount is the fair value.

	Capital Lease Obligation
	PET Isotope Production System		Ancillary Equipment		Total
Total lease commitment	$	1,875,000	$	933,888	$	2,808,888
Advances made for purchases	$	1,511,268	$	933,888	$	2,445,156
Principal portion of payments		179,337		126,966		306,303
Net balance of advances payable	$	1,331,931	$	806,922	$	2,138,853
Add factor to arrive at total future minimum lease payments		372,139		153,788		525,927
Total future minimum lease payments		1,704,070		960,710		2,664,780
Less amount representing interest		372,139		153,788		525,927
Present value of net minimum lease payments		1,331,931		806,922		2,138,853
Less amounts due within one year		182,750		169,369		352,119
Amounts due after one year	$	1,149,181	$	637,552	$	1,786,733

F-20

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 10: CAPITAL LEASE OBLIGATIONS - continued

The lease requires the Company to maintain a minimum debt service coverage ratio of 1:1 measured at fiscal year end; non compliance with this provision shall constitute a default and guarantors must contribute capital sufficient to fund any deficit in the debt service coverage ratio.

The definition of debt service coverage ratio is EBITDA (earnings before interest, taxes, depreciation and amortization), minus cash taxes, minus unfunded capital expenditures, plus capital injections, divided by (interest plus current portion of long-term debt). According to the debt service coverage ratio computation, the Company is not in compliance with the minimum debt service coverage ratio stipulated in the loan covenants. Accordingly the lenders could accelerate the debt; causing the Company to seek replacement funding from other sources. There is no guarantee the Company could find replacement funding.

The Company’s actual results of the minimum debt service ratio calculation for the years December 31, 2008 and 2007 are as follows:

	December 31,
	2008			2007
Net loss	$	(6,158,755	)	$	(2,869,391	)
Add (subtract)
Interest		219,453			238,984
Depreciation and amortization		1,531,214			1,135,841
Unfunded capital expenditures		(72,485	)		(191,347	)
Capital injections		(1,838,188	)		-
	$	(6,318,761	)	$	(1,685,913	)
Interest plus current portion of long-term debt		571,572			325,967
Debt service coverage ratio	$	0.000		$	0.000

Principal maturities on the amount of the capital lease obligations advanced through December 31, 2008 are due as follows:

Year ended December 31,	Production Facility		Ancillary Equipment
2009	$	182,749	$	169,369
2010		193,384		180,983
2011		210,776		197,115
2012		229,554		201,337
2013		250,378		58,117
Thereafter		265,090		-
	$	1,331,931	$	806,921

The capital lease obligation is the only Company debt that contains covenants.

NOTE 11: INCOME TAXES

Income taxes are provided based upon the liability method of accounting pursuant to SFAS No. 109, “Accounting for Income Taxes.” Under this approach, deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end. A valuation allowance is recorded against deferred tax assets if management does not believe the Company has met the “more likely than not’ standard imposed by SFAS No. 109 to allow recognition of such an asset.

The amount of deferred income tax benefit is impacted by the difference between the estimated Federal and State statutory income tax rates used to estimate deferred tax assets and liabilities and actual rates utilized when determining income taxes due or the application of net operating losses which are impacted by lower rates for taxable income less than $100,000 along with differences in state tax rates. In addition, other estimates utilized in determining deferred income tax benefit resulting from anticipated timing differences may differ from amounts initially determined when the timing differences are realized.

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

F-21

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 11: INCOME TAXES - continued

Net deferred tax assets consist of the following components as of December 31, 2008 and 2007:

	2008			2007
Deferred tax assets:
Net operating loss carryover	$	4,133,788		$	1,395,015
Deferred tax liabilities:
Depreciation		(683,007	)		(383,664	)
Valuation allowance		(3,450,781	)		(1,011,351	)
Net deferred tax asset	$	-		$	-

The income tax provision differs from the amount of income tax determined by applying the U.S. Federal income tax rate to pretax income from continuing operations for the years ended December 31, 2008 and 2007 due to the following:

	2008			2007
Book income	$	(2,401,914	)	$	(535,323	)
Depreciation		(498,618	)		69,060
Meals and entertainment		3,595			587
Stock for services		285,158			75,660
Options expense		472,443			-
Officers life insurance		2,094			-
Gain/loss on disposal		(693,666	)		-
Valuation allowance		2,830,908			390,016
	$	-		$	-

At December 31, 2008 and 2007, the Company had net operating loss carryovers of approximately $10,600,000 and $3,300,000, respectively, that may be offset against future taxable income from the year 2009 through 2028. No tax benefit has been reported in the years ended December 31, 2008 and 2007 consolidated financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryovers for Federal income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carryovers mat be limited as to use in future years.

In July 2006, the FASB issued Interpretation No. 48, ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES – AN INTERPRETATION OF FASB STATEMENT NO. 109” (“FIN 48”), which clarifies the accounting and disclosure for uncertainty in tax positions, as defined. FIN 48 seeks to reduce the diversity in practice associated with certain aspects of the recognition and measurement related to accounting for income taxes. The Company is subject to the provisions of FIN 48 as of January 1, 2007, and has analyzed filing positions in all of the Federal and state jurisdictions where it is required to file income tax returns. The Company has not filed its Federal income tax return since 1998, however the Company believes that its income tax filing positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material impact on the Company’s financial condition, results of operations, cash flows or net operating loss carry-forwards. Therefore, no reserves for uncertain income tax positions have been recorded pursuant to FIN 48. In addition, the Company did not record a cumulative effect adjustment related to the adoption of FIN 48. The Company is subject to audit by the IRS and various states for the prior 3 years.

The Company’s policy for recording interest and penalties associated with taxes is to recognize at as a component of income tax expense.

F-22

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 12: STOCKHOLDERS’ EQUITY

Common stock sale

On October 13, 2006, the Company issued 150,000 shares of its $.001 par value common stock to shareholders for common stock subscriptions received in 1999.

In April 2007 the Company issued 112,277 shares for cash of $79,717 at $.71 per share.

In June 2007 the Company issued 2,125,000 shares for cash of $850,000 at $.40 per share.

In February 2008, the Company issued 825,893 shares of its $.001 par value common stock to shareholders for common stock subscriptions of $185,688 received in 2007.

In April 2008, the Company issued 92,856 shares of its $.001 par value common stock to shareholders for common stock subscriptions of $16,812 received in 2007.

In January 2008 the Company issued 137,500 shares for cash of $55,000 at $.40 per share.

In January 2008 the Company issued 250,000 shares for cash of $72,500 at $.29 for exercised options.

In February 2008 the Company issued 950,000 shares for cash of $380,000 at $.40 per share.

In March 2008 the Company issued 550,700 shares for cash of $220,280 at $.40 per share.

In July 2008 the Company issued 250,000 shares for cash of $100,000 at $.40 per share.

In August 2008 the Company issued 150,000 shares for cash of $60,000 at $.40 per share.

In November 2008 the Company issued 333,333 shares for cash of $100,000 at $.30 per share.

Preferred stock

On September 27, 2006, the Company acquired the assets of Neu-Hope Technologies, Inc (“NHTI”), a Florida corporation from UTEK Corporation (“UTEK”), a Delaware corporation. UTEK is a shareholder of less than 5% of the Company’s issued and outstanding common stock. The Company acquired NHTI’s assets from UTEK in exchange for 100,000 shares of the Company’s Series A preferred stock. At any time after September 27, 2007, these Series A preferred stock shares can be converted to unrestricted common stock in the amount of $3,350,000. The number of shares shall be calculated based on the previous 10 day average closing price on the day of conversion. Additionally, during the initial twelve months period in which UTEK is holding said preferred stock, interest shall accrue at the annual rate of five percent, compounded quarterly, payable in cash or in common shares of the Company. The Company conducted the acquisition in order to obtain NHTI’s cash, rights, and customer relationships. The details of this transaction can be found in Footnote 7.

In December 2007, 5,000 shares of the Company’s Series A preferred stock were converted to 299,642 shares of common stock at $.559 per share.

Common stock issued for services

During May 2006, the Company paid for $120,000 two year business consulting services through the issue of 600,000 shares of its common stock based on the quoted market price of stock on the transaction date, or $.20 per share. Stock-based compensation expense of $50,000 and $70,000 has been recognized in the accompanying financial statements for the years ended December 31, 2007 and 2006. The remaining $0 and $50,000 is reported as prepaid expenses paid with stock in the accompanying financial statements for the years ended December 31, 2007 and 2006.

During October 2006, the Company paid for $45,000 two year business consulting services through the issue of 250,000 shares of its common stock based on the quoted market price of stock on the transaction date, or $.18 per share. Stock-based compensation expense of $22,500 and $7,500 has been recognized in the accompanying financial statements for the years ended December 31, 2007 and 2006. The remaining $15,000 and $37,500 is reported as prepaid expenses paid with stock in the accompanying financial statements as of December 31, 2007, and 2006.

During September 2006, the Company issued 1,500,000 shares of its common stock as bonus compensation to the CEO. The transaction was recorded based on the quoted market price of stock on the transaction date, or $.18 per share. Stock-based compensation expense of $270,000 has been recognized in the accompanying financial statements for the year ended December 31, 2006.

F-23

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 12: STOCKHOLDERS’ EQUITY - continued

During September 2006, the Company issued 500,000 shares of its common stock as bonus compensation to the Chief Science Officer. The transaction was recorded based on the quoted market price of stock on the transaction date, or $.18 per share. Stock-based compensation expense of $90,000 has been recognized in the accompanying financial statements for the year ended December 31, 2006.

During September 2006, the Company paid for $54,000 in legal services through the issue of 300,000 shares of its common stock based on the quoted market price of stock on the transaction date, or $.18 per share. Stock-based compensation expense of $54,000 has been recognized in the accompanying financial statements for the year ended December 31, 2006.

During February 2007, the Company purchased a patent license for $54,000 through the issue of 250,000 shares of its common stock based on the quoted market price of stock on the transaction date, or $.30 per share. A long term asset valued at $75,000 has been recognized in the accompanying financial statements for the year ended December 31, 2007.

During March 2007, the Company paid for $217,500 two year business consulting services through the issue of 250,000 shares of its common stock based on the quoted market price of stock on the transaction date, or $.87 per share. Stock-based compensation expense of $81,562.50 has been recognized in the accompanying financial statements for the year ended December 31, 2007. The remaining $135,937.50 is reported as prepaid expenses paid with stock in the accompanying financial statements.

During June 2007, the Company issued 160,000 shares of its common stock in exchange for debt. The value if the transaction totaled $120,000 based on the quoted market price of stock on the transaction date, or $.75 per share. Loss on extinguishment of debt of $40,000 has been recognized in the accompanying financial statements for the year ended December 31, 2007.

During August 2007, the Company paid for $187,500 prepaid rent through the issue of 416,667 shares of its common stock based on the quoted market price of stock on the transaction date, or $.45 per share. Stock-based rent expense of $15,625 has been recognized in the accompanying financial statements for the year ended December 31, 2007. The remaining $171,875 is reported as prepaid expenses paid with stock in the accompanying financial statements.

During September 2007, the Company paid for $82,000 business consulting services through the issue of 100,000 shares of its common stock based on the quoted market price of stock on the transaction date, or $.82 per share. Stock-based compensation expense of $41,000 has been recognized in the accompanying financial statements for the year ended December 31, 2007. The remaining $41,000 is reported as prepaid expenses paid with stock in the accompanying financial statements.

During November 2007, the Company paid for $74,000 business consulting services through the issue of 100,000 shares of its common stock based on the quoted market price of stock on the transaction date, or $.74 per share. Stock-based compensation expense of $26,000 has been recognized in the accompanying financial statements for the year ended December 31, 2007. The remaining $48,000 is reported as prepaid expenses paid with stock in the accompanying financial statements.

F-24

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 12: STOCKHOLDERS’ EQUITY - continued

During November 2007, the Company paid for $12,563 business consulting services through the issue of 17,000 shares of its common stock based on the quoted market price of stock on the transaction date, or $.74 per share. Stock-based compensation expense of $12,563 has been recognized in the accompanying financial statements for the year ended December 31, 2007.

During November 2007, the Company paid for $11,250 business consulting services through the issue of 15,000 shares of its common stock based on the quoted market price of stock on the transaction date, or $.75 per share. Stock-based compensation expense of $11,250 has been recognized in the accompanying financial statements for the year ended December 31, 2007.

During December 2007, the Company paid for $18,725 business consulting services through the issue of 25,000 shares of its common stock based on the quoted market price of stock on the transaction date, or $.75 per share. Stock-based compensation expense of $18,725 has been recognized in the accompanying financial statements for the year ended December 31, 2007.

During December 2007, the Company issued 7,000 shares of its common stock to two employees as a bonus. The value of the transaction totaled $5,733 based on the quoted market price of stock on the transaction date, or $.82 per share. Stock-based compensation expense of $5,733 has been recognized in the accompanying financial statements for the year ended December 31, 2007.

During December 2007, the Company issued 1,000,000 shares of its common stock to its CEO in exchange for consideration of past services and for the 1,000,000 options previously granted to the CEO in September of 2006. Because the 1,000,000 shares were given to the CEO and were not purchased using cash by the CEO, the Company recognized stock-based compensation expense of $70,000 in the accompanying financial statements for the year ended December 31, 2007. The $70,000 compensation was determined by multiplying the number of options exercised (1,000,000) times the exercise price per share ($0.07). The exercise price per share was determined at the time the options were granted in September of 2006.

During March 2008, the Company issued 299,642 shares of its common stock in exchange for stock offering costs associated with the acquisition of the assets of Neu-Hope Technologies, Inc. The value of the transaction totaled $233,720 based on the quoted market price of stock on the transaction date, or $.78 per share.

During April 2008, the Company issued 190,000 shares of its common stock as bonus compensation to the Chief Science Officer. The value of the transaction totaled $142,500 based on the quoted market price of stock on the transaction date, or $.75 per share. Stock-based compensation expense of $142,500 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During April 2008, the Company issued 50,000 shares of its common stock as bonus compensation to employees. The value of the transaction totaled $37,500 based on the quoted market price of stock on the transaction date, or $.75 per share. Stock-based compensation expense of $37,500 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During April 2008, the Company issued 70,000 shares of its common stock in exchange for business consulting services. The value of the transaction totaled $52,500 based on the quoted market price of stock on the transaction date, or $.75 per share. Stock-based compensation expense of $52,500 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During July 2008, the Company issued 3,818 shares of its common stock in exchange for business consulting services. The value of the transaction totaled $2,405 based on the quoted market price of stock on the transaction date, or $.63 per share. Stock-based compensation expense of $2,405 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During October 2008, the Company issued 27,900 shares of its common stock in exchange for business consulting services. The value of the transaction totaled $14,787 based on the quoted market price of stock on the transaction date, or $.53 per share. Stock-based compensation expense of $14,787 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During October 2008, the Company issued 60,000 shares of its common stock to employees as bonuses. The value of the transaction totaled $31,800 based on the quoted market price of stock on the transaction date, or $.53 per share. Stock-based compensation expense of $31,800 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During October 2008, the Company issued 35,000 shares of its common stock in exchange for $7,000 of prepaid services and $13,300 in services performed in 2008. The value of the transaction totaled $20,300 based on the quoted market price of stock on the transaction date, or $.58 per share. Stock-based compensation expense of $13,300 has been recognized in the accompanying financial statements for the year ended December 31, 2008 and the remaining $7,000 is recorded as prepaid expenses paid in stock at December 31, 2008.

F-25

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 12: STOCKHOLDERS’ EQUITY - continued

During November 2008, the Company issued 129,765 shares of its common stock in exchange for business consulting services previously rendered and included in accounts payable. The value of the transaction totaled $22,060 based on the consultants other contractual agreement, or $.17 per share. Stock-based compensation expense of $22,060 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During November 2008, the Company issued 35,000 shares of its common stock in exchange for business consulting services. The value of the transaction totaled $15,750 based on the quoted market price of stock on the transaction date, or $.45 per share. Stock-based compensation expense of $15,750 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During November 2008, the Company issued 350,000 shares of its common stock in exchange for business consulting services. The value of the transaction totaled $178,500 based on the quoted market price of stock on the transaction date, or $.51 per share. Stock-based compensation expense of $178,500 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During November 2008, the Company issued 25,000 shares of its common stock to employees as a bonus. The value of the transaction totaled $12,750 based on the quoted market price of stock on the transaction date, or $.51 per share. Stock-based compensation expense of $12,750 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During December 2008, the Company issued 27,573 shares of its common stock in exchange for business consulting services. The value of the transaction totaled $9,100 based on the quoted market price of stock on the transaction date, or $.33 per share. Stock-based compensation expense of $9,100 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

Common stock issued for convertible debt

During September 2008, the Company issued 100,000 shares of its common stock in exchange for $250,000 convertible note ; convertible at $1.05 per share at the election of noteholder . The value of the $250,000 debt plus the $.70 fair market value of the 100,000 shares at the date of the agreement was prorated to arrive at the allocation of the original $250,000 debt and the value of the 100,000 shares. This computation resulted in an allocation of $195,313 toward the debt and $54,688 to the shares. The $54,688 value of the shares is then amortized to interest over the twelve month life of the debt. Interest expense of $18,229 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

During November 2008, the Company issued 20,000 shares of its common stock in exchange for $50,000 convertible note ; convertible at $0.40 per share at the election of shareholder . The value of the $50,000 debt plus the $.53 fair market value of the 20,000 shares at the date of the agreement was prorated to arrive at the allocation of the original $50,000 debt and the value of the 20,000 shares and the beneficial conversion feature. This computation resulted in an allocation of $16,258 toward the debt and $8,746 to the shares and $24,996 to the beneficial conversion feature. The $8,746 value of the shares and the $24,996 value of the beneficial conversion feature are then amortized to interest over the twelve month life of the debt. Interest expense of $5,624 has been recognized in the accompanying financial statements for the year ended December 31, 2008.

On December 16, 2008, Advanced Medical Isotope Corporation (the “Company”) issued a convertible promissory note in the amount of $375,000 with interest payable at 10% per annum. The Note matures on December 16, 2009 (the "Maturity Date"). The entire outstanding principal balance and any outstanding fees or interest is due and payable in full on the Maturity Date. Interest on the Note is payable every six months until the Note is paid in full. Additionally, in connection with the convertible note, 150,000 shares of the Company’s common stock were issued to the note holder. At the option of the holder, the note is convertible, in whole or in part, into the Company’s common stock by taking the principal to be converted and dividing it by fifty percent of the volume-weighted average trading price of the Company’s common stock for the 10 consecutive trading days immediately preceding the date of conversion. The note is convertible at any time.

The embedded conversion feature within the convertible promissory note was assessed under paragraph 12 of SFAS 133 to determine whether the embedded conversion feature should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings.

Paragraph 12 of FAS 133 requires that an embedded derivative instrument shall be separated from the host contract and accounted for as a derivative instrument if, and only if, certain criteria are met. The company believes that those certain criteria have not been met as the Company’s stock is not considered to be readily convertible to cash as defined in paragraph 57c(3) of Appendix A, “A security that is publicly traded but for which the market is not very active is readily convertible to cash if the number of shares or other units of the security to be exchanged is small relative to the daily transaction volume. That same security would not be readily convertible if the number of shares to be exchanged is large relative to the daily transaction volume.” Per the agreement the Company is required to deliver shares of its common stock and there is no mechanism outside the contract that facilitates that settlement therefore the convertible feature does not meet the criteria of paragraph 9, it does not meet the criteria of paragraph 6, and in turn it does not meet the criteria of paragraph 12 of FAS 133. Therefore the company concluded that conversion feature should not be bifurcated from the host instrument and should be accounted for in accordance with EITF 00-27.

EITF 00-27 requires the Company to allocate the proceeds to the shares issued and the debt and then calculate a beneficial conversion feature. The company performed these calculations which resulted in a beneficial conversion feature with an intrinsic value of $322,234. The 150,000 shares of common stock were valued at $46,053 and the debt was recorded at $6,713. Because the debt is immediately convertible, the value of the beneficial conversion feature is calculated as if converted on the commitment date. The $322,234 allocated to the beneficial conversion feature along with the $46,053 allocated to the 150,000 shares of common stock is being accreted to interest expense over the twelve month life of the debt. Interest expense of $15,345 has been accreted and added to the note payable bringing the total debt balance related to this convertible promissory note to $22,058 in the accompanying financial statements as of December 31, 2008.

F-26

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 12: STOCKHOLDERS’ EQUITY - continued

Common stock options

Options granted to non-employees, accounted for under the fair value method

During September 2006, the Company granted a consultant options to purchase an aggregate of 250,000 shares of the Company’s common stock at an exercise price of $.15 per share. The options are fully vested and expire September 1, 2008. The quoted market price of the common stock at the time of issuance of the options was $.07 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $17,500, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2006.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		4.77	%
Dividend yield		0.00	%
Volatility factor		404.0	%
Weighted average expected life	2 years

During September 2006, the Company granted three board members options to purchase an aggregate of 250,000 shares each of the Company’s common stock and granted the CEO options to purchase 1,000,000 shares of the Company’s common stock, all at an exercise price of $.07 per share. The options are fully vested and expire September 1, 2009. The quoted market price of the common stock at the time of issuance of the options was $.07 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $17,500 for each of the board members and $70,000 for the CEO, for an aggregate of $122,500, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2006.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		4.69	%
Dividend yield		0.00	%
Volatility factor		325.0	%
Weighted average expected life	3 years

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		4.79	%
Dividend yield		0.00	%
Volatility factor		329.1	%
Weighted average expected life	3 years

During April 2007, the Company granted a consultant options to purchase an aggregate of 100,000 shares of the Company’s common stock at an exercise price of $.50 per share. The options are fully vested and expire April 2010. The quoted market price of the common stock at the time of issuance of the options was $.85 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $84,735, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2007.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		4.60	%
Dividend yield		0.00	%
Volatility factor		329.1	%
Weighted average expected life	3 years

F-27

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 12: STOCKHOLDERS’ EQUITY - continued

During May 2007, the Company granted its Chief Financial Officer options to purchase an aggregate of 1,500,000 shares of the Company’s common stock at an exercise price of $.50 per share. The options vest at 500,000 shares May 2008, 500,000 shares May 2009, and 500,000 shares May 2010 and expire May 2012. The quoted market price of the common stock at the time of issuance of the options was $.70 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $1,046,837, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2007 on a pro-rata bases of the months worked compared to the total of the vesting schedule.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		4.67	%
Dividend yield		0.00	%
Volatility factor		257.3	%
Weighted average expected life	5 years

During December 2007, the Company granted a consultant options to purchase 122,400 shares of the Company’s common stock, at an exercise price of $.17 per share. The options are fully vested and expire December 31, 2012. The quoted market price of the common stock at the time of issuance of the options was $.72 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $87,975 and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2007.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		3.49	%
Dividend yield		0.00	%
Volatility factor		257.3	%
Weighted average expected life	5 years

During February 2008, the Company granted a consultant options to purchase 714,286 shares of the Company’s common stock, at an exercise price of $1.05 per share. The options are fully vested and expire February 12, 2009. The quoted market price of the common stock at the time of issuance of the options was $.65 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $461,827 and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		2.05	%
Dividend yield		0.00	%
Volatility factor		312.5	%
Weighted average expected life	1 year

During March 2008, the Company granted a consultant options to purchase 106,800 shares of the Company’s common stock, at an exercise price of $.17 per share. The options are fully vested and expire March 31, 2013. The quoted market price of the common stock at the time of issuance of the options was $.84 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $89,565 and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		2.48	%
Dividend yield		0.00	%
Volatility factor		257.3	%
Weighted average expected life	5 years

During June 2008, the Company granted a consultant options to purchase 39,600 shares of the Company’s common stock, at an exercise price of $.17 per share. The options are fully vested and expire June 30, 2013. The quoted market price of the common stock at the time of issuance of the options was $.69 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $27,276 and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		3.49	%
Dividend yield		0.00	%
Volatility factor		257.5	%
Weighted average expected life	5 years

F-28

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 12: STOCKHOLDERS’ EQUITY - continued

During July 2008, the Company granted a consultant options to purchase 100,000 shares of the Company’s common stock, at an exercise price of $.50 per share. The options are fully vested and expire January 29, 2011. The quoted market price of the common stock at the time of issuance of the options was $.40 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $39,850 and was recorded as stock-based compensation in the accompanying financial statements for the nine months ended September 30, 2008.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		2.87	%
Dividend yield		0.00	%
Volatility factor		337.6	%
Weighted average expected life	3 years

During November 2008, the Company granted two board members options to purchase an aggregate of 100,000 shares each and one board member options to purchase an aggregate of 25,000 shares of the Company’s common stock at an exercise price of $.55 per share. The options are fully vested and expire November 26, 2011. The quoted market price of the common stock at the time of issuance of the options was $.51 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $50,819 for each of the two board members and $12,705 for the other board member, for an aggregate of $114,343, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		1.51	%
Dividend yield		0.00	%
Volatility factor		337.2	%
Weighted average expected life	3 years

During November 2008, the Company granted four employees options to purchase an aggregate of 115,000 shares of the Company’s common stock at an exercise price of $.55 per share. The options are fully vested and expire November 26, 2011. The quoted market price of the common stock at the time of issuance of the options was $.51 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $58,441, and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		1.51	%
Dividend yield		0.00	%
Volatility factor		337.2	%
Weighted average expected life	3 years

During November 2008, the Company granted five consultants options to purchase 140,000 shares of the Company’s common stock, at an exercise price of $.55 per share. The options are fully vested and expire November 26, 2011. The quoted market price of the common stock at the time of issuance of the options was $.51 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $71,147 and was recorded as stock-based compensation in the accompanying financial statements for the year ended December 31, 2008.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		1.51	%
Dividend yield		0.00	%
Volatility factor		337.2	%
Weighted average expected life	3 years

F-29

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 12: STOCKHOLDERS’ EQUITY - continued

The following schedule summarizes the changes in the Company’s stock option plan:

						Weighted				Weighted
	Options Outstanding					Average				Average
	Number			Exercise		Remaining		Aggregate		Exercise
	Of			Price		Contractual		Intrinsic		Price
	Shares			Per Share		Life		Value		Per Share

Balance at December 31, 2005		-		$	0.00		-	$	-	$	-
Options granted		2,000,000			0.07-0.15	2.52 years			0.00		0.08

Balance at December 31, 2006		2,000,000			0.07-0.15	2.52 years			0.00		0.08

Options granted		4,947,400			0.17-1.05	1.99 years			402,320		0.56
Options exercised		(1,750,000	)		0.07	2.6 years			0.00		0.07
Options expired		-			-		-		-		-

Balance at December 31, 2007		5,197,400		$	0.15-1.05	2.03 years		$	402,320	$	0.56

Options granted		3,516,386			0.17-1.05	1.50 years			91,953		0.93
Options exercised		(379,765	)		0.17-0.29	3.0 years			-72,244		0.25
Options expired		(2,725,000	)		0.15-1.05	1.09 years			0.00		0.69

Balance at December 31, 2008		5,609,021		$	0.15-1.05	1.52 years		$	422,029	$	0.75

Exercisable at December 31, 2006		2,000,000		$	0.07-0.15	2.52 years		$	0.00	$	0.08

Exercisable at December 31, 2007		5,197,400		$	0.15-1.05	2.03 years		$	402,300	$	0.56

Exercisable at December 31, 2008		5,609,021		$	0.15-1.05	1.52 years		$	422,029	$	0.75

NOTE 13: CONCENTRATIONS OF CREDIT AND OTHER RISKS

Accounts Receivable

The Company’s accounts receivable result from credit sales to customers. The Company had four and three customers whose sales were greater than 10% for the years ended December 31, 2008 and December 31, 2007, respectively. These customers represented 72.2% and 57.9% of the Company’s total revenues for the years ended December 31, 2008 and December 31, 2007, respectively. Those same customers accounted for 100% and 71.6% of the Company’s net accounts receivable balance at December 31, 2008 and December 31, 2007, respectively.

Sales to the Company’s four customers whose sales were greater than 10% for the year ended December 31, 2008 totaled 28.5%, 17.9%, 14.2%, and 11.6% of total revenues in 2008. Sales to the Company’s three customers whose sales were greater than 10% for the year ended December 31, 2007 totaled 24.9%, 17.5%, and 15.5% of total revenues in 2007.

The loss of any of these significant customers would have a temporary adverse effect on the Company’s revenues, which would continue until the Company located new customers to replace them

The Company routinely assesses the financial strength of its customers and provides an allowance for doubtful accounts as necessary.

Inventories

The Company has two products, one of which is produced in the Company’s production facility and the other product sold by the Company is purchased from one supplier. The failure of this supplier to meet its commitment on schedule could have a material adverse effect on the Company’s business, operating results and financial condition. If the sole-source supplier were to go out of business or otherwise become unable to meet its supply commitments, the process of locating and qualifying alternate sources could require up to several months, during which time the Company’s sales could be delayed. Such delays could have a material adverse effect on the Company’s business, operating results and financial condition.

F-30

Advanced Medical Isotope Corporation

(A Development Stage Company)

Notes to Consolidated Financial Statements

For the years ended December 31, 2008 and 2007

NOTE 14: SUPPLEMENTAL CASH FLOW INFORMATION

During the year ended December 31, 2008, the Company had the following non-cash investing and financing activities:

Increased prepaid expense paid with stock by $45,250, increased common stock by $87, and increased paid in capital by $45,163.

Increased stock based consulting fee payable by $117,344, increased common stock by $241, and increased paid in capital by $117,103.

Decreased accounts payable $22,060, and increased common stock $130, and increased paid in capital $21,930.

Decreased common stock subscriptions by $202,500, increased common stock by $919, increased paid in capital by $201,581.

During the year ended December 31, 2007, the Company had the following non-cash investing and financing activities:

Increased prepaid expense paid with stock by $561,000, increased common stock by $867, and increased paid in capital by $560,133.

Increased patent license fee by $75,000, increased common stock by $250, and increased paid in capital by $74,750.

Increased common stock by $160, increased paid in capital by $119,840, decreased note payable – related party by $80,000, and increased loss on debt extinguishment by $40,000.

Increased common stock by $300, increased paid in capital by $167,200, decreased preferred stock redeemable as common by $167,495, and decreased convertible preferred stock by $5.

During the year ended December 31, 2006, the Company had the following non-cash investing and financing activities:

Increased prepaid consulting by $165,000, increased common stock by $850, and increased paid in capital by $164,150.

Increased preferred stock redeemable as common by $3,207,525, increased convertible preferred stock by $100, and increased license fees by $2,897,625.

Increased common stock subscription payable and paid in capital by $30,000.

NOTE 15: SUBSEQUENT EVENTS

In January 2009 the Company made a $25,000 deposit towards a $235,000 used Cyclotron.

In February 2009 the Company issued 80,000 shares of its common stock valued at $0.42 per share on the date of issuance, in exchange for business consulting services.

In March 2009 the Company issued 100,000 shares of its common stock valued at $0.30 per share on the date of issuance, in exchange for business consulting services.

In March 2009 the Company issued 33,333 shares of its common stock valued at $0.36 per share on the date of issuance, in exchange for business consulting services.

In March 2009 one of the members of the Board of Directors converted 95,000 shares of the Company’s Series A Preferred Stock into 10,857,142 shares of the Company’s common stock. The Series A Preferred Shares were originally issued in September, 2006 to Utek Corporation for the Company’s purchase of technology from Utek. The board member acquired the Company’s Series A Preferred Stock from Utek in February 2009. The Series A Preferred Stock conversion was based on the Company’s common stock’s average closing price for the ten trading days before the date of conversion.

In March 2009 the Company sold 37,037 common stock shares at $0.27 per share.

In March 2009 the Company sold 1,500,000 common stock shares at $0.15 per share and issued 750,000 two year warrants.

In February and March the Company received $22,800 from an officer and shareholder for funds needed to meet operating expenses. The Company repaid $4,700 leaving a balance of $18,100 at March 31, 2009.

F-31

Advanced Medical Isotope Corporation
(A Development Stage Company)
Balance Sheets

	March 31,			December 31,
	2009			2008
	(unaudited)
ASSETS

Current Assets:
Cash and cash equivalents	$	221,170		$	86,631
Accounts receivable		12,600			35,747
Prepaid expenses		4,042			3,000
Prepaid expenses paid with stock, current portion		73,969			140,579
Inventory		888			7,100
Total current assets		312,669			273,057

Fixed assets, net of accumulated depreciation		2,138,366			2,272,784

Other assets:
License fees, net of amortization		20,833			27,083
Patents		25,192			24,594
Prepaid expenses paid with stock, long-term portion		87,500			96,875
Deposits		180,406			155,406

Total other assets		313,931			303,958
Total assets	$	2,764,966			2,849,799

LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)

Current liabilities:
Accounts payable	$	491,447		$	580,258
Accrued interest payable		35,418			188,956
Payroll liabilities payable		5,900			9,098
Preferred stock redeemable as common		-			3,182,405
Loans from shareholder		204,335			194,599
Convertible notes payable		447,322			257,481
Current portion of capital lease obligations		2,097,934			2,138,853
Total current liabilities		3,282,356			6,551,650

Long term liabilities:
Capital lease obligations, net of current portion		-			-
Total liabilities		3,282,356			6,551,650

Shareholders’ Equity (Deficit):
Preferred stock, $.001 par value; 100,000 authorized;
0 and 95,000 shares issued and outstanding, respectively		-			95
Common stock, $.001 par value; 100,000,000 shares authorized;
49,691,124 and 36,778,612 shares issued and outstanding,
respectively		49,691			36,779
Subscriptions receivable		-
Paid in capital		14,078,230			9,546,087
Accumulated deficit prior to the development stage		(2,884,043	)		(2,884,043	)
Deficit accumulated during the development stage		(11,761,268	)		(10,400,769	)

Total shareholders’ equity (deficit)		(517,390	)		(3,701,851	)

Total liabilities and shareholders’ equity (deficit)	$	2,764,966	)	$	2,849,799	)

The accompanying notes are an integral part of these financial statements.

F-32

Advanced Medical Isotope Corporation
(A Development Stage Company)
Statements of Operations
(unaudited)

	Three months ended March 31,						From inception of development stage on January 1, 2006 through March 31,
	2009			2008			2009

Revenues	$	60,975		$	32,335		$	459,272
Cost of goods sold		21,836			17,537			233,134
Gross profit		39,139			14,798			226,138

Operating expenses
Sales and marketing expenses		165			7,698			51,898
Start up costs		-			-			62,510
Depreciation and amortization		140,668			320,302			3,129,681
Impairment expense		-			-			903,535
Professional fees		169,687			252,433			2,637,831
Stock options granted		87,236			638,628			2,031,075
Payroll expenses		100,129			140,924			871,915
General and administrative
expenses		112,939			106,753			860,689
Total operating expenses		610,824			1,466,738			10,549,134
Operating loss		(571,685	)		(1,451,940	)		(10,322,996	)

Non-operating income (expense):
Interest expense		(181,870	)		(16,076	)		(733,828	)
Investment loss		-			-			(28,500	)
Loss on settlement of debt		(606,944	)		-			(675,944	)
Non-operating income (expense), net		(788,814	)		(16,076	)		(1,438,272	)

Loss before Income Taxes		(1,360,499	)		(1,468,016	)		(11,761,268	)

Income Tax Provision		-			-			-

Net loss	$	(1,360,499	)	$	(1,468,016	)	$	(11,761,268	)

Loss per common share	$	(0.03	)	$	(0.04	)

Weighted average common shares
outstanding		39,334,865			33,025,124

The accompanying notes are an integral part of these financial statements.

F-33

Advanced Medical Isotope Corporation
(A Development Stage Company)
Statement of Changes in Shareholders' Equity (Deficit) (unaudited)


															Accumulated			Deficit
															Deficit			Accumulated
	Series A Preferred														Prior to			During
	Stock						Common Stock				Paid in		Subscriptions		Development			Development
	Shares			Amount			Shares		Amount		Capital		Receivable		Stage			Stage			Total

Balances at December 31,
2008		95,000		$	95			36,778,612	$	36,779	$	9,546,087	$	-	$	(2,884,043	)	$	(10,400,769	)	$	(3,701,851	)

Common stock issued for:
Debt settlement January
2009 ($.27 per share)		-			-			190,000		190		51,110		-		-			-			51,300
Services February 2009
($.42 per share)		-			-			80,000		80		33,520		-		-			-			33,600
Debt settlement March
2009 ($.35 per share)		-			-			150,000		150		52,350		-		-			-			52,500
Debt settlement March
2009 ($.35 per share)		-			-			33,333		33		11,633		-		-			-			11,666
Services March 2009
($.35 per share)		-			-			25,000		25		8,725		-		-			-			8,750
Loan fee March 2009		-			-
($.28 per share)								40,000		40		10,992		-		-			-			11,032
Cash March 2009
($.27 per share)		-			-			37,037		37		9,963		-		-			-			10,000
Cash March 2009
($.15 per share)		-			-			1,500,000		1,500		223,500		-		-			-			225,000
Convert 95,000 convertible
preferred shares ($.351
per share)		(95,000	)		(95	)		10,857,142		10,857		3,800,095		-		-			-			(3,810,857	)
Debt settlement January
2009 through issuance
of 500,000, 3 year, stock
options exercisable at
$.50 per share		-			-			-		-		228,654		-		-			-			228,654
Intrinsic value of convertible
debt issued March 2009		-			-			-		-		14,365		-		-			-			14,365
Vesting of stock options
March 2009		-			-			-		-		87,236		-		-			-			87,236
Net loss		-			-			-		-		-		-		-			(1,360,499	)		(1,360,499	)
Balances at March 31,
2009 (unaudited)		-		$	-			49,691,124	$	49,691	$	14,078,230	$	-	$	(2,884,043	)	$	(11,761,268	)	$	(517,390	)

The accompanying notes are an integral part of these financial statements.

F-34

Advanced Medical Isotope Corporation
(A Development Stage Company)
Statements of Cash Flows

							From inception of
							development stage on
	Three months ended			Three months ended			January 1, 2006 through
	March 31, 2009			March 31, 2008			March 31, 2009
CASH FLOW FROM OPERATING ACTIVITIES:
Net Loss	$	(1,360,499	)	$	(1,468,016	)	$	(11,761,268	)

Adjustments to reconcile net loss to net cash
used by operating activities:
Depreciation of fixed assets		134,418			9,562			444,987
Amortization of licenses and intangible assets		6,250			310,740			2,707,007
Amortization of convertible debt discount		115,238			-			154,436
Amortization of prepaid expenses paid with stock		75,985			87,075			609,782
Impairment of intangible assets		-			-			903,535
Common stock issued for services		33,600			-			1,777,312
Stock options issued for services		87,236			638,628			1,167,105
Stock issued for repairs and maintenance		-			-			7,875
Loss on settlement of debt		606,944			-			606,944
Loss on conversion of shareholder loan		-			-			40,000
Changes in operating assets and liabilities:
Accounts receivable		23,147			7,275			(12,600	)
Inventory		6,212			15,975			(888	)
Prepaid expenses		(1,042	)		(28,750	)		(4,042	)
Deposits		(25,000	)		-			(180,408	)
Accounts payable		144,789			26,420			651,808
Payroll liabilities		(3,198	)		(36,579	)		5,900
Stock based consulting fees payable		(30,850	)		66,048			181,794
Accrued interest rolled into notes payable		-			-			142,375
Accrued interest		18,090			-			207,046
Net cash used by operating activities		(168,680	)		(371,622	)		(2,351,300	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Cash acquired from investment		-			-			310,000
Cash used to acquire equipment		-			(1,203,427	)		(2,583,353	)
Cash used to acquire patents		(598	)		-			(25,192	)
Cash used to acquire intangible assets		-			-			(658,750	)
Net cash used in investing activities		(598	)		(1,203,427	)		(2,957,295	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds received from bank line of credit		-			-			219,908
Payments on line of credit		-			(20,000	)		(219,908	)
Proceeds from Washington Trust debt		-			-			199,908
Payments on Washington Trust debt		(8,364	)		-			(13,673	)
Proceeds from capital lease		-			1,197,611			2,445,156
Principal payments on capital lease		(40,919	)		(44,492	)		(347,222	)
Proceeds from convertible note		100,000			-			775,000
Proceeds from officers related party debt		22,800			-			70,800
Payments on officers related party debt		(4,700	)		-			(52,700	)
Proceeds received from shareholder loan		-			-			80,000
Proceeds from cash sales of common shares		235,000			655,280			2,044,996
Proceeds from exercise of options and warrants		-			72,500			125,000
Proceeds from subscription shares payable		-			-			202,500
Net cash provided by financing activities		303,817			1,860,899			5,529,765

F-35

Advanced Medical Isotope Corporation
(A Development Stage Company)
Statements of Cash Flows

Statements of Cash Flow (unaudited) - continued

Net increase in cash and cash equivalents		134,539		285,850		221,170
Cash and cash equivalents, beginning of period		86,631		54,508		-
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	221,170	$	340,358	$	221,170


Supplemental disclosures of cash flow information:
Cash paid for interest	$	48,542	$	16,076	$	92,816
Cash paid for income taxes	$	-	$	-	$	-

The accompanying notes are an integral part of these financial statements.

F-36

Advanced Medical Isotope Corporation

Notes to Consolidated Financial Statements

For the three months ended March 31, 2009 and the year ended December 31, 2008

NOTE 1: BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements of the Company have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures required by accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the results of operations of the Company for the period presented. The results of operations for the three months ended March 31, 2009, are not necessarily indicative of the results that may be expected for any future period or the fiscal year ending December 31, 2009.

Reclassification

Certain expenses for the period ended March 31, 2008 were reclassified to conform with the expenses for the period ended March 31, 2009. Certain liabilities at December 31, 2008 were reclassified to conform with the liabilities at March 31, 2009.

NOTE 2: GOING CONCERN

We anticipate a requirement of $3 million in funds over the next twelve months to maintain current operation activities. In addition we anticipate a requirement of approximately $7 million in funds over the next twelve months due to the anticipation of adding additional staff in the future assuming we are successful in selling our medical isotopes and/or the start of development by us on future manufacturing sites or other projects. Currently we have $221,170 cash on hand which means there will be an anticipated shortfall of nearly the full $10 million requirement in additional funds over the next twelve months. There are currently commitments to vendors for products and services purchased, plus, the employment agreements of the CFO and other employees of the company and our current lease commitments that will necessitate liquidation of the Company if we are unable to raise additional capital. The current level of cash is not enough to cover the fixed and variable obligations of the Company.

F-37

Advanced Medical Isotope Corporation

Notes to Consolidated Financial Statements

For the three months ended March 31, 2009 and the year ended December 31, 2008

NOTE 3: FIXED ASSETS

Fixed assets consist of the following at March 31, 2009 and December 31, 2008:

	March 31, 2009			December 31, 2008
Production equipment	$	2,113,218			2,113,218
Building		446,772			446,772
Leasehold improvements		3,235			3,235
Office equipment		20,128			20,128
		2,583,353			2,583,353
Less accumulated depreciation		(444,987	)		(310,569	)
	$	2,138,366			2,272,784

Accumulated depreciation related to fixed assets is as follows:

	March 31, 2009		December 31, 2008
Production equipment	$	358,420		252,759
Building		82,060		54,707
Office equipment		3,760		2,543
Leasehold improvements		747		560
	$	444,987	$	310,569

Depreciation expense for the above fixed assets for the three months ended March 31, 2009 and the three months ended March 31, 2008, respectively, was $134,418 and $9,562.

NOTE 4: INTANGIBLE ASSETS


Intangible assets consist of the following at March 31, 2009 and December 31, 2008:

	March 31, 2009			December 31, 2008
Intellectual property	$	-		$	250,750
Contracts and agreements		-			213,000
Customer lists		-			195,000
License Fee		75,000			2,972,625
Patents		25,192			24,594
		100,192			3,655,969
Less accumulated amortization		(54,167	)		(2,700,757	)
Less Impairment Expense		-			(903,535	)
Intangible assets net of accumulated amortization	$	46,025		$	51,677

Amortization expense for the above intangible assets for the three months ended March 31, 2009 and the three months ended March 31, 2008, respectively, was $6,250 and $310,740.

F-38

Advanced Medical Isotope Corporation

Notes to Consolidated Financial Statements

For the three months ended March 31, 2009 and the year ended December 31, 2008

NOTE 5: RELATED PARTY TRANSACTIONS

Indebtedness from related parties

The Company had a $200,000 revolving line of credit with Washington Trust Bank that was to expire in September 2009. The Company had $199,908 in borrowings under the line of credit as of October 28, 2008 at which time it was paid off and replaced with a loan from two of the major shareholders. The loan calls for $4,066 monthly payments, including 8% interest, beginning November 30, 2008, with a balloon payment for the balance at October 31, 2009. There is no security held as collateral for this loan. As of March 31, 2009, the balance was $186,235 and all payments were current on this shareholder loan.

During the first three months of 2009 the Company received a total of $22,800 from a shareholder and officer in the form of a loan and the Company repaid $4,700 of this loan, leaving a balance of $18,100 as of March 31, 2009. All of the $18,100 balance was repaid in April 2009. There was no interest obligation on this loan to the Company.

Rent expenses

The Company began renting office and warehouse space, known as the Production Facility, effective August 1, 2007, located in Kennewick, Washington from a shareholder holding less that 5% of the total shares outstanding. The lease agreement calls for monthly rental payments starting at $3,500, increasing every August 1st until they become $4,762 as of August 1, 2011. During the three months ended March 31, 2009 and the three months ended March 31, 2008 the Company incurred rent expenses for this facility totaling $11,340 and $10,500 respectively. In addition, the lease agreement called for the issuance of $187,500 in common stock valued at $.40 per share for a total of 416,667 shares. The company recognized the issuance of all 416,667 shares in 2007 and will amortize the $187,500 value of that stock over the sixty month term of the lease. For the three months ended March 31, 2009 and the three months ended March 31, 2008 the Company amortized $9,375 and $9,375, respectively, of this stock issuance and recognized it as rent expense.

Additionally, in June 2008, the Company entered into a twelve month lease for its corporate offices with three four month options to renew, but in no event will the lease extend beyond May 31, 2010. The lease agreement calls for monthly rental payments of $5,061 per month. During the three months ended March 31, 2009 and the three months ended March 31, 2008 the Company incurred rent expenses for this facility totaling $15,184 and $0, respectively.

Future minimum rental payments required under the Company’s current rental agreements in excess of one year as of March 31, 2009, are as follows:

	Production		Corporate
	Facility		Offices		Total
Twelve months ended March 31, 2010	$	47,779	$	60,736	$	108,515
Twelve months ended March 31, 2010		51,602		10,123		61,725
Twelve months ended March 31, 2012		55,730		-		55,730
Twelve months ended March 31, 2013		19,047		-		19,047

Total	$	174,158	$	70,859	$	245,017

Rental expense for the three months ended March 31, 2009 and the three months ended March 31, 2008 consisted of the following:

	Three Months ended March 31, 2009		Three Months ended March 31, 2008
Office and warehouse lease effective August 1, 2007
Monthly rental payments	$	11,340	$	10,500
Rental expense in the form of stock issuance		9,375		9,375
Corporate office		15,184		-
Total Rental Expense	$	35,899	$	19,875

F-39

Advanced Medical Isotope Corporation

Notes to Consolidated Financial Statements

For the three months ended March 31, 2009 and the year ended December 31, 2008

NOTE 6: PREPAID EXPENSES PAID WITH STOCK

The Company has issued stock to companies for various service agreements extending beyond March 31, 2009; however all of which are expected to expire sometime within the next twelve months. Additionally, the Company issued stock for prepaid rent which will expire annually through July 2012 at the rate of $37,500 per year. Prepaid Expenses are expected to mature as follows:

For the twelve month period ending March 31, 2010	$	73,969
For the twelve month period ending March 31, 2011		37,500
For the twelve month period ending March 31, 2012		37,500
For the twelve month period ending March 31, 2013		12,500
	$	161,469

NOTE 7: INCOME TAXES

At March 31, 2009, the Company has net operating loss carry forwards available to offset future taxable income if any of approximately $10,600,000, which will begin to expire in 2028. The utilization of the net operating loss carry forwards is dependent upon the tax laws in effect at the time the net operating loss carry forwards can be utilized. The Tax Reform Act of 1986 significantly limits the annual amount that can be utilized for certain of these carry forwards as a result of the changes in ownership.

In July 2006, the FASB issued FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes – and interpretation of FASB Statement No. 109” (“FIN 48”), which clarifies the accounting and disclosure for uncertainty in tax positions, as defined. FIN 48 seeks to reduce the diversity in practice associated with certain aspects of the recognition and measurement related to accounting for income taxes. The Company is subject to provisions of FIN 48 as of January 1, 2007, and has analyzed filing positions in all of the Federal and state jurisdictions where it is required to file income tax returns. Upon review of the Company’s historical tax filings and consultation with its tax advisors, the Company believes that it has taken tax positions in preceding years that could potentially result in reductions to its cumulative net operating loss carry-forwards of approximately $1,395,015. The Company is subject to audit by the IRS and the State of Delaware for the prior three years.

The Company, as a matter of policy, would record any interest and penalties associated with taxes as a component of income tax expenses.

NOTE 8: STOCKHOLDERS’ EQUITY

Common stock sale

In March 2009 the Company issued 37,037 shares for cash of $10,000 at $.27 per share.

In March 2009 the Company issued 1,500,000 shares for cash of $225,000 at $.15 per share. The Company granted 750,000 warrants in conjunction with this transaction. The warrants have an exercise price of $0.15 and a two year life.

Preferred stock

The Company issued 95,000 shares of preferred stock in September, 2006 to Utek Corporation for the Company’s purchase of technology from Utek. A board member of the Company acquired the 95,000 shares of the Company’s Series A Preferred Stock from Utek in February 2009. In March 2009 the board member converted the 95,000 shares of the Company’s Series A Preferred Stock and the related accrued interest into 10,857,142 shares of the Company’s common stock. The value of the transaction totaled $3,810,857 based on common stock’s average closing price for the ten trading days before the date of conversion of $0.351 per share. The Company’s Preferred Stock Redeemable as Common liability was reduced by $3,182,405, accrued interest was reduced by $171,628, preferred stock was reduced by $95, and a loss on settlement of debt of $456,823 has been recognized in the accompanying financial statements for the three months ended March 31, 2009.

Common stock issued for services and debt settlement

During January 2009, the Company issued 190,000 shares of its common stock in payment of accounts payable for business consulting services. The value of the transaction totaled $51,300 based on the quoted market price of stock on the transaction date, or $.27 per share. The company’s accounts payable was reduced by $52,500 and a gain on settlement of debt of $1,200 has been recognized in the accompanying financial statements for the three months ended March 31, 2009.

F-40

Advanced Medical Isotope Corporation

Notes to Consolidated Financial Statements

For the three months ended March 31, 2009 and the year ended December 31, 2008

NOTE 8: STOCKHOLDERS’ EQUITY – continued

During February 2009, the Company issued 80,000 shares of its common stock in exchange for business consulting services. The value of the transaction totaled $33,600 based on the quoted market price of stock on the transaction date, or $.42 per share. Stock-based compensation expense of $33,600 has been recognized in the accompanying financial statements for the three months ended March 31, 2009.

During March 2009, the Company issued 150,000 shares of its common stock in payment of accounts payable for business consulting services. The value of the transaction totaled $52,500 based on the quoted market price of stock on the transaction date, or $.35 per share. The Company’s account payable was reduced by $50,000 and loss on settlement of debt of $2,500 has been recognized in the accompanying financial statements for the three months ended March 31, 2009.

During March 2009, the Company issued 33,333 shares of its common stock in payment of accounts payable for business consulting services. The value of the transaction totaled $11,667 based on the quoted market price of stock on the transaction date, or $.35 per share. The Company’s accounts payable was reduced by $12,000 and gain on settlement of debt of $333 has been recognized in the accompanying financial statements for the three months ended March 31, 2009.

During March 2009, the Company issued 25,000 shares of its common stock in exchange for business consulting services. The value of the transaction totaled $8,750 based on the quoted market price of stock on the transaction date, or $.35 per share. Stock-based compensation expense of $8,750 has been recognized in the accompanying financial statements for the three months ended March 31, 2009.

Common stock issued for convertible debt

In March 2009, the Company issued 40,000 shares of its common stock and a convertible promissory note in the amount of $100,000 with interest payable at 10% per annum. The Note matures in March of 2010. The entire outstanding principal balance and any outstanding fees or interest is due and payable in full on the Maturity Date. At the option of the holder, the note and interest is convertible into the Company’s common stock at $0.30 per share. The value of the $100,000 debt plus the $0.35 fair market value of the 40,000 shares at the date of the agreement was prorated to arrive at the allocation of the original $100,000 debt and the value of the 40,000 shares and the beneficial conversion feature. The computation resulted in an allocation of $74,603 toward the debt and $11,032 to the shares and $14,365 to the beneficial conversion feature. The $11,032 value of the shares and the $14,365 value of the beneficial conversion feature are then amortized to interest over the twelve month life of the debt. Interest expense of $1,058 has been recognized in the accompanying financial statements for the three months ending March 31, 2009.

Common stock options

Options granted to non-employees, accounted for under the fair value method

During February 2009, the Company granted three consultants options to purchase 500,000 shares of the Company’s common stock, at an exercise price of $.50 per share. The options are fully vested and expire February 5, 2012. The quoted market price of the common stock at the time of issuance of the options was $.49 per share. The Company valued the options in accordance with SFAS 123(R). The fair value of the options totaled $228,654 using the Black-Scholes option pricing model. The Company’s accounts payable was reduced by $79,500 and a loss on settlement of debt of $149,154 has been recognized in the accompanying financial statements for the three months ended March 31, 2009.

The fair value of the options was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions:

Risk-free interest rate		1.37	%
Dividend yield		0.00	%
Volatility factor		211.2	%
Weighted average expected life	3 years

F-41

Advanced Medical Isotope Corporation

Notes to Consolidated Financial Statements

For the three months ended March 31, 2009 and the year ended December 31, 2008

NOTE 8: STOCKHOLDERS’ EQUITY – continued

The following schedule summarizes the changes in the Company’s stock option plan:

						Weighted				Weighted
	Options Outstanding					Average				Average
	Number			Exercise		Remaining		Aggregate		Exercise
	Of			Price		Contractual		Intrinsic		Price
	Shares			Per Share		Life		Value		Per Share

Balance at December 31, 2008		5,609,021		$	0.15-1.05	1.52 years		$	424,138	$	0.75
Options granted		1,250,000			0.15-0.50	2.34 years			150,000		0.29
Options exercised		-			-		-		-		-
Options expired		(2,389,986	)		1.05		-		-		1.05
Balance at March 31, 2009		4,469,035		$	0.15-1.05	2.32 years		$	574,138	$	0.46
Exercisable at December 31, 2008		5,609,021		$	0.15-1.05	1.52 years		$	424,138	$	0.75
Exercisable at March 31, 2009		4,469,035		$	0.15-1.05	3.86 years		$	574,138	$	0.46

NOTE 9: SUPPLEMENTAL CASH FLOW INFORMATION

During the three months ended March 31, 2008, the Company had the following non-cash investing and financing activities:

Decreased Common Stock Subscriptions Payable by $185,688 and increased common stock by $826 and increased paid in capital by $184,862.

During the three months ended March 31, 2009, the Company had the following non-cash investing and financing activities:

Decreased trade accounts payable by $114,500 and increased paid in capital by $115,093 and increased common stock by $373 and decreased loss on settlement of debt by $966.

Decreased Accrued Interest Payable by $171,628 and decreased Preferred Stock Redeemable by $3,182,405 and decreased Preferred Stock by $95 and increased Paid In Capital by $3,800,095 and increased Common Stock by $10,857 and increased loss on settlement of debt by $456,824.

NOTE 10: SUBSEQUENT EVENTS

In April 2009 the Company sold 55,556 shares of its common stock at $.27 per share.

In April 2009 the Company sold 525,000 shares of its common stock at $.20 per share plus an equal amount of one year warrants, exercisable at $0.40.

In April 2009 the Company purchased a cyclotron for $235,000 to establish a second production facility at a site yet to be determined.

In April 2009 the Company issued 50,000 shares of its common stock valued at $0.31 per share on the date of issuance, in exchange for rent.

In May 2009 the Company named a new member to the Company’s Board of Directors and issued that member 200,000, three year, options to purchase the Company’s common stock at an exercise price of $0.26 per share.

F-42

INDEX TO EXHIBITS.

Exhibit
Number		Description

3.1		Certificate of Incorporation of Savage Mountain Sports Corporation dated January 11, 2000.1
3.2		By-Laws1
3.3		Articles and Certificate of Merger of HHH Entertainment Inc. and Savage Mountain Sports Corporation dated April 3, 2000.1
3.4		Articles and Certificate of Merger of Earth Sports Products Inc. and Savage Mountain Sports Corporation dated May 11, 2000.1
3.5		Certificate of Amendment of Certificate of Incorporation changing the name of the Company to Advanced Medical Isotope Corporation dated May 23, 2006.1
3.6		Certificate of Amendment of Certificate of Incorporation increasing authorized capital dated September 26, 2006.1
10.1		Agreement and Plan of Reorganization, dated as of December 15, 1998, by and among HHH Entertainment, Inc. and Earth Sports Products, Inc.1
10.2		Agreement and Plan of Merger of HHH Entertainment, Inc. and Savage Mountain Sports Corporation, dated as of January 6, 2000.1
10.3		Employment Agreement dated August 15, 2006 with William J. Stokes.1
10.4		Agreement and Plan of Acquisition by and between Neu-Hope Technologies, Inc., UTEK Corporation and Advanced Medical Isotope Corporation dated September 22, 2006.1
10.5		Employment Agreement dated May 16, 2007 with Leonard Bruce Jolliff.1
10.6		Agreement and Plan of Acquisition by and between Isonics Corporation and Advanced Medical Isotope Corporation dated June 13, 2007.1
10.7		Employment Agreement dated January 15, 2008 with Dr. Fu-Min Su.1
23.1		Independent Registered Public Accounting Firm's Consent.3

1. Incorporated by reference to the Company's Registration Statement on Form 10 as filed with the SEC on November 12, 2008.

2. Incorporated by reference to the Company's Registration Statement on Form 10/A as filed with the SEC on February 17, 2009.

3. Filed herewith.

SIGNATURES

In accordance with Section 12 of the Securities Exchange Act of 1934, the registrant caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

	ADVANCED MEDICAL ISOTOPE CORPORATION

Date: June 24 , 2009	By:	/s/ James C. Katzaroff
		Name: James C. Katzaroff
		Title: Chief Executive Officer and Chairman


Date: June 24, 2009	By:	/s/ L. Bruce Jolliff
		Name: L. Bruce Jolliff
		Title: Chief Financial Officer and Controller


Date: June 24, 2009	By:	/s/ Carlton Cadwell
		Name: Carlton Cadwell
		Title: Director